download
FREE KOL List
    • KOL
    • Harry Roger Büller
    • Harry Roger Büller

      Harry Roger Büller

      Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ...

       

       

      KOL Resume for Harry Roger Büller

      Year
      2022

      Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands

      2021

      From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.).

      Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.).

      2020

      From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.)

      Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands

      2019

      Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands.

      Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

      2018

      Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands

      2017

      Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands.

      From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy.

      2016

      Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands

      2015

      Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands

      2014

      From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.).

      Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and

      2013

      Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands

      Academic Medical Center, Amsterdam (H.R.B.)

      2012

      Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.)

      Vascular Medicine, AMC, Amsterdam, the Netherlands

      2011

      Internal Medicine, Academic Medical Center, Amsterdam, Netherlands,

      From the Academic Medical Center

      and Slotervaart Hospital, Amsterdam

       

       

      Harry Roger Büller: Influence Statistics

      Sample of concepts for which Harry Roger Büller is among the top experts in the world.
      Concept World rank
      easier monitoring #1
      dimer clinical #1
      prospective management study #1
      laalleles #1
      uedvt clinical #1
      travellers thrombosis #1
      prothrombin individuals #1
      leg ultrasonography patients #1
      pulmonary embolism tests #1
      diagnostic strategies strategies #1
      non‐invasive diagnostic work‐up #1
      25mg apixaban #1
      presenting vte location #1
      elderly outpatients combination #1
      evaluable patients apixaban #1
      nadroparin aspirin #1
      inr range ttr #1
      cancer edoxaban #1
      vte trial #1
      asymptomatic extension #1
      safety outcome #1
      efficacy vte #1
      vte arterial #1
      tests venography #1
      anticoagulant treatment patients #1
      activecontrol placebo #1
      rhir lmwh #1
      adjusted dose ufh #1
      2 diagnostic management #1
      smoking graft patency #1
      rfviia idraparinux #1
      intravenous injections lmwh #1
      postthrombotic symptoms patients #1
      bleeding risk treatment #1
      heparinoid #1
      vitamin anticoagulants #1
      excluding pulmonary #1
      avws prevalence #1
      carriers thrombophilic defects #1
      vka netherlands #1
      edoxabantreated #1
      presentation category #1
      d‐dimer level #1
      pulmonary embolism basis #1
      popliteal veins sensitivity #1
      uesvt patients #1
      wells rules #1
      cstatistic major bleeding #1
      elevated cardiac troponins #1
      15 lmwh #1
      united states rnapc2 #1
      acute recurrent patients #1
      intensity vkas doacs #1
      oral anticoagulants phase #1
      predefined outcomes #1
      early time recurrence #1
      heparins data #1
      realtime bmode ultrasonography #1
      members symptomatic carriers #1
      category fxainhibitors #1
      followup overt cancer #1
      tinaquant assay comparison #1
      diagnostic strategy primary #1
      dose rnapc2 #1
      lmwh acute treatment #1
      probability cdr #1
      vte day #1
      mutation relatives #1
      botticelli dvt dose‐ranging #1
      exclusion pulmonary #1
      cancer 145 patients #1
      xageneration #1
      relatives normal fviii #1
      ventilation lung scanning #1
      submassive incidence #1
      elevated fviii age #1
      cdr normal #1
      lmwhmediated #1
      einsteindvt #1
      fviii hyperhomocysteinemia #1
      compression ultrasonography detection #1
      qscan 3 weeks #1
      avidin placebo #1
      relevant major #1
      lmwh edoxaban #1
      reocclusion antithrombotic drug #1
      venous thrombosis vwf #1
      patients unexplained dvt #1
      fetal loss carriers #1
      strategies diagnostic management #1
      efficiency subgroups #1
      study centre duration #1
      age recurrent vte #1
      monoclonal antibodies apc #1
      fondaparinux rfviia injection #1
      gentamicin patients netilmicin #1
      clinically relevant disease #1
      vte airline pilots #1
      relatives normal levels #1
      tests pulmonary embolism #1
      selective beta‐blocker treatment #1
      edoxaban dalteparin #1
      subsequent diagnosis malignancy #1
      venous thrombosis recurrence #1
      amplify trial #1
      matisse clinical trials #1
      unexplained dvt patients #1
      extensive screening cancer #1
      pulmonary angiography ultrasonography #1
      bmi fondaparinux #1
      absolute thrombotic risk #1
      acenocoumarol heparin #1
      recurrent dvt dvt #1
      thromboembolism relatives #1
      diagnostic strategies patients #1
      smoking patency #1
      hokusaivte trial #1
      0·620·74 #1
      clinical uedvt #1
      lmwh immobilization #1
      doubleheterozygotes #1
      ctscanreading #1
      systematic search cteph #1
      molecular weight fondaparinux #1
      heparin vitamin #1
      loss subsequent pregnancy #1
      single dose tb402 #1
      simple diagnostic strategy #1
      initial treatment dvt #1
      patients treatment duration #1
      gastrointestinal cancer edoxaban #1
      anticoagulant treatment vte #1
      warfarin cstatistic #1
      factual hemorrhage heparin #1
      simplified rule proportion #1
      ipe expert radiologists #1
      bleeding clinically #1
      management study #1
      einsteinextension #1
      combination cdrscore #1
      obese controls difference #1
      standalone ddimer testing #1
      silent dvt #1
      malignancy achieved inr #1
      standardintensity vkas doacs #1
      abdominal pelvic strategies #1
      category perelated death #1
      compression ultrasonography presentation #1
      fetal loss miscarriage #1
      patients khorana #1
      crptest #1
      combined training gps #1
      feasibility venography #1
      proportion pulmonary embolism #1
      cart lower levels #1
      nadroparin patients #1
      aptt org #1
      incidence ctni #1
      noncarriers annual incidence #1
      patients artificial graft #1
      wells cdr #1
      idraparinux #1
      3633 patients edoxaban #1
      enoxaparin heparin treatment #1
      0·2 3633 patients #1
      org heparin #1
      cdrscore combination #1
      incidence venous #1
      5‐snp scores #1
      controlled trials thrombophilia #1
      treatment idraparinux #1
      enoxaparin primary efficacy #1
      vka recipients #1
      baseline pvo #1
      elevated levels fviii #1
      elevated ctni patients #1
      amplify trial apixaban #1
      oral edoxaban dose #1
      rivaroxaban replacement #1
      test venography #1
      elderly patients dvt #1
      treated vka #1
      replacement vka #1
      aged nadroparin #1
      evaluable patients 95 #1
      perelated death category #1
      outcome recurrent #1
      age multiple comorbidities #1
      thrombosis vitamin #1
      dimer result #1
      departments pharmacological prophylaxis #1
      year prophylaxis #1
      milliliter enoxaparin #1
      neoplasms heparin #1
      sgs pretest probability #1
      crt cvc #1
      graft patency patency #1
      doacs initial heparin #1
      long haul flights #1
      uedvt recurrent vte #1
      pulmonary angiography study #1
      warfarin cancer patients #1
      heparins vitamin antagonists #1
      wellscdr #1
      enoxaparin initial treatment #1
      simplified geneva score #1
      efficacy outcome #1
      ivte clinical practice #1
      ultrasonography dvt #1
      lmwh plasma levels #1
      acute treatment lmwh #1
      double heterozygous carriers #1
      treatment experimental thrombosis #1
      fxainhibitors vka recipients #1
      vte risk day #1
      patients advanced malignancy #1
      venography tests #1
      hyperhomocysteinemia relatives #1
      pharmacological methods prophylaxis #1
      death vte studies #1
      heparins inhibition #1
      fviii concentration #1
      rate recurrent #1
      major bleeds vka #1
      hellp syndrome mutations #1
      69 conclusions #1
      acenocoumarol efficacy #1
      normal lung scan #1
      rnapc2 groups #1
      beta thromboglobulin org #1
      aged venous #1
      uesvt #1
      time recombinant #1
      patients advanced prostate #1
      initial heparin patients #1
      ddimer levels cdr #1
      acquired atiii deficiency #1
      rivaroxaban lmwh vka #1
      relatives elevated levels #1
      393 patients warfarin #1
      pulmonary embolism cdr #1
      sensitivity 100 percent #1
      subcutaneous idraparinux #1
      nondiagnostic lung scan #1
      cip diagnostic management #1
      5395 patients #1
      noacs prevention #1
      qscan #1
      endotoxemia tests #1
      extra hospital visits #1
      venous thrombosis hyperglycemia #1
      apixaban extended treatment #1
      risk percentage points #1
      administration lmwh #1
      vkas efficacy #1
      idraparinux 25 #1
      95 3633 patients #1
      prevention topic guidelines #1
      normal dimer #1
      suspected perfusion scan #1
      —brachial #1
      recurrent vte statin #1
      major bleeding cancer #1
      lowmolecularweight heparin 95 #1
      intracranial clinical presentation #1
      ldf cus #1
      lmprovement #1
      extended anticoagulation apixaban #1
      apixaban conventional therapy #1
      023 relatives #1
      lowmolecularweight heparin category #1
      enoxaparin vkas treatment #1
      8h flight #1
      presenting location women #1
      idrabiotaparinux idraparinux #1
      ventilation scan chest #1
      hokusaivte trial patients #1
      relatives tafi levels #1
      cvc crt #1
      thrombophilia late loss #1
      patients tb402 #1
      fondaparinux unfractionated #1
      frequency venous thromboembolism #1
      level loss patency #1
      reduceddose noacs warfarin #1
      death venous thromboembolism #1
      wound haematoma #1
      acenocoumarol therapy acenocoumarol #1
      patients acute recurrent #1
      phase doacs #1
      rnapc2 patients #1
      95 intracranial #1
      severity clinical presentation #1
      selective ddimer thresholds #1
      9 incidence #1
      12 kg1 enoxaparin #1
      annual incidence patients #1
      travel‐related venous thrombosis #1
      upper extremity uedvt #1
      probability categories #1
      crp test patients #1
      proximal location ipe #1
      sspe proximal #1
      95ci tb402 #1
      progression vte #1
      venous thromboembolism idraparinux #1
      cancer patients ufh #1
      practiceassistants #1
      apc resistance factor #1
      quantitative ddimer tests #1
      therapeutic doses lmwh #1
      included patients study #1
      clinically suspected uedvt #1
      types major bleeding #1
      recurrent thromboembolism enoxaparin #1
      idraparinux versus #1
      dvt costs #1
      wellsrule #1
      treat thrombosis #1
      ddimer test #1
      orthopedic surgery netherlands #1
      heparins cancer patients #1
      embolism radionuclide #1
      patients uedvt uesvt #1
      presenting location vte #1
      chest perfusion scintigraphy #1
      probabilityscan #1
      bleeding risk lmwh #1
      heparin acenocoumarol #1
      plateletactivating antibodies risk #1
      2479 relatives #1
      embolism wells #1
      cancer patients uedvt #1
      nadroparin therapeutic dose #1
      carriers pulmonary embolism #1
      pulmonary angiography strategies #1
      thiazoles venous #1
      vte fatal #1
      547253 #1
      months standard therapy #1
      specificity pulmonary embolism #1
      strategies abdominal pelvic #1
      acenocoumarol initial treatment #1
      deficiency proteins #1
      simplified wells rule #1
      doses 75 microg #1
      limited screening 95 #1
      preference doacs #1
      idraparinux patients #1
      treatment venous #1
      20210a mutation #1
      6 months avidin #1
      protecht shr #1
      gogh dvt trial #1
      symptomatic venous #1
      vte risk coc #1
      netherlands lmwh #1
      threemonth incidence #1
      pulmonary embolism carriers #1
      screening carriers #1
      submassive elevated ctni #1
      anticoagulants chemotherapy #1
      withheld #1
      study ecq #1
      anticoagulants probability #1
      inr studies #1
      apixaban randomized patients #1
      patients wells rule #1
      patients protein deficiencies #1
      excluded pulmonary #1
      venous thrombosis pregnancy #1
      p0001 saline #1
      age∗10μg #1
      cancer patients cancer #1
      quantitative dimer #1
      departments orthopedic surgery #1
      ml1 ctpa #1
      low levels ft4 #1
      pulmonary embolism fondaparinux #1
      patency smokers #1
      ankle brachial prevalence #1
      avidin idrabiotaparinux #1
      extended treatment edoxaban #1
      venous thrombus growth #1
      bleeding einstein #1
      topic thrombophlebitis #1
      vte difference #1
      symptomatic legs dvt #1
      quantitative ddimer test #1
      rnapc2 inhibition #1
      levonorgestrel desogestrelcontaining #1
      cdrscore #1
      flebography #1
      5mg apixaban #1
      pulmonary embolism idraparinux #1
      standard therapy months #1
      riskstroponin #1
      carriers recurrence #1
      studies 3 months #1
      combination nonhigh cdr #1
      intrinsic coagulation vivo #1
      intestinal microbiota coagulation #1
      patients idraparinux #1
      achieved inr patients #1
      clinically suspected cancer #1
      nonhigh cdr #1
      ldf diagnosis #1
      animal female heparin #1
      extended anticoagulation doacs #1
      levels procoagulant factors #1
      hokusaivte study #1
      fviii homocysteine #1
      reduceddose noacs #1
      rabinov #1
      safety clinical utility #1
      enoxaparin warfarin antiplatelet #1
      diagnosis deepvein thrombosis #1
      deep vein thrombosis #1
      clinically suspected dvt #1
      recurrent thrombosis pts #1
      risk homozygous women #1
      tsh antitpo #1
      oral rivaroxaban treatment #1
      individualized duration #1
      idraparinux 6 months #1
      dose daily edoxaban #1
      respondents lmwh #1
      fviii normal levels #1
      dimer test #1
      risk pulmonary embolism #1
      cdrs patients #1
      rnapc2 united states #1
      patients mismatched scan #1
      doacs factor #1
      conventional therapy enoxaparin #1
      studies ttr #1
      international thrombosis experts #1
      cancer clinical presentation #1
      wells rule exclusion #1
      venous thromboembolism edoxaban #1
      dvt 3 #1
      edoxaban warfarin groups #1
      absolute annual incidences #1
      anticoagulation period #1
      cdr ddimer levels #1
      patients clinical probability #1
      association travel #1
      vte study #1
      anticoagulant fondaparinux #1
      recurrent vte immobilization #1
      normotensive patients studies #1
      intravenous unfractionated #1
      scenarioanalysis #1
      s1p1activation #1
      lmwh replacement #1
      7268 patients suspected #1
      poc test patients #1
      mortality postthrombotic symptoms #1
      ctscan qscan #1
      iii plg #1
      thrombo‐embolic events #1
      fibrinolysis levels #1
      dalteparin 6 months #1
      12 months edoxaban #1
      elevated fviii #1
      cancer patients cvcs #1
      ddimer test patients #1
      pulmonary embolism life #1
      p0424 #1
      subcutaneous length life #1
      relatives mutation #1
      thrombophilia patients doacs #1
      undvt #1
      false normal #1
      failure cip #1
      weight heparinoid #1
      individuals air travel #1
      ifngamma pselectin #1
      rivaroxaban dvt treatment #1
      subsequent symptomatic cancer #1
      association protein levels #1
      suspected symptomatic #1
      elevated fviii patients #1
      isolated deficiencies proteins #1
      guidelines abi #1
      apc resistance tests #1
      elevated biomarkers hospital #1
      fviii vte #1
      uedvt terms #1
      ufh grade #1
      protein resistance control #1
      rnapc2 groups placebo #1
      clinical presentation category #1
      carriers relative risks #1
      studies doac treatment #1
      strategies ultrasonography #1
      avidin vte #1
      scores occult cancer #1
      embolism randomized #1
      heparin vitamin antagonist #1
      208791 #1
      wells clinical #1
      calf dvt ultrasound #1
      women elevated levels #1
      relevant bleeding #1
      53 amputations #1
      pvo qscan #1
      vitamin antagonists time #1
      clinical decision rule #1
      recurrence major bleeding #1
      thromboembolism 3 #1
      hokusai‐vte cancer study #1
      clinical probability exclusion #1
      abnormal ipg #1
      respondents 60 #1
      embolism sensitivity #1
      patients retropubic prostatectomy #1
      dalteparin major bleeding #1
      rule cdr #1
      superficial thrombophlebitis incidence #1
      lmwh venous thrombosis #1
      xainhibitors #1
      initial heparin edoxaban #1
      netherlands 5 years #1
      segmental subsegmental #1
      compression ultrasonography patients #1
      patients compression ultrasonography #1
      95 elevated ctni #1
      rfviia 3 #1
      anticoagulants double #1
      symptomatic recurrent vte #1
      prescriptionbased #1
      wells rule primary #1
      mdct expert radiologist #1
      ldfr symptomatic legs #1
      deepvein thrombosis incidence #1
      ultrasound strategies patients #1
      oral apixaban treatment #1
      laalleles platelets #1
      ultrasound compression ultrasound #1
      severe presentation patients #1
      lowmolecularweight heparin treatment #1
      recommendations dvt #1
      doacs anatomical extent #1
      heparins cancer spread #1
      cdr physicians #1
      normal ddimer concentration #1
      560 pharmacies #1
      normohomocysteinemic relatives hyperhomocysteinaemia #1
      00515 #1
      plasma concentration fviii #1
      outpatients symptomatic dvt #1
      residual thrombotic mass #1
      quantitative ddimer testing #1
      platelets iqr #1
      org aptt #1
      cdr ddimer test #1
      venography feasibility #1
      50 rivaroxaban #1
      uesvt mortality #1
      oral administration bsf #1
      older patients cdr #1
      death category #1
      inherited thrombophilia patients #1
      lmwh users incidence #1
      standardintensity vkas #1
      idraparinux recurrent thromboembolism #1
      coagulation clinical #1
      controlledstudy #1
      dvt impedance plethysmography #1
      compression ultrasonography #1
      orthopedic thromboprophylaxis #1
      hokusai vte cancer #1
      vte addition #1
      lmwh rtap #1
      survival fondaparinux #1
      combination cdrs #1
      pregnancyrelated complications relatives #1
      failure diagnostic management #1
      models development studies #1
      matisse trials #1
      matisse dvt #1
      somittrial #1
      idraparinux vitamin antagonist #1
      local radiologist experts #1
      normal levels fviii #1
      atherosclerosis hemophilia patients #1
      scan pulmonary embolism #1
      pvo ctscan #1
      tb402 50 #1
      presence venous thrombosis #1
      enoxaparin vkas #1
      ecq ankle brachial #1
      proportion 75 years #1
      category death #1
      rtap lmwh #1
      mutation arg506 #1
      antithrombotic prescriptions adherence #1
      7268 patients #1
      tests prevalence abi #1
      dalteparin vte treatment #1
      patients deep #1
      dvt 56 #1
      ultrasonography leg veins #1
      baseline characteristics duration #1
      protein levels mortality #1
      tb402 enoxaparin #1
      polyethylenglycolhirudin #1
      suspected cdr #1
      synthetic selective factor #1
      diagnostic management patients #1
      reported incidence vte #1
      thromboembolism treated #1
      cancer patients cdr #1
      total vte patients #1
      combination cdr #1
      coagulation factors markers #1
      prolactin venous thrombosis #1
      chest perfusion scan #1
      svt lmwh #1
      perfusion scan #1
      prothrombin 20210a mutation #1
      increasing levels ft4 #1
      vka treatment treatment #1
      lmwhs 95 #1
      control anticardiolipin antibodies #1
      97 compression ultrasonography #1
      hokusai‐vte trial #1
      incidental symptomatic vte #1
      falsenormal #1
      suspected deep #1
      equinox study #1
      antidote vitamin #1
      coagulationinhibiting #1
      factor viii homocysteine #1
      factor viii relatives #1
      vitamin antagonist patients #1
      successful attenuation #1
      analysis hokusai #1
      venous thromboembolism episode #1
      placebo 25mg apixaban #1
      5 avidin infusion #1
      378 patients edoxaban #1
      ft4 level patients #1
      randomized studies efficacy #1
      single‐detector row #1
      ivte #1
      ddimer test combination #1
      wells simplified #1
      puerperium diagnostic suspicion #1
      decisions duration #1
      patients enoxaparin vkas #1
      dvt anticoagulants #1
      procoagulant factors levels #1
      vte procoagulant activity #1
      ambulatory computers #1
      early discharge strategies #1
      efficacy heparin therapy #1
      symptomatic pts #1
      2630 pilots #1
      rule dimer #1
      normal venogram #1
      venous thrombosis mutations #1
      treatment cumulative incidence #1
      obstetric complications relatives #1
      uesvt median #1
      daily dalteparin treatment #1
      current practise #1
      50 years combination #1
      ultrasonography diagnostic #1
      tb402 prevention #1
      ddimer result #1
      prevalence coagulation #1
      patients initial heparin #1
      questionnaires thrombosis #1
      65±9years #1
      pyridines recurrence #1
      patients laalleles #1
      recurrence bleeding risk #1
      dose response apixaban #1
      einstein dvt patients #1
      patients ivte #1
      rfviia fondaparinux #1
      tb402 12 kg1 #1
      prophylaxis crt #1
      standard treatment idraparinux #1
      safety idraparinux #1
      comparison vidas assay #1
      beneficial lmwh #1
      wellscdrscore #1
      role exclusion #1
      referral basis #1
      proximal extent ipe #1
      vka share #1
      timeperiod #1
      0·2 edoxabantreated #1
      presentation major #1
      prediction models recurrence #1
      heparin initial #1
      sustained antithrombotic effects #1
      fviii venous thromboembolism #1
      women factor leiden #1
      echocardiography normotensive patients #1
      ddimer test result #1
      local radiologist #1
      patients tests prevalence #1
      fxiaso enoxaparin #1
      predefined outcomes vte #1
      thrombophlebitis tomography #1
      impedance thrombophlebitis #1
      thrice daily gentamicin #1
      scores riete score #1
      combination ddimer testing #1
      idraparinux vte #1
      vte occurred #1
      pulmonary embolism #1
      failure rate efficiency #1
      prophylaxis idraparinux #1
      patients inherited thrombophilia #1
      heparin survival #1
      symptomatic recurrent #1
      rivaroxaban acute dvt #1
      presentation 1 week #1
      fxainhibitors #1
      clinical probability patients #1
      preferred oral anticoagulant #1
      longhaul flight #1
      outcome clinically #1
      influenza case patients #1
      idraparinux months #1
      method factor #1
      probability lung scan #1
      tomography angiography vte #1
      standard therapy rivaroxaban #1
      casedescription #1
      ccus 4 #1
      ili score #1
      heparin org 10172 #1
      d‐dimer test #1
      cancer cdr #1
      cus strategies #1
      edoxaban risk factors #1
      fetal loss stillbirth #1
      netherlands vka #1
      pulmonary embolism metaanalysis #1
      embolism suspected #1
      messages justification #1
      duration heparin treatment #1
      pioped study study #1
      patients reduceddose noacs #1
      placebo rnapc2 #1
      edoxaban east asian #1
      double reports #1
      compression ultrasound dvt #1
      women edoxaban #1
      clinical probability risk #1
      doac recipients #1
      infections gentamicin #1
      hemorrhage heparin #1
      alternative diagnoses patients #1
      250 patients cancer #1
      leg veins patients #1
      desogestrelcontaining coagulation factors #1
      normal ddimer result #1
      heparin initial treatment #1
      dvt 69 #1
      3 idraparinux #1
      doacs cirrhosis patients #1
      patients antithrombotic prescriptions #1
      timerequirement #1
      revascularisation procedures patients #1
      idraparinux placebo #1
      lmwh departments #1
      guideline adherence justification #1
      dvt symptomatic #1
      adjunct thrombolysis #1
      relatives antithrombin #1
      cstatistic model discrimination #1
      uesvt uedvt #1
      abelacimab #1
      variable d‐dimer thresholds #1
      idraparinux standard therapy #1
      vitamin antagonists treatment #1
      patients normal tests #1
      reduceddose noacs stroke #1
      axa activity 5 #1
      5 years lmwh #1
      consensus strategy strategy #1
      positive vte #1
      coagulation fibrinolytic proteins #1
      cancer patients patients #1
      survival lmwh #1
      patients malignancy #1
      uesvt recurrent vte #1
      probability normal #1
      pvoq #1
      abnormal vaginal bleeding #1
      fviii women #1
      strategy abdominal pelvic #1
      thrombosis vte #1
      perelated death classification #1
      rabinovpaulin #1
      rule exclusion #1
      relative risks carriers #1
      calfvein thrombi #1
      bleeding rates quality #1
      3 rfviia #1
      obese hemophilic patients #1
      vte location #1
      initial treatment patients #1
      pulmonary embolism role #1
      500 org #1
      vkas lmwh #1
      vivo coagulation factor #1
      distal clots #1
      principal safety #1
      unexplained dvt #1
      750 μg l1 #1
      original wells #1
      subcutaneous nadroparin placebo #1
      36 papers #1
      3633 patients edoxabantreated #1
      ufh grade 1a #1
      rivaroxaban standard therapy #1
      ventricular dysfunction edoxaban #1
      chromogenic endotoxin #1
      lmwh delivery #1
      patients examiner #1
      cdr dimer #1
      enoxaparin tb402 #1
      recurrent vte doacs #1
      safety 60 dose #1
      efficacy conventional treatment #1
      khorana #1
      aptt org 10172 #1
      protein mortality #1
      previous surveys netherlands #1
      current comprehensions #1
      pulmonary embolism studies #1
      progression svt #1
      123362 #1
      constans score #1
      travel venous thromboembolism #1
      probability ventilation #1
      edoxaban cancer patients #1
      advanced malignancy #1
      thrombophilic defects risk #2
      quality warfarin treatment #2
      vein compressibility #2
      suspected pulmonary embolism #2
      ufh 6 months #2
      warfarintreated #2
      major bleeding edoxaban #2
      inflammation neutrophils thrombosis #2
      efficiency strategy #2
      nct00633893 #2
      normal ddimer test #2
      clinical pretest probability #2
      primary efficacy outcome #2
      raskob #2
      events severe #2
      score dimer #2
      enoxaparin difference #2
      efficiency diagnostic strategies #2
      major clinically #2
      embolism deep #2
      regression pravastatin #2
      composite scores area #2
      sspe patients patients #2
      rule proportion #2
      hokusai vte #2
      patients abi measurement #2
      clinically suspected #2
      decision rule #2
      absolute incidence #2
      hokusai vtecancer study #2
      euro138 #2
      gauge plethysmography #2
      exclusion pulmonary embolism #2
      impedance plethysmography diagnosis #2
      limits cancer #2
      f5 r506q #2
      mutations propeptide #2
      ddimer assay #2
      years 36 #2
      heparin nadroparin #2
      mutations cleavage sites #2
      protein rnapc2 #2
      primary hospitalbased strategies #2
      healthcare settings findings #2
      nematode anticoagulant #2
      thrombosis normal #2
      pentasaccharide fondaparinux #2
      major bleeding recurrent #2
      incidence recurrent #2
      pravastatin therapy children #2
      vte svt #2
      thyroid hormone coagulation #2
      recurrent deep #2
      gcpg #2
      fvl carriers carriers #2
      performance constans rule #2
      influenza coagulation #2
      hospitalbased strategies #2
      tinaquant vidas #2
      plasma d‐dimer concentration #2
      secondary efficiency #2
      safety pravastatin therapy #2
      95 cancer patients #2
      standardised time intervals #2
      influenza prothrombotic state #2
      fibrinolytic proteins #2
      treatment deep #2
      hasbled score hemorr2hages #2
      lower clinical utility #2
      crd42017056309 #2
      8 wk risk #2
      factor iia #2
      n832 #2
      treated anticoagulants #2
      levothyroxine exposure #2
      adapted ddimer thresholds #2
      subcutaneous length #2
      plasmin activity inhibition #2
      alife study #2
      model cancer patients #2
      patients peripheral graft #2
      thromboembolism thrombophilia #2
      pulmonary embolism purpose #2
      vte elevated fviii #2
      cancer addition #2
      incidental venous #2
      oral direct inhibitors #2
      cdr variables cdr #2
      diagnostic lung #2
      rule combined #2
      age‐adjusted d‐dimer testing #2
      received edoxaban #2
      incidental vte #2
      endotoxininduced activation coagulation #2
      venous thromboembolism enoxaparin #2
      treated edoxaban #2
      ddimer determination #2
      major bleeding cindexes #2
      uedvt efficiency #2
      resource utilisation treatment #2
      prothrombin pulmonary embolism #2
      rivaroxaban 30 bid #2
      thrombophilic disorders #2
      comparator individuals 95 #2
      duration anticoagulant #2
      crnm bleeds #2
      17 apixaban #2
      vte 12 #2
      95 comparator individuals #2
      subsegmental emboli #2
      extended constans score #2
      coagulation fibrinolytic #2
      arterial thrombotic disease #2
      compression doppler #2
      vitamin antagonist rivaroxaban #2
      suspected pulmonary #2
      ageadjusted ddimer testing #2
      pregnancy coc #2
      surgical casts #2
      heparin treatment influenza #2
      pharmacological strategies #2
      prolactin relation #2
      annual incidences #2
      treatment ttr #2
      months 25 #2
      medscape #2
      low‐molecular‐weight heparin #2
      cdr wells cdr #2
      ufh survival #2
      95 dvt #2
      idraparinux vitamin #2
      heparin effective #2
      undiagnosed malignancy #2
      travel venous #2
      major bleeding intermediate #2
      bleeding occurred #2
      duration anticoagulant treatment #2
      vitamin antagonists quality #2
      lmwh efficacy #2
      interleukin‐10 response #2
      hemorr2hages atria scores #2
      risk anticoagulation therapy #2
      recombinant hirudin cgp #2
      antagonists vka #2
      patients hemorr2hages #2
      coumarin sensitivity #2
      impedance plethysmography patients #2
      enoxaparin warfarin #2
      fibrinolysis influenza #2
      uedvt performance #2
      sustained antithrombotic #2
      serum tnf activity #2
      mdct reference standard #2
      efficiency original score #2
      computerized impedance #2
      amadeus study #2
      hmb primary outcome #2
      exposure flights #2
      brain metastases doacs #2
      dimer thresholds #2
      venous #2
      heparin administered #2
      angioplasty clopidogrel #2
      acquired antithrombin #2
      blood coagulation inhibition #2
      apixaban lmwh vka #2
      secondary strategies #2
      patients prior vte #2
      clinical probability estimate #2
      rivaroxaban thiazoles #2
      6 months scores #2
      c1173t dimorphism #2
      statins recurrent vte #2
      women therapeutic doses #2
      ultrasonography patients #2
      patients oral factor #2
      deficiencies proteins #2
      concomitant thrombophilic #2
      sr34006 #2
      measurement ankle brachial #2
      8292 patients #2
      negative ageadjusted ddimer #2
      blood coagulation rnapc2 #2
      hyperglycemia diagnosis #2
      patients low probability #2
      global public awareness #2
      relation coagulation factors #2
      vte orthopedic surgery #2
      embolism primary #2
      pregnancy venous thrombosis #2
      beta‐receptor blockade #2
      graft occlusion patients #2
      venous thrombophlebitis #2
      common alternative diagnoses #2
      embolism safely #2
      normohomocysteinemic relatives #2
      nonpermanent heart failure #2
      central localization #2
      anticoagulated patients permanent #2
      simplified wells #2
      primary healthcare secondary #2
      lmwh users #2
      n1423 #2
      uptake noacs #2
      current clinical challenges #2
      apixaban enoxaparin warfarin #2
      test cancer #2
      computed venous #2
      khorana protecht #2
      employees longhaul flight #2
      wells cdr cdr #2
      bleeding edoxaban #2
      ate cancer patients #2
      biomarkers casecontrol studies #2
      single administration tb402 #2
      wells cdr patients #2
      rfviia injection rfviia #2
      risk deep #2
      3306 patients #2
      rnapc2 doses #2
      lowmolecularweight heparin women #2
      outcome symptomatic #2
      venographically #2
      relevant patient subgroups #2
      patients khorana score #2
      uedvt cancer patients #2
      95 0·2 #2
      presentation dvt #2
      rnapc2 #2
      symptomatic outpatients #2
      coagulation factors prolactin #2
      clinical prediction model #2
      risk khorana #2
      pulmonary embolism efficacy #2
      analysis venous #2
      vidas assay #2
      principal safety outcome #2
      pulmonary embolism asthma #2
      administration rviia #2
      referred patients secondary #2
      heparin compounds #2
      mutation 35 #2
      exclude pulmonary #2
      recurrent vte risk #2
      vte 1000 personyears #2
      20210a mutations #2
      mild risk factor #2
      screening fvl #2
      recombinant nematode #2
      fibrinolysis pentoxifylline #2
      failure rate strategy #2
      scan normal #2
      hellp syndrome prevalence #2
      endogenous activated protein #2
      intrinsic cascade #2
      cancer recurrent vte #2
      amuse strategy #2
      ventilation scanning #2
      fviii increased risk #2
      simplired test #2
      bleeding complications treatment #2
      thromboinflammation cardiovascular disease #2
      bleeding rate patients #2
      levels coagulation factors #2
      life treatment duration #2
      recurrence thromboembolism #2
      cha2ds2vasc nri #2
      death vte #2
      suspected upper #2
      plasma concentrations endotoxin #2
      intermediate phenotype vte #2
      ddimer threshold #3
      activecontrol #3
      venous thromboembolism apixaban #3
      einstein patients #3
      primary rule #3
      cancer patients ate #3
      older children vte #3
      dimer blood #3
      prevalence avws #3
      6575 years #3
      thromboembolism low #3
      rnapc2 fviia #3
      normal ctnt presentation #3
      studies cus strategies #3
      placebo n4 #3
      normal result #3
      predictable pharmacokinetics #3
      composite stroke #3
      safely excluded #3
      enoxaparin follow #3
      patients 6 months #3
      compensated dic #3
      capillary blood sample #3
      recurrence thrombophlebitis #3
      02011 #3
      100 years year #3
      dvt systematic differences #3
      thromboembolism background #3
      presenting location #3
      heparins cancer #3
      outpatients dvt #3
      dalteparin difference #3
      outpatient treatment dvt #3
      nadroparin placebo #3
      efficacy heparin #3
      vte venous thrombosis #3
      pph lmwh #3
      treatment lowmolecularweight heparin #3
      patients venography #3
      einstein studies #3
      einstein dvt #3
      standard therapy treatment #3
      subcutaneous fondaparinux #3
      apc protective #3
      vte low #3
      diagnosis pulmonary #3
      3month incidence #3
      multiple comorbidities polypharmacy #3
      administration rnapc2 #3
      pulmonary embolism‐related death #3
      warfarin subgroup #3
      subcutaneous lmwh #3
      dvt primary #3
      lowmolecularweight heparin placebo #3
      embolism‐related #3
      intravenous loading dose #3
      patients venous #3
      healthy donor fmt #3
      diagnosis deep #3
      mechanisms heparin #3
      safely exclude #3
      plethysmography impedance #3
      deep vein #3
      selectine #3
      discontinuation ufh #3
      low probability models #3
      pad smokers #3
      patients 6575 years #3
      venous thrombosis positive #3
      impedance predictive #3
      patients proximalvein thrombosis #3
      heparin edoxaban #3
      safety acenocoumarol #3
      factors prothrombin #3
      introduction mdct #3
      idiopathic venous #3
      ctnt risk stratification #3
      atria hemorr2hages #3
      oral hormonal cross #3
      dip placebo #3
      ddimer assays #3
      hasbled #3
      protein thrombophilia #3
      treatment vte recurrence #3
      pulmonary embolism gestalt #3
      ventilation scan #3
      approaches primary #3
      lmwh pph #3
      knee factor #3
      cardiac troponine #3
      clinical models patients #3
      3month vte incidence #3
      influence heparins #3
      users incidence #3
      pulmonary embolism primary #3
      therapy venous #3
      “gestalt #3
      alternative diagnoses #3
      dose reduction edoxaban #3
      vte 3 #3
      vte major burden #3
      sensitivity compression #3
      platelet agents #3
      gestalt probability #3
      incidental pulmonary embolism #3
      dvt einstein #3
      desogestrelcontaining #3
      recombinant hirudin rhir #3
      treatment vka #3
      favour lmwh #3
      monoclonal replacement #3
      proximalvein thrombosis #3
      venous thromboembolism #3
      products follow #3
      definition perelated death #3
      factor viiic #3
      cdr combination #3
      tb‐402 #3
      recurrent thromboembolic #3
      thombosis #3
      prevalence hemostatic abnormalities #3
      ultrasonography strategies #3
      vte performance #3
      crt cancer patients #3
      cohort study employees #3
      iii deficiency #3
      patients ft4 level #3
      vte denmark #3
      antithrombin iii concentrate #3
      coagulation air travel #3
      idrabiotaparinux warfarin #3
      ipe cancer patients #3
      bleeding 3 #3
      inhibition blood coagulation #3
      cancer randomised trials #3
      female hemorrhage humans #3
      probability dimer #3
      wells rule gestalt #3
      stable acute #3
      coagulation influence #3
      tfindependent #3
      safely #3
      gestalt 95 #3
      lowmolecularweight humans length #3
      time venous thrombosis #3
      diagnosis pulmonary embolism #3
      revised geneva efficiency #3
      idrabiotaparinux #3
      mutation venous #3
      patients incidental vte #3
      studies hemorrhage #3
      incidence total vte #3
      venous thrombosis cancer #3
      axa activity #3
      thiophenes venous #3
      thrombophilic defect #3
      negative predictive proportion #3
      topic heparin heparin #3
      fxiaso #3
      age annual incidence #3
      lmwh #3
      simplified wells specificity #3
      chemotherapy prophylaxis #3
      primary wells rule #3
      prolactin controls #3
      strategies efficiency #3
      dvt hip #3
      outcome venous #3
      travel venous thrombosis #3
      patients ultrasonography #3
      cancer active cancer #3
      adult patients vte #3
      95 wells rule #3
      thrombophlebitis treatment #3
      12month study period #3
      wells rule dvt #3
      patients gastrointestinal cancer #3
      ft4 risk #3
      patients wells #3
      single diagnostic #3
      nct00643201 #3
      endogenous apc #3
      svt vte #3
      death clinical studies #3
      failurerate #3
      female humans inhibitors #3
      extensive screening #3
      tinaquant assay #3
      heparin heparin #3
      baseline values placebo #3
      dvt major #3
      hf severity risk #3
      vein thrombosis #3
      pulmonary embolism models #3
      bleeding major #3
      cancer patients ipe #3
      detection dvt #3
      incidence enoxaparin #3
      treatment low #3
      hokusai‐vte #3
      20210ga #3
      combination wells score #3
      3633 patients #3
      venous arterial #3
      venous thrombosis travel #3
      treatment vitamin antagonists #3
      venous thromboembolism thrombophilia #3
      thrombosis symptomatic #4
      thrombosis ischemic stroke #4
      apixaban efficacy #4
      coagulation endotoxin #4
      venography patients #4
      vka treatment #4
      noacs cancer patients #4
      vitamin antagonists patients #4
      patients submassive #4
      embolism roc #4
      cancer vwf #4
      tinaquant #4
      contraindications treatment #4
      idiopathic venous thrombosis #4
      edoxaban patients #4
      dutch orthopedic #4
      enoxaparin day #4
      levels ft4 #4
      sankyo #4
      rviia thrombin generation #4
      netherlands pulmonary #4
      thrombophilia 95 #4
      doac studies #4
      diagnosis uedvt #4
      daily netilmicin #4
      vte netherlands #4
      patients clinically #4
      chinese korean ethnicity #4
      150 microg desogestrel #4
      ageadjusted cutoff patients #4
      clot resolution #4
      chromogenic compounds #4
      treatment unfractionated heparin #4
      thrombosis uedvt #4
      serial impedance #4
      35±4 #4
      patients venous thromboembolism #4
      lowmolecularweight heparin #4
      vte global #4
      chemotherapy shr #4
      thrombosis air #4
      lmwh cancer patients #4
      women normal levels #4
      point dimer #4
      rivaroxaban 20 #4
      embolism tomography #4
      ultrasonography venous #4
      embolism dimer #4
      questionnaires venous #4
      prophylaxis lmwh #4
      estrogen therapy patients #4
      disease vte #4
      risk vkas #4
      global burden vte #4
      amadeus trial #4
      safety pravastatin #4
      coagulation factors risk #4
      vte global burden #4
      symptomatic deep #4
      episode venous #4
      proximal patients #4
      vte highincome countries #4
      preexisting heparin #4
      primary failure rate #4
      dose noacs #4
      patient education treatment #4
      “reversal #4
      patients alternative diagnosis #4
      diagnostic management #4
      gramnegative bacteria humans #4
      patients nonpermanent #4
      thromboembolism treatment #4
      chads2 p0001 #4
      10172 #4
      criteria dose reduction #4
      probability prospective #4
      dimer assays #4
      vitamin antagonists #4
      rfviia injection #4
      hemorr2hages #4
      recurrent vte months #4
      mbe patients #4
      150 microg levonorgestrel #4
      0651 #4
      hemostatic profile #4
      fibrin generation test #4
      diagnostic management strategies #4
      nct00571649 #4
      3587 #4
      clot lysis patients #4
      received warfarin #4
      arterial thrombotic #4
      abdomen relationship #4
      serial impedance plethysmography #4
      measurement abi #4
      chemotherapy vte prophylaxis #4
      risk occult cancer #4
      enoxaparin female humans #4
      total vte #4
      warfarin 3 months #4
      hyperhomocysteinemic relatives #4
      population rivaroxaban #4
      bleeding anticoagulants #4
      thromboembolism factor #4
      rule pulmonary #4
      vte treatment patients #4
      predilution postdilution #4
      thrombosis deep #4
      primary pulmonary embolism #4
      thromboembolism vitamin #4
      procoagulant factors #4
      life duration #4
      6 months prophylaxis #4
      extended treatment #4
      venous thrombosis levels #4
      control anticoagulation #4
      patient category #4
      thromboembolism arterial #4
      women apc resistance #4
      noacs netherlands #4
      disease burden vte #4
      thromboembolism systematic #4
      patients primary healthcare #4
      embolism background #4
      protecht #4
      cleavage sites apc #4
      refuted #4
      335 patients #4
      impedance plethysmography #4
      postthrombotic symptoms #4
      pregnancies carriers #4
      travel thrombosis #4
      patients fondaparinux #4
      vitamin antagonist treatment #4
      death survey #4
      series venograms #4
      lmwhs standard heparin #4
      oral rivaroxaban #4
      lmwh female heparin #4
      vte total #4
      patients dimer #4
      lowmolecular weight heparins #4
      leiden carriers #4
      thrombophilic families #4
      global disease burden #4
      thromboembolism occurred #4
      patients edoxaban #4
      advanced cancer 95 #4
      ddimer assay patients #4
      negative point #4
      venous thromboembolism patients #4
      clinically relevant bleeding #4
      patients crcl 60 #4
      activation fibrinolytic #4
      thromboembolism study #4
      diagnostic prediction models #4
      2 rules #5
      thromboembolism #5
      antithrombotic drug treatment #5
      lmwh incidence #5
      consensus strategy #5
      factor leiden 95 #5
      thromboembolism thrombosis #5
      risk prediction scores #5
      low molecularweight humans #5
      patients recurrent dvt #5
      outcome major #5
      8292 #5
      ventricular dysfunction echocardiography #5
      treatment acute dvt #5
      thrombosis leg #5
      clinical probability #5
      thrombosis upper #5
      fviia rnapc2 #5
      bleeding cancer #5
      venous thromboembolism studies #5
      women warfarin #5
      burden vte #5
      patients pulmonary embolism #5
      pulmonary embolism patients #5
      compression ultrasound #5
      8491 #5
      isolated calfvein thrombosis #5
      treatment fondaparinux #5
      thrombophlebitis ultrasonography #5
      ft4 level #5
      molecularweight heparin #5
      patients parenteral anticoagulants #5
      thromboembolism studies #5
      cgp 39393 #5
      vte patients cancer #5
      diagnosis questionnaire #5
      coronary angioplasty angioplasty #5
      thromboembolism idraparinux #5
      suspected uedvt #5
      pregnancy pph #5
      secondary venous thrombosis #5
      preschool contraceptives #5
      netilmicin patients #5
      repeated ultrasonography #5
      inhibition plasminogen activation #5
      adjusted dimer #5
      severe pph women #5
      endogenous activated #5
      coc pregnancy #5
      efficiency patients #5
      deepvein thrombosis #5
      fviii families #5
      patients subtherapeutic #5
      previous venous thromboembolism #5
      patients wells score #5
      thrombosis primary #5
      diagnostic strategies #5
      patients superficial thrombophlebitis #5
      cdr patients #5
      fh patients cvd #5
      clinical presentation clinical #5
      vte factor #5
      pad smoking #5
      medea study #5
      hirudin treatment #5
      specificity thrombophlebitis #5
      low‐molecular‐weight #5
      elevated plasma level #5
      endotoxin chimpanzees #5
      dvt prevalence #5
      rivaroxaban enoxaparin vka #5
      dimer combination #5
      panwards #5
      clinical probability assessment #5
      predilution #5
      phlebography plethysmography #5
      daiichi sankyo #5
      embolism reproducibility #5
      vka patients #5
      endotoxin testing #5
      secondary dvt #5
      recurrent dvt patients #5
      day rivaroxaban #5
      sensitivity negative predictive #5
      heparin compared #5
      outpatients hospital #5
      lmwh recommended #5
      asymptomatic carriers mutation #5
      iii plasminogen #5
      incidence prognostic significance #5
      exclusion venous thromboembolism #5
      upper extremity thrombosis #5
      vte 6 #5
      normal ctpa #5
      cancer strategy #5
      transfusion blood loss #5
      hokusai #5
      gestalt #5
      southern latin america #5
      symptoms intermittent claudication #6
      patients suspected #6
      39393 #6
      subcutaneous low #6
      risk khorana score #6
      edoxaban efficacy #6
      apixaban treatment dose #6
      vte anticoagulant treatment #6
      daily gentamicin #6
      vka #6
      conventional therapy treatment #6
      treatment ufh #6
      svt extension #6
      subcutaneous nadroparin #6
      lmwh users users #6
      venograms #6
      patients tests #6
      clinically relevant subgroups #6
      anticoagulants female #6
      treatment pulmonary embolism #6
      patients proximal #6
      049 95 #6
      proportion cancer patients #6
      vte controls #6
      isolated deficiencies #6
      12month cumulative incidence #6
      repeatedly normal #6
      outcome occurred #6
      factor leiden carriers #6
      compression stockings patients #6
      ft4 patients #6
      women hyperhomocysteinemia #6
      probability pulmonary #6
      10±4 #6
      recurrent pulmonary #6
      combined utility #6
      d‐dimer testing #6
      patients iohexol #6
      standardized morbidity ratio #6
      blood coagulation mechanism #6
      treatment intermittent claudication #6
      endotoxininduced activation #6
      pembqol questionnaire #6
      dimer cut #6
      grade 1a ufh #6
      arterial cardiovascular #6
      severe dic #6
      effects levonorgestrel #6
      393 patients #6
      risk increasing levels #6
      fviia inhibition #6
      cancer primary patients #6
      c1173 #6
      neoplasms pulmonary embolism #6
      funding bayer #6
      patients pulmonary angiography #6
      levonorgestrel desogestrel #6
      initial heparin treatment #6
      thrombophilic defects #6
      rate major bleeding #6
      wells rule #6
      oral edoxaban #6
      anticoagulant treatment #6
      effects ufh #6
      pulmonary embolism presence #6
      efficiency proportion #6
      patients diagnostic #6
      synthetic pentasaccharides #6
      symptomatic legs #6
      stressinduced hyperglycaemia #6
      oral anticoagulants dabigatran #6
      antagonists treatment #6
      dvt trial #6
      patients factor mutation #6
      selective beta #6
      myocardial infarction ctni #6
      thromboembolism bleeding #6
      low absolute risk #6
      severe antithrombin #6
      dabigatran etexilate dabigatran #6
      warfarin venous thromboembolism #6
      patients lowmolecularweight heparin #6
      prevalence vte #6
      enoxaparin incidence #6
      patients uedvt #6
      dalteparin dose #6
      treatment svt #6
      patients anticoagulation clinic #6
      anticoagulants hemorrhage #6
      duration rivaroxaban #6
      ultrasonography normal #6
      leiden #6
      elisapositive #6
      lmwh cancer #6
      perioperative blood loss #6
      fixeddose regimen #6
      vte cancer #6
      embolism ventricular #6
      amplify #6
      thrombosis guidelines #6
      endotoxin assays #6
      simplired dimer #6
      subjects vte #6
      embolism pulmonary #6
      assay fibrin #6
      incidence recurrence #6
      diagnostic workup #6
      anticoagulant parameters #7
      mpc1609 #7
      diagnosis venous thrombosis #7
      venous thrombosis treatment #7
      treatment doac #7
      unselected women #7
      antithrombin protein #7
      phenprocoumon polymorphism #7
      patients standard heparin #7
      ottawa score #7
      vitamin antagonists vka #7
      levels factor viii #7
      relation prolactin levels #7
      597939 #7
      tb402 #7
      proportion older patients #7
      factor female humans #7
      presence cteph #7
      primary efficacy #7
      combination ipg #7
      deepvein thrombosis patients #7
      major bleeding #7
      stockings control #7
      thromboembolism total #7
      embolism prospective #7
      primary dvt #7
      prothrombin risk #7
      silent pulmonary embolism #7
      leg ultrasonography #7
      pulmonary embolism sensitivity #7
      negative ddimer test #7
      vka therapy #7
      administration bsf #7
      major bleeding vkas #7
      negative predictive npv #7
      nondiagnostic lung scans #7
      coagulation humans #7
      inhibitor apixaban #7
      noncompressibility #7
      day initial treatment #7
      mutations factor viii #7
      carriers venous thromboembolism #7
      major bleeding rate #7
      heparin org #7
      680 #7
      thromboembolism vte #7
      rates edoxaban #7
      thrombophlebitis adolescent #7
      thromboembolism adult #7
      specific antidotes #7
      recurrent dvt #7
      relation levels #7
      thrombophilia pregnancy loss #7
      ufh treatment #7
      doppler skin #7
      arterial cardiovascular disease #7
      lung scan #7
      etexilate oral #7
      dvt ipg #7
      plasma levels ifngamma #7
      neoplasms pulmonary #7
      tnf injection #7
      220 dabigatran #7
      diagnostic suspicion #7
      vte cancer diagnosis #7
      blood coagulation humans #7
      statin treatment risk #7
      incidence recurrent vte #7
      general practitioners guideline #7
      placebo rivaroxaban #7
      aspirin combined #7
      spiral sensitivity #7
      perelated death #7
      rivaroxaban 10 #7
      protein protein deficiencies #7
      carriers defects #7
      v617f jak2 #8
      optimal intensity #8
      dimer concentration #8
      proximal deepvein thrombosis #8
      products humans #8
      inr determination #8
      euro55 #8
      increased fibrinolytic #8
      compression surveys #8
      bnp ctnt #8
      consecutive outpatients #8
      vitamin antagonists vkas #8
      ufh initial treatment #8
      nondiagnostic scan #8
      enoxaparin vka #8
      probability lung #8
      normal computed #8
      homocysteine markers #8
      wells scores #8
      anticoagulation unprovoked vte #8
      severe preeclampsia patients #8
      0·2 #8
      current approach #8
      aged phlebography #8
      levonorgestrelcontaining #8
      vte score #8
      inr values patients #8
      leiden prothrombin #8
      dimer tests #8
      thrombosis adolescent #8
      nafronyl #8
      p0001 hasbled score #8
      low clinical probability #8
      symptomatic deepvein thrombosis #8
      contrast venography #8
      proximal deep #8
      lmwh grade 1a #8
      oac adherence #8
      tests pulmonary #8
      thrombosis prophylaxis #8
      treatment venous thrombosis #8
      analysis apixaban #8
      deficiency antithrombin #8
      recurrent vte mb #8
      recurrent vte bleeding #8
      arg506 factor #8
      administration low #8
      vka lmwh #8
      risks dvt #8
      discontinuation anticoagulant treatment #8
      anticoagulants antineoplastic #8
      patients extended anticoagulation #8
      97 95 #8
      prospective management #8
      agnelli #8
      carriers fvl #8
      apixaban enoxaparin #8
      point ultrasonography #8
      testing rule #8
      heparin vitamin antagonists #8
      1599 patients #8
      cancer pulmonary embolism #8
      acute symptomatic vte #8
      unprovoked vte patients #8
      occult cancer patients #8
      years cumulative incidence #8
      venous thrombosis hyperhomocysteinaemia #8
      funding daiichi #8
      risk employees #8
      persistent risk factors #8
      structured algorithm #8
      overt cancer #8
      prevention vte #8
      patients excluded #8
      comorbidity polypharmacy #8
      pvoct #8
      oral glucocorticoids risk #8
      inherited thrombophilic #8
      patients symptomatic vte #8
      initial heparin #8
      physicians stockings #8
      ageadjusted ddimer cutoff #8
      duration treatment #8
      warfarin hazard ratio #8
      chemotherapy low risk #8
      150 enoxaparin #8
      objectively confirmed #8
      xii deficient #8
      fxi aso #8
      vascular endothelial barrier #8
      international organisations #8
      oral apixaban #8
      patients fxa inhibitors #9
      cancer episode #9
      thromboembolism cancer #9
      vte rcts #9
      ultrasonogram #9
      compression stockings prevention #9
      treatment prophylaxis #9
      abnormal vaginal #9
      thrombosis venous thromboembolism #9
      therapeutic dose patients #9
      atiii concentrates #9
      heparin therapy patients #9
      incidental pulmonary #9
      lipoproteina women #9
      apixaban oral factor #9
      oral antithrombins #9
      normal ddimer #9
      comorbidities polypharmacy #9
      independent committee #9
      longterm treatment vte #9
      major bleeding treatment #9
      diagnosis mdct #9
      bled bleeding #9
      treatment edoxaban #9
      büller #9
      tafi levels #9
      enoxaparin factor #9
      lmwh mortality #9
      oral contraceptive pregnancy #9
      carriers factor leiden #9
      iii concentrate #9
      concomitant cancer #9
      thrombosis thromboinflammation #9
      cancer factor #9
      anticoagulant pathways #9
      hemorr2hages atria #9
      factors thrombophlebitis #9
      cancer cell extravasation #9
      embolism venous #9
      daiichisankyo #9
      strategies dimer #9
      male oligosaccharides #9
      weight heparin #9
      placebo plasma levels #9
      cofact #9
      postdilution #9
      nonpermanent #9
      diagnostic prediction model #9
      edoxaban major bleeding #9
      characteristics severity #9
      acute medical illnesses #9
      crcl 60 #9
      generation pill #9
      vte relatives #9
      fxa inhibitor #9
      fondaparinux cancer patients #9
      method enoxaparin #9
      patients active cancer #9
      homocysteine women #9
      prothrombin 20210a #9
      incidence postthrombotic syndrome #9
      discontinuing anticoagulation #9
      months efficacy #9
      thrombosis compared #9
      serotonin platelet #9
      combination stroke #9
      crp test #10
      cvd fh patients #10
      4470 #10
      embolism clinical #10
      anticoagulants #10
      oral administration dabigatran #10
      snp scores #10
      thrombophlebitis adult #10
      vnv #10
      animal heparin #10
      treatment vitamin #10
      patients endotoxemia #10
      probability pulmonary embolism #10
      nadroparine #10
      rfviia blood loss #10
      rates recurrent vte #10
      magellan study #10
      retrospective study efficacy #10
      injection avidin #10
      heparin nomogram #10
      fii mutation #10
      pregnancy carriers #10
      cus diagnosis #10
      year years #10
      ageadjusted cutoff #10
      factor levels patients #10
      ddimer concentration #10
      inherited thrombophilic factors #10
      deficiencies antithrombin #10
      gramnegative septicemia #10
      embolism patients #10
      extremity deep #10
      vte efficacy #10
      incidence major bleeding #10
      normohomocysteinemic #10
      fondaparinux risk #10
      bled scores #10
      aged antithrombin #10
      leg veins #10
      simplified geneva #10
      intimamedia thickness imt #10
      thrombosis background #10
      incidence 1000 personyears #10
      major bleeding crnmb #10
      subcutaneous metaanalysis #10
      100 years discontinuation #10
      venous thromboembolic event #10
      lmwh studies #10
      dvt lower extremity #10
      wells #10
      thr incidence #10
      factor prevention #10
      venous thrombosis #10
      cancer patients lmwh #10
      oral thrombin inhibitor #10
      severity clinical #10
      inr cases #10
      598 patients #10
      rabbits administration #10
      protein dic #10
      treatment aprotinin #10
      patients venous thrombosis #10
      schedule heparin #10
      single loss #10
      cancer patients vte #10
      induced coagulation #10
      treatment uedvt #10
      1215 patients #10
      hypocoagulable state #10
      asymptomatic pulmonary embolism #10
      magellan trial #10
      sulfates dermatan #11
      dvt #11
      crnmb 95 #11
      dabigatran enoxaparin #11
      mutations prevalence #11
      knee clinical trials #11
      pyridines thiazoles #11
      vte vwf #11
      pulmonary angiography venography #11
      intensity anticoagulation #11
      adult anticoagulants #11
      haemophilia vwd #11
      edoxaban #11
      ldfr #11
      endotoxin pentoxifylline #11
      screening cancer #11
      oral dabigatran #11
      combination dimer #11
      incidence major #11
      patients cancer vte #11
      880 patients #11
      air travel #11
      lmwh pregnancies #11
      endotoxin assay #11
      hospital lmwh #11
      carriers factor #11
      750 μg #11
      weight humans #11
      fondaparinux hemorrhage #11
      d‐dimer levels #11
      clinical pretest #11
      lmwh pregnancy #11
      embolism recurrence #11
      inhibitors hemorrhage #11
      recombinant human tnf #11
      heparinoid org #11
      medical conferences #11
      thromboembolism major #11
      cancer patients evidence #11
      pcc dabigatran #11
      levels prolactin #11
      patients anticoagulant treatment #11
      embolism prevalence #11
      pregnancyrelated complications #11
      reference testing #11
      patients probability #11
      variation inr #11
      pulmonary embolism incidence #11
      gps training #11
      ufh studies #11
      patients cvcs #11
      factor venous #11
      gentamicin treatment patients #11
      30 microg ethinylestradiol #11
      org 10172 #11
      cancer patients dvt #11
      previous venous #11
      topic venous #12
      thrombin generation fibrinolysis #12
      outpatient management patients #12
      factor leiden prothrombin #12
      risk venous #12
      safety efficiency #12
      observation risk #12
      thrombophilic #12
      bayer schering pharma #12
      geneva score #12
      dvt treatment #12
      doseadjustment #12
      livebirth rate #12
      nephro #12
      72 children #12
      warfarin treated #12
      pioped study #12
      crd42013003526 #12
      venous thromboembolism incidence #12
      perelated #12
      hirulog1 #12
      anticoagulant factor #12
      fondaparinux unfractionated heparin #12
      event recurrence #12
      bnp cardiac troponin #12
      patients incidental #12
      concomitant disorders #12
      anticoagulation unprovoked #12
      prevention venous thrombosis #12
      annual incidence vte #12
      patients lupus anticoagulant #12
      proximal vein #12
      female heparin humans #12
      warfarin recurrent vte #12
      noacs vka #12
      recurrent vte anticoagulation #12
      vka noacs #12
      months primary #12
      recurrent vte #12
      women factor #12
      outcomes venous thromboembolism #12
      humanized arthroplasty #12
      paulin #12
      treatment crt #12
      subsegmental pulmonary emboli #12
      patients lmwhs #12
      hemodynamically stable #12
      control metaanalysis #12
      vte recurrence risk #12
      deficient women #12
      warfarin therapy inr #12
      peghirudin #12
      ageadjusted ddimer #12
      proximal veins #12
      thrombosis dvt #12
      9295 #12
      stopping anticoagulation #12
      9702 #12
      95 carriers #13
      thrombosis young #13
      bleeding events edoxaban #13
      plethysmograms #13
      obesity haemophilia patients #13
      heparin low #13
      antithrombin iii activity #13
      dimer testing #13
      vte recurrence 95 #13
      groups inr #13
      vte 64 #13
      dabigatran 220 #13
      patients thrombophilia #13
      inhibition tnf #13
      association venous thrombosis #13
      safety oral #13
      conventional anticoagulants #13
      clinical decision rules #13
      vte female humans #13
      bayer healthcare #13
      arterial thromboembolism ate #13
      continuous intravenous heparin #13
      strain gauge plethysmography #13
      pselectin patients #13
      deepvein thrombosis dvt #13
      dabigatran vte #13
      treatment venous thromboembolism #13
      recombinant hirudin rhirudin #13
      patients anticoagulant #13
      daily subcutaneous #13
      randomized cross #13
      inferiority efficacy #13
      factor leiden mutation #13
      vte #13
      occult cancer #13
      safety doacs #13
      category studies #13
      uedvt #13
      factor viii apc #13
      prevention venous thromboembolism #13
      selective testing #13
      thrombosis acute #13
      nct00986154 #13
      marder score #13
      time prothrombin #13
      spiral computed tomography #13
      ufh dalteparin #13
      vte major #13
      arixtra #13
      dimer threshold #13
      levels factor #13
      hematologic pregnancy trimester #13
      vte groups #13
      rivaroxaban thiophenes #13
      86 percent #13
      superficial thrombophlebitis #13
      indication anticoagulation #13
      major hip #13
      dvt lower #13
      plethysmography #13
      concomitant antiplatelet therapy #13
      gastrointestinal bleeding patients #14
      cadherins endothelium #14
      unprovoked vte vte #14
      thrombophilia patients #14
      anticoagulant rivaroxaban #14
      aged plethysmography #14
      vte statin #14
      12 kg1 #14
      plasminogen apoa #14
      recurrent venous thromboembolism #14
      female fibrin #14
      standard heparin #14
      riete score #14
      recurrent venous #14
      fvl carriers #14
      vte months #14
      incidence severe pph #14
      aged anticoagulants #14
      thrombosis #14
      ultrasound strategies #14
      placebo rfviia #14
      cancer patients anticoagulation #14
      17 placebo #14
      obstetric complications women #14
      bolus intravenous injection #14
      patients vka therapy #14
      patients dvt #14
      treated lmwh #14
      higher ddimer levels #14
      revised geneva #14
      experimental endotoxaemia #14
      safety edoxaban #14
      edoxaban oral factor #14
      low molecular #14
      lmwh vka #14
      factor viii levels #14
      dvt lower extremities #14
      loss women #14
      costs dvt #14
      conventionaltherapy #14
      awareness pad #14
      acute deep #14
      doseranging study #14
      pregnancy venous #14
      patients acute vte #14
      limited screening #14
      effects hyperthyroidism #14
      patients outpatients #14
      edoxaban warfarin #14
      atiii deficiency #14
      aspirin women #14
      crnm #14
      symptomatic pulmonary #14
      thromboembolism age #14
      treatment duration patients #14
      anticoagulants patients #15
      symptomatic events #15
      arg562 #15
      recombinant factor viia #15
      coc vte #15
      lmwh ufh #15
      treatment 12 months #15
      lomoparan #15
      vitaminkantagonists #15
      patients vitamin antagonists #15
      coagulation #15
      primary safety outcome #15
      thrombinography #15
      established vte #15
      prior venous thromboembolism #15
      antagonist vka #15
      factor leiden #15
      control subjects prevalence #15
      clinically relevant endpoints #15
      generation oral #15
      experimental thrombosis #15
      oral direct factor #15
      khorana score #15
      studies pulmonary #15
      subcutaneous enoxaparin #15
      edoxaban treatment #15
      inr range #15
      500 pg #15
      cardiovascular diseases thrombosis #15
      enoxaparin vte #15
      inr patient #15
      arg506 #15
      prophylaxis venous thromboembolism #15
      thrombosis diagnosis #15
      thyroid hormone excess #15
      activation contact #15
      probability assessment #15
      thrombus growth #15
      abdominal pelvic #15
      diagnosis venous #15
      doacs aspirin #15
      subcutaneous regimen #15
      pregnancy outcome pregnancy #15
      patients ctpa #15
      hyperthyroidism atrial fibrillation #15
      cteph incidence #15
      fondaparinux efficacy #15
      thromboembolism time #16
      warfarin acenocoumarol #16
      positivity threshold #16
      major bleeding events #16
      netilmicin gentamicin #16
      dvt lmwh #16
      avws patients #16
      subsequent pregnancy loss #16
      deep venous thrombosis #16
      thrombosis association #16
      major bleeding anticoagulation #16
      venous thrombosis warfarin #16
      test clinical #16
      thrombosis adult #16
      combination clinical #16
      impaired fibrinolysis #16
      vterelated death #16
      arterial vascular events #16
      risk clinically #16
      postthrombotic syndrome children #16
      ddimer levels patients #16
      vte khorana score #16
      factor inhibitor #16
      analysis rivaroxaban #16
      100 95 #16
      occult cancer detection #16
      thrombosis haemostasis #16
      cancer cancer patients #16
      viia activity #16
      bleeding aged #16
      women unexplained #16
      abdomino #16
      thrombosis low #16
      cancer screening patients #16
      patients acenocoumarol #16
      factors major #16
      6 months placebo #16
      recurrent symptomatic #16
      prohemostatic #17
      anticoagulant therapy patients #17
      diagnosis svt #17
      rivaroxaban oral factor #17
      mutation women #17
      recurrent vte events #17
      ctscans #17
      topic hemorrhage humans #17
      vkorc1 gene #17
      lower specificity #17
      thromboembolism patients #17
      fibrinolysis treatment #17
      fragment f1 #17
      anticoagulants drug #17
      factor monoclonal #17
      permanent patients #17
      anticoagulants clinical #17
      patients overt hypothyroidism #17
      excessive blood loss #17
      gentamicin netilmicin #17
      dimer assay #17
      12 months patients #17
      factors venous #17
      female humans vte #17
      2688 #17
      dvt prevention #17
      vte edoxaban #17
      lmwhs patients #17
      hematoma heparin #17
      patients impedance #17
      endotoxemia bacteremia #17
      pharmo record linkage #17
      women mutation #17
      516 patients #17
      thrombosis clinical #17
      incidence pts #17
      scan classification #17
      management crt #17
      compared enoxaparin #17
      relevant nonmajor #18
      treatment vkas #18
      aptt heparin #18
      4 clinical #18
      vka vte #18
      warfarin hazard #18
      023 #18
      hivinfected patients cart #18
      weight adjusted #18
      cancer vte #18
      lmwh doacs #18
      proximal vein thrombosis #18
      edoxaban vte #18
      favor lmwh #18
      patients strategy #18
      diagnostic strategy #18
      thrombosis total #18
      intravenous heparin therapy #18
      combined form #18
      commercial airline pilots #18
      prothrombin g20210a #18
      antithrombotic treatment patients #18
      women pregnancy loss #18
      annual incidence #18
      flight hours #18
      sanofi aventis #18
      stable anticoagulation #18
      poc test #18
      simplired #18
      apc thrombin generation #18
      thromboembolism venous #18
      thrombosis pulmonary #18
      vka edoxaban #18
      venous thromboembolism rivaroxaban #18
      outcome events #18
      patients elevated biomarkers #19
      extended oral #19
      ipdma #19
      patients derivation #19
      recurrent venous thrombosis #19
      retropubic prostatectomy #19
      adjusted dose #19
      low platelets #19
      endogenous fibrinolysis #19
      studies factor #19
      vitamin antagonist #19
      56 95 #19
      acute recurrent #19
      active search #19
      doubleblinding #19
      lmwh patients #19
      35 women #19
      versions version #19
      venography sensitivity #19
      ddimer tests #19
      increased risk relatives #19
      ufh lmwh #19
      venous thromboembolism relatives #19
      abnormal ultrasound #19
      thromboembolism administration #19
      subcutaneous dalteparin #19
      patients prevalence #19
      fibrinolytic response #19
      antibodynegative #19
      local angiogenesis #19
      symptomatic dvt #19
      patients major bleeding #19
      coagulation studies #19
      treatment heparin #19
      fondaparinux enoxaparin #19
      vwf vte #19
      recurrence vte #19
      oral dabigatran enoxaparin #19
      increased fibrinolytic activity #19
      prognostic echocardiography #19
      edoxaban dose #19
      dvt rivaroxaban #19
      objective testing #19
      systemic activation coagulation #19
      patients sspe #19
      standardtherapy hazard ratio #20
      blindly #20
      abi risk factors #20
      risk thrombophilia #20
      intravenous injections #20
      carriers prothrombin #20
      thrombophilia vte #20
      malignancy time #20
      warfarin edoxaban #20
      antagonists vkas #20
      calf veins #20
      excluded patients #20
      established atherosclerosis #20
      prothrombin mutation #20
      incidences death #20
      pregnancyrelated vte #20
      guidance ssc #20
      ctnt bnp #20
      recurrence bleeding #20
      treatment vte #20
      dabigatran 150 #20
      absolute risk #20
      statin vte #20
      versions questionnaire #20
      life venous thrombosis #20
      injections subcutaneous #20
      abi measurement #20
      synthetic cross #20
      thrombosis ultrasonography #20
      diagnostic workup patients #20
      proteins thrombin #20
      new agent #20
      patients ddimer testing #20
      antitpo #20
      cancer severity #20
      portola #20
      anticoagulation clinic #20
      subsegmental #20
      symptomatic venous thrombosis #20
      impedance plethysmography ipg #20
      nadroparin #20
      compared ufh #20
      single criterion #20
      therapy rivaroxaban #20
      control situation #20
      shr 95 #20
      distance treatment #20
      residual venous #20
      thromb #21
      prothrombin 20210 #21
      hemostatic abnormalities #21
      treatment acenocoumarol #21
      concomitant anti #21
      disease ischemic #21
      occult malignancy #21
      ddimer concentrations #21
      deep venous #21
      vte patients #21
      patients 3 months #21
      doacs lmwhs #21
      distance quality #21
      thrombosis anticoagulants #21
      major bleeding patients #21
      discriminatory performance #21
      internists cardiologists #21
      venogram #21
      treatment apixaban #21
      fibrinolysis inflammation #21
      current standard treatment #21
      hemodynamically stable patients #21
      risk cohort study #21
      outcome incidence #21
      carriers noncarriers #21
      d‐dimer #21
      hormonal cross #22
      bleeding treatment #22
      patientyears #22
      acute vte #22
      host defense response #22
      ttr inr #22
      patients recurrent symptoms #22
      doppler venous thrombosis #22
      venous thromboembolic #22
      cttr #22
      public awareness #22
      time inr #22
      thrombophilia screening #22
      dichotomously #22
      dose subcutaneous #22
      daily enoxaparin #22
      safety treatment #22
      patients severe hf #22
      dimer age #22
      recurrent thromboembolism #22
      riskbenefit ratio #22
      vascular endotoxins #22
      anticoagulants humans #22
      alternative anticoagulation #22
      patients immobilization #22
      lpa plasminogen #22
      anticoagulants heparin #22
      treatment dvt #22
      cmax ctrough #22
      normal angiogram #23
      patients coagulation disorders #23
      vte studies #23
      clotbound thrombin #23
      percentage increase #23
      kakkar #23
      enoxaparin 40 #23
      thromboembolism anticoagulants #23
      venous arterial thrombosis #23
      011 #23
      cancer patients risk #23
      n1157 #23
      time platelet #23
      ambulatory cancer patients #23
      bidirectional relation #23
      direct factor inhibitors #23
      rivaroxaban dosing #23
      5392 #23
      2 investigators #23
      lower extremity amputation #23
      hasbled score #23
      elevated ctni #23
      development dic #23
      odis #23
      fondaparinux #23
      standardduration #23
      gentamicin patients #23
      recurrence venous #23
      prevalence venous thromboembolism #23
      life pulmonary embolism #23
      presence dvt #24
      fondaparinux placebo #24
      overt hyperthyroidism #24
      ddimer testing #24
      specific antidote #24
      recurrent pulmonary embolism #24
      bleeding complication #24
      a21gly #24
      therapy heparin #24
      patients severe bleeding #24
      patients acute treatment #24
      subtherapeutic #24
      followup incidence #24
      parameters fibrinolysis #24
      independent external validation #24
      patients abnormal perfusion #24
      desogestrel levonorgestrel #24
      recurrent thromboembolism patients #24
      rates venous thromboembolism #24
      ufh patients #24
      thrombosis carriers #24
      049 #24
      safety fondaparinux #24
      levels fviii #24
      prevalence deficiencies #24
      lowmolecularweight humans #24
      years episode #24
      predefined criteria #24
      viiic #24
      month incidence #24
      food drugs #24
      treatment symptomatic #25
      studies lmwh #25
      middeldorp #25
      expert radiologists #25
      thromboembolism acute #25
      fibrinogen degradation #25
      specificity efficiency #25
      perfusion lung scan #25
      factors anticoagulants #25
      patients gastrointestinal bleeding #25
      sepsis intravascular coagulation #25
      anatomical extent #25
      influence smoking #25
      vte clinical #25
      lmwh treatment #25
      fatima #25
      xii activity #25
      f1 2 levels #25
      amadeus #25
      willebrand factor adamts13 #25
      suggestions improvement #25
      cha2ds2vasc chads2 #25
      specificity negative predictive #26
      hormonal manipulation #26
      major bleeding bleeding #26
      rate recurrent vte #26
      rethoracotomy #26
      9715 #26
      venous thromboemboli #26
      edoxaban vka #26
      treatment lmwh #26
      homozygous carriers #26
      unprovoked vte #26
      dalteparin ufh #26
      doacs vitamin antagonists #26
      edoxaban versus #26
      parameters risk #26
      events year #26
      failure rate #26
      patients essential thrombocythaemia #26
      miscarriage stillbirth #26
      viia complex #26
      patients symptomatic dvt #26
      asymptomatic carriers #26
      ecq #26
      patients cdr #26
      thromboprophylaxis hospitalized patients #26
      training gps #27
      unprovoked venous #27
      anticoagulants blood #27
      enoxaparin female #27
      thrombosis venous #27
      extremity venous #27
      patients elevated levels #27
      vte thr #27
      patients 50 #27
      thrombocytopenia antibodies #27
      patients major hemorrhage #27
      airline pilots #27
      months studies #27
      lmwh prophylaxis #27
      venous thromboembolism carriers #27
      0·63 #27
      npv patients #27
      low molecularweight heparin #27
      thrombophlebitis #27
      combined training #27
      female heterozygote #27
      cancer spread #27
      vte doacs #27
      perfusion lung #27
      treating physician #27
      day 35 #27
      nonmajor #27
      noncarriers 95 #27
      current guidance #27
      lowmolecularweight heparin patients #27
      anticoagulants factor #27
      embolism retrospective #28
      hirudin therapy #28
      monitoring therapy #28
      rfviia placebo #28
      anticoagulation women #28
      vitamin aged #28
      patients unprovoked #28
      presentation followup #28
      pph severe pph #28
      tests diagnostic #28
      unexplained #28
      factors recurrent #28
      4650 #28
      #28
      specific reversal agent #28
      apc plasma #28
      pembqol #28
      acutely medical patients #28
      coagulation tissue factor #28
      vte 6 months #28
      anticoagulants compared #28
      objective tests #28
      receiving rivaroxaban #28
      cancer venous thromboembolism #28
      therapeutic doses #28
      diagnosis dvt #29
      years year #29
      patients standard therapy #29
      prediction scores #29
      pbac score #29
      patients avws #29
      dvt pulmonary embolism #29
      thrombosis 95 #29
      pulmonary angiography #29
      pulmonary embolism death #29
      septicemia #29
      major bleeding rivaroxaban #29
      dutch famine #29
      acenocoumarol patients #29
      aspirin placebo #29
      sex‐specific differences #29
      oral glucocorticoids #29
      heparin versus #29
      g20210a mutation #29
      aged morpholines #29
      spread cancer #29
      bleeding increased #29
      8240 #29
      pulmonary embolism recurrence #29
      recurrence svt #29
      cindexes #29
      current management strategies #29
      direct oral anticoagulants #29
      blind trials #29
      authors incidence #29
      aminoglycoside therapy #29
      plateletactivating antibodies #29
      dabigatran pcc #29
      thrombosis treatment #29
      thrombo #29
      resistance activated protein #29
      1000 individuals #29
      rule patients #30
      subcutaneous heparin #30
      residual thrombosis #30
      thromboembolism warfarin #30
      support techniques #30
      administration pentoxifylline #30
      vte coc #30
      95 risk #30
      f1 2 #30
      new anticoagulants #30
      costs diagnosis #30
      direct oral factor #30
      markers coagulation activation #30
      cancer venous #30
      doac vka #30
      ufh vte #30
      prevention venous #30
      patients vte #30
      xii factor #30
      1000 personyears incidence #30
      embolism risk #30
      prevalence probability #31
      rfviia novoseven #31
      ventilation scintigraphy #31
      incidence pph #31
      bled #31
      antithrombotic therapies #31
      rhir #31
      8755 #31
      thromboprophylaxis risk #31
      pharmacological prophylaxis #31
      0206 #31
      dvt pulmonary #31
      activation blood coagulation #31
      recurrent patients #31
      analysis reviewers #31
      ufh fondaparinux #31
      experimental endotoxemia #31
      recurrent vte patients #31
      2 antiplasmin #31
      incidence cteph #31
      extended prophylaxis #31
      iii activity #31
      placebo observation #31
      term risk #31
      patients deepvein thrombosis #31
      vte ufh #31
      inhibitor edoxaban #31
      apixaban placebo #31
      imaging sensitivity specificity #31
      women recurrent miscarriage #31
      events 95 #31
      recurrent episode #31
      thromboembolism adolescent #31
      dimer cutoff #31
      standardtherapy #31
      year 95 #32
      varicosis #32
      ufh #32
      negative septicemia #32
      warfarin vte #32
      normal genotype #32
      low clinical #32
      age adjusted #32
      suspected patients #32
      generation patients #32
      khorana score patients #32
      negative dimer #32
      factors thrombolytic #32
      factor female #32
      parenteral anticoagulants #32
      netherlands predictive #32
      treatment anticoagulants #32
      international society thrombosis #32
      parenteral anticoagulation #32
      leiden mutation #32
      resistance activated #32
      heparin lmwh #33
      warfarin risks #33
      mega study #33
      anticoagulant protein #33
      thromboembolism young #33
      rhirudin #33
      pulmonary angiogram #33
      additional tests #33
      apixaban treatment #33
      active implementation #33
      unitage #33
      data meta #33
      low probability #33
      cancer patients diagnosis #33
      activation factors #33
      factor viii patients #33
      subcutaneous male #33
      chapter patients #33
      prophylaxis vte #33
      nephrotoxicity gentamicin #33
      grade 1a #34
      subsegmental pulmonary embolism #34
      lmwh unfractionated heparin #34
      warfarin adult #34
      compare efficacy #34
      anticoagulant #34
      deficiency protein #34
      bilateral venography #34
      vte thrombophilia #34
      pregnancy loss women #34
      thrombosis lower #34
      9241 #34
      10 95 #34
      3 months treatment #34
      reocclusion patients #34
      phytonadione #34
      590 #34
      control trials #34
      plasmin alpha #34
      hemorrhage heparin humans #34
      apcsr #34
      vte compared #34
      enoxaparin prevention #35
      risk members #35
      patients efficiency #35
      pph blood loss #35
      surgery hip #35
      radiologists diagnosis #35
      rviia #35
      activation coagulation #35
      lung scanning #35
      neoplasms venous #35
      weekly subcutaneous #35
      statin association #35
      prevention model #35
      anticoagulants benzimidazoles #35
      embolism #35
      36 95 #35
      acute symptomatic #36
      fibrinogen depletion #36
      factors travel #36
      hellp patients #36
      dose reduction patients #36
      287 patients #36
      venous thromboembolic disease #36
      levels coagulation #36
      novoseven #36
      studies echocardiography #36
      4139 #36
      fibrinolytic activation #36
      catheterrelated infection #36
      viii levels #36
      1698 #36
      peripheral endovascular #36
      regular monitoring #36
      treatment acute vte #36
      inherited risk factors #36
      thrombophilia venous #36
      venous thromboembolism dabigatran #36
      riskbenefit #36
      iii antithrombin #36
      perelated mortality #37
      risk factors pts #37
      bagsvaerd #37
      venography #37
      suspected venous #37
      thrombosis humans #37
      anticoagulants prevention #37
      outcome composite #37
      factors thrombophilia #37
      screening occult #37
      anticoagulant action #37
      ototoxicity nephrotoxicity #37
      genotype 95 #37
      rivaroxaban thromboprophylaxis #37
      prophylactic heparin #37
      tat complexes #37
      pad studies #37
      recombinant hirudin #37
      risk venous thrombosis #37
      ctpa patients #37
      vte increased #37
      excluding #37
      lwmh #37
      magellan #37
      cumulative incidence vte #37
      warfarin 95 #37
      3306 #38
      catheterrelated thrombosis #38
      submassive pulmonary #38
      2835 #38
      rivaroxaban placebo #38
      congenital deficiencies #38
      coagulation protein #38
      nonmajor bleeding #38
      restenosis reocclusion #38
      vte cancer patients #38
      10 total #38
      fetal loss women #38
      doac lmwh #38
      patients ddimer levels #38
      sensitivity biomarkers #38
      recurrence day #38
      age recurrence #38
      anticoagulants female humans #38
      vte bleeding #38
      incidence cancer #39
      continued treatment #39
      enoxaparin placebo #39
      embolus #39
      low molecular weight #39
      heparins lmwhs #39
      time compression #39
      submassive #39
      superficial vein thrombosis #39
      fibrin fibrinogen #39
      277 patients #39
      diagnostic prediction #39
      compression stocking #39
      systemic inflammatory responses #39
      children familial hypercholesterolemia #39
      septic syndrome #39
      specificity patients #39
      subcutaneous intention #39
      incidence patients #39
      doacs #39
      ambulatory cancer #40
      standardized definition #40
      endotoxininduced #40
      arterial vascular #40
      anticoagulation therapy patients #40
      grade 1a patients #40
      fviiic #40
      pemb #40
      anticoagulant therapy #40
      clotting activation #40
      dalteparin treatment #40
      international clinical #40
      therapeutic dosages #40
      tfmp #40
      thrombinantithrombin complexes #40
      activatable fibrinolysis #40
      patients normal #40
      episode venous thromboembolism #40
      common femoral vein #40
      bleeding #40
      day 6 months #40
      pentasaccharides #41
      dabigatran etexilate #41
      lung scintigraphy #41
      calf vein thrombosis #41
      heparin therapy #41
      endotoxin induced #41
      submassive pulmonary embolism #41
      cancer lmwh #41
      95 genotype #41
      7268 #41
      triage tests #41
      risk recurrent vte #41
      lowmolecularweight heparins #41
      placebo 6 months #41
      anticoagulated patients #41
      patients vasopressors #42
      anticoagulation risk #42
      cell extravasation #42
      patients silent #42
      standardization committee #42
      type graft #42
      neoplasms thrombosis #42
      major contributor #42
      patients prospective #42
      prophylaxis venous #42
      8101 #42
      stroke thrombosis #42
      thrombosis administration #42
      netilmicin #42
      fetal loss #43
      patients vte risk #43
      warfarin anticoagulants #43
      543 patients #43
      monthly incidence #43
      initial treatment #43
      post‐thrombotic syndrome #43
      rtap #43
      heparin risk #43
      cancer adjusted #43
      venous thromboembolism vte #43
      venous thrombosis thrombophilia #43
      probability patients #43
      vkas patients #43
      ischemic events #43
      draft document #43
      patients tinzaparin #44
      restoration euthyroidism #44
      mild hyperhomocysteinaemia #44
      efficiency models #44
      indications patients #44
      95 pulmonary embolism #44
      recurrent vte 95 #44
      rate venous #44
      10–14 #44
      role coagulation #44
      protein sepsis #44
      factors thromboembolism #44
      nonvka oral anticoagulants #44
      edoxaban therapy #44
      20 30 #44
      uedvt patients #44
      expert physicians #44
      enoxaparin risk #44
      experimental venous thrombosis #44
      treated warfarin #45
      dose lmwh #45
      95 warfarin #45
      coumarin therapy #45
      oral direct #45
      fondaparinux patients #45
      revascularisation procedures #45
      wells score #45
      venous thrombotic #45
      dvt patients #45
      coagulation activation #45
      patients bnp #45
      years algorithm #45
      dose adjusted #45
      standard therapy #46
      treatment model #46
      stroke risk assessment #46
      prothrombin fragment f1 #46
      hospital outpatients #46
      patients unprovoked vte #46
      ruling #46
      abtpo #46
      ssc isth #46
      day levels #46
      management venous #46
      bleeding rivaroxaban #46
      healthcare settings #46
      extended duration #46
      pioped #46
      daily rivaroxaban #46
      major bleeding placebo #46
      percent confidence #46
      ambulatory anticoagulants #47
      boehringer ingelheim #47
      outcome vitamin #47
      iiia receptors #47
      central venous lines #47
      episode vte #47
      male methimazole #47
      new oral anticoagulant #47
      bristol myers squibb #47
      roccurve #47
      mutation pregnancy #47
      plasma ddimer levels #47
      mechanical prophylaxis #47
      thromboprophylactic #48
      subcommittee #48
      elevated plasma levels #48
      risk recurrent #48
      rivaroxaban compared #48
      intermediate risk risk #48
      fondaparinux heparin #48
      factors rivaroxaban #48
      small studies #48
      daiichi #48
      thrombotic burden #48
      recurrence venous thromboembolism #48
      patients pulmonary #48
      travel risk #48
      diagnosis physicians #48
      patients acute dvt #48
      rivaroxaban prevention #49
      vte diagnosis #49
      calf vein #49
      levels protein #49
      women aspirin #49
      lowmolecularweight heparin lmwh #49
      enoxaparin #49
      factor viii deficiency #49
      acute respiratory insufficiency #50
      prospective diagnostic #50
      incidence venous thromboembolism #50
      cardiac surgery mortality #50
      transient risk factor #50
      etexilate #50
      intensity treatment #50
      nonselective betablockers #50
      thromboembolism aged #50
      outpatient therapy #50
      treatment threshold #50
      atria patients #50
      buller #50
      vitamink antagonists #50
      dvt diagnosis #50
      protein deficiencies #51
      discrimination model #51
      95 apixaban #51
      acenocoumarol #51
      tomography pulmonary #51
      patients 11 #51
      effects coagulation #51
      normal perfusion #51
      strategies treatment #51
      global disease #51
      previous survey #51
      factor vte #51
      hematologic malignancies patients #52
      patients comorbid conditions #52
      pdvt #52
      svt patients #52
      inhibitors heparin #52
      unnecessarily #52
      doacs vka #52
      free thyroxine ft4 #52
      lmwh fondaparinux #52
      risk venous thromboembolism #52
      3 month #52
      apixaban vte #52
      vte major bleeding #52
      lung scans #52
      1·12 #52
      versus enoxaparin #53
      thromboembolism prevention #53
      absolute risks #53
      patients initially #53
      thrombophilic factors #53
      warfarintreated patients #53
      reported incidence #53
      postthrombotic syndrome #53
      suspected venous thromboembolism #53
      479 patients #53
      1522 #53
      preference patients #53
      cross study #53
      40 daily #53
      hemostatic balance #53
      patients obese #54
      chads2 cha2ds2vasc #54
      familial thrombophilia #54
      2537 #54
      endocrine disorders #54
      antithrombotic drug #54
      034 #54
      acquired risk factors #54
      prethrombotic #54
      male pulmonary embolism #54
      pai1 levels patients #54
      378 patients #54
      bled score #54
      major bleeds #54
      patients incidence #54
      vte mortality #54
      thromboembolism death #54
      unfractionated heparin #55
      legs patients #55
      treatment thresholds #55
      compared lmwh #55
      dosereduction #55
      long term risk #55
      methods randomized #55
      rivaroxaban #55
      anticoagulants arthroplasty replacement #55
      unfractionated heparin ufh #55
      insurances #55
      proximal extent #55
      nondeficient #55
      biological pan #55
      vitamin warfarin #56
      time event #56
      major bleeding apixaban #56
      vte death #56
      level mortality #56
      preeclampsia hellp syndrome #56
      vasopressors #56
      deficiency prevalence #56
      enoxaparin patients #56
      seventh accp conference #56
      20210a #56
      weight heparins #56
      tromboembólica #56
      physicians guidelines #56
      risk major bleeding #56
      inr values #56
      venous outflow obstruction #56
      reduced capacity #56
      enoxaparin rivaroxaban #56
      ctscan #57
      clinical models #57
      inhibitors female humans #57
      calf dvt #57
      risk factors vte #57
      subsegmental pulmonary #57
      antithrombin iii heparin #57
      levels survival #57
      inhibitors female #58
      unfractionated heparin patients #58
      fibrinolysis humans #58
      ruled #58
      spiral computed #58
      lowmolecular weight heparin #58
      thrombin activatable #58
      malignancy mortality #58
      pharmo #58
      doacs patients #58
      mutation prothrombin #59
      factor generation #59
      risk periods #59
      clot lysis time #59
      safety warfarin #59
      bias trial #59
      acute venous thromboembolism #59
      warfarin treatment #59
      thrombosis aged #59
      risk vte #59
      incidence symptomatic #59
      aventis #59
      heterozygous factor #59
      direct oral #59
      risk factors sensitivity #59
      acute pulmonary embolism #60
      awareness risk factors #60
      women difference #60
      fixeddose #60
      pulmonary embolism 95 #60
      hemorrhage humans #60
      target inr #60
      constans #60
      anticoagulants treatment #60
      atrial fibrillation metaanalysis #60
      079 95 #60
      prevalence pulmonary #60
      pediatric venous thromboembolism #60
      long‐term treatment #61
      3633 #61
      free thyroxine #61
      rosendaal #61
      month surgery #61
      amuse #61
      association protein #61
      hypocoagulable #61
      dvt 95 #61
      cdr score #61
      tests prevalence #61
      benzimidazoles dabigatran #61
      perfusion ventilation #61
      250 patients #62
      procoagulant state #62
      activated partial #62
      combined contraceptives oral #62
      general practitioners patients #62
      ttr patients #62
      human endotoxemia #62
      post thrombotic #62
      273 patients #62
      informatizado #62
      protein fibrinogen #62
      patients administration #62
      rivaroxaban lmwh #63
      smoking smoking cessation #63
      treatment network #63
      physicians predictive #63
      revised geneva score #63
      injection endotoxin #63
      cvrs #63
      vte thromboprophylaxis #63
      common odds ratio #63
      venous thromboembolisms #63
      quantitative test #63
      management anticoagulation #63
      33 women #63
      factor leiden risk #63
      symptoms dvt #63
      women mutations #63
      acute pulmonary #64
      thrombophilic risk #64
      prior vte #64
      cancer noncancer patients #64
      dvts #64
      superficial vein #64
      selfadjustment #64
      oral thrombin #64
      factor inhibitors #64
      patients aortic valve #64
      blinded trial #64
      decision rules #64
      bleeding events patients #64
      vkas treatment #64
      heparin fondaparinux #64
      postthrombotic #64
      stroke thromboembolism #65
      prevalence abnormalities #65
      accuracy diagnostic tests #65
      treatment pad #65
      fvl vte #65
      ultrasonograms #65
      prothrombin g20210a mutation #65
      statin therapy risk #66
      elfa #66
      95 bleeding #66
      newer anticoagulants #66
      0 points #66
      rapid triage #66
      death classification #66
      dvt sensitivity #66
      female heparin #66
      risk factor thrombosis #66
      axa #66
      patients tertiles #67
      rate major #67
      patients factor #67
      atrial fibrillation stroke #67
      standard therapy patients #67
      apixaban #67
      1127 #67
      academic medical centre #68
      1894 #68
      05 95 #68
      perioperative blood #68
      ranging study #68
      20210g #68
      3594 #68
      patients bnp levels #68
      patients benefits #68
      fibrinolytic #68
      coagulation fibrinolysis #68
      thrombosis blood #69
      plasma interleukin #69
      postphlebitic #69
      suspected #69
      heparin ufh #69
      certoparin #69
      recurrent thrombosis patients #69
      justify #69
      enfermedad tromboembólica #69
      ionis #69
      elevated cardiac #70
      gramnegative sepsis #70
      ischemic events patients #70
      withhold #70
      rivaroxaban treatment #70
      α2ap #70
      thrombosis recurrence #70
      fixed dose #70
      major bleeding complications #70
      aged predictive #70
      8190 #70
      cutoff levels #70
      patients protein #70
      test patients #70
      vwfrco #70
      mantelhaenszel #70
      vte vka #71
      unfractionated #71
      thromboprophylaxis #71
      tests prospective #71
      plasminogen plg #71
      diagnostic sensitivity specificity #71
      clopidogrel placebo #71
      topic costs #71
      asymptomatic atherosclerosis #71
      levels vwf #71
      viia factor #72
      versus vitamin #72
      hf studies #72
      new anticoagulant #72
      antithrombin iii iii #72
      activation prothrombin #72
      ddimer values #72
      elevated factor #72
      patients lmwh #72
      overt hypothyroidism #72
      pooled rate #72
      trifurcation #72
      complications hematologic #72
      noacs #73
      12 months 95 #73
      analysis diagnostic #73
      reversal agent #73
      prolongations #73
      tomography spiral #73
      ingelheim #73
      ddimer measurement #73
      soluble fibrin #73
      2550 #74
      suspected dvt #74
      female hemorrhage #74
      5395 #74
      study selection #74
      carriers #74
      dvt study #74
      prethrombotic state #74
      1732 #74
      2124 #74
      experimental metastasis #74
      longterm risk #74
      proteins patients #74
      soluble thrombomodulin #74
      carotid femoral arteries #75
      selective factor #75
      thrombolytic therapy patients #75
      2904 #75
      incidence bleeding events #75
      retrospective follow #75
      1334 #75
      8492 #75
      postoperative dvt #75
      tests primary #76
      early time #76
      oral combined contraceptives #76
      angiography ctpa #76
      duration thromboprophylaxis #76
      risk thrombosis #76
      extended anticoagulation #76
      combined contraceptives #76
      factor xii deficiency #76
      thrombosis pregnancy #77
      social aspects #77
      boehringer #77
      individual patient #77
      p023 #77
      patients secondary #77
      elevated dimer #78
      arterial wall thickness #78
      unprovoked #78
      women thrombophilia #78
      ipg #78
      arterial thromboembolism #78
      20 daily #78
      female fibrinolysis #78
      suspected acute #79
      time therapeutic #79
      limulus test #79
      factor adult #79
      topic heparin #79
      humans pulmonary #79
      vte fvl #79
      2486 #79
      efficacy agents #79
      vkas #79
      validation models #80
      thromboembolism incidence #80
      alife #80
      heterozygous deficiency #80
      daily bid #80
      patient data #80
      sspe patients #80
      subhazard ratio #80
      95 05 #80
      bleeding mortality #80
      suspected cancer #80
      vte rate #80
      walking distance #81
      test evaluation #81
      vascular events #81
      knee arthroplasty patients #81
      weitz #81
      lmwh vte #81
      topic risk #81
      systemic inflammatory #81
      prothrombin complex concentrate #81
      outpatient basis #81
      thrombosis incidence #82
      thrombosis thrombophilia #82
      placebo women #82
      crnmb #82
      heparin prevention #82
      mammography patients #82
      symptomatic carriers #82
      thrombolytic drugs #82
      50 micrograms #82
      posthoc analysis #82
      clinical sign #82
      prospective validation #82
      common practice #82
      3month followup #82
      timeperiods #82
      elective coronary #83
      dimer patients #83
      patients thrombi #83
      2213 #83
      bistro #83
      287 #83
      inhibitor dabigatran #83
      bleeding women #83
      screening humans #84
      inhibitor rivaroxaban #84
      normotensive patients #84
      diagnostic outcome #84
      duration therapy #84
      healthcare setting #84
      inherited thrombophilia #84
      prophylactic dose #84
      heparin treatment #84
      anticoagulants antiphospholipid #85
      endotoxins #85
      thrombosis svt #85
      asymptomatic dvt #85
      normal levels #85
      peripheral vascular diseases #85
      antithrombin iii protein #85
      venous thrombosis patients #85
      major bleeding warfarin #86
      dabigatran vka #86
      elevated ddimer levels #86
      4576 #86
      10⁶ #86
      venovenous hemofiltration #86
      75 microg #86
      rhapc #86
      post‐hoc analysis #87
      clinical impact #87
      acute venous #87
      ≤50 #87
      obstetric patients #87
      95 100 #87
      patients 28 #87
      avws #87
      contact activation #87
      vidas #87
      4 points #88
      venographic #88
      lmwhs #88
      aged multicenter #88
      treatment incidence #88
      washout period #88
      internist #88
      3319 #88
      treatment statins #88
      cdr #88
      activation factor #88
      cytokine release #89
      beta blockers #89
      adequate treatment #89
      rates major bleeding #89
      vte venous thromboembolism #89
      matisse #89
      costs patient #89
      stroke bleeding #89
      ventilation lung #89
      smoking incidence #89
      severe hf #89
      safety noacs #89
      anticoagulants dabigatran #89
      ddimer #89
      reversal strategies #89
      tests test #89
      unexplained recurrent #89
      popliteal vein #90
      outweighs #90
      venous thrombosis risk #90
      vka dabigatran #90
      fibrinolytic factors #90
      thrombophilic risk factors #90
      pediatric venous #90
      2293 #90
      new patients #90
      primary thromboprophylaxis #90
      cdrs #91
      anticoagulants doacs #91
      thrombosis women #91
      60 95 #91
      20210 #91
      pyridines pyridones #91
      agents hemorrhage #91
      thromboembolism pregnancy #91
      inconvenience #91
      perfusion ratio #91
      prophylaxis incidence #92
      combined clinical #92
      thrombotic disease #92
      single intravenous #92
      rivaroxaban edoxaban #93
      incidence knee #93
      compression patients #93
      95 years #93
      scenario analyses #93
      anticoagulation reversal #93
      direct thrombin inhibitors #93
      hf severity #94
      test result #94
      patients symptomatic #94
      heparins #94
      children vte #94
      atherogenic lipid #94
      1027 #94
      125 patients #94
      vte surgery #94
      viia rfviia #95
      2 levels #95
      european consensus statement #95
      direct oral anticoagulant #95
      efficacy rivaroxaban #96
      6 12 months #96
      fondaparinux treatment #96
      randomised crossover study #96
      risk symptomatic #96
      symptomatic vte #96
      ddimer level #96
      xii deficiency #96
      invasive testing #97
      pyrazoles pyridones #97
      haemophilia patients #97
      fibrin generation #97
      doacs risk #97
      symptomatic pulmonary embolism #97
      tpa release #97
      studies evaluated #97
      abnormal perfusion #97
      difference rates #97
      hypercoagulable #98
      activated protein apc #98
      2875 #98
      simplify #98
      16slice #98
      pregnancy postpartum period #98
      major bleed #98
      essential thrombocythaemia #98
      supervised exercise therapy #98
      probast #99
      unselected #99
      risk arterial #99
      hirudin #99
      acute dvt #99
      perfusion scintigraphy #99
      lmwh warfarin #99
      2·0 #99
      previews #100
      3 trials #100
      gbd 2010 #100
      increasing levels #100
      doubleblind trial #100
      warfarin patients #100
      prevention recurrent #100
      fatty foods #100
      1116 #100
      patient groups #100
      morpholines #101
      factor viia #101
      factor vii factor #101
      aptts #101
      alternative diagnosis #102
      low pretest probability #102
      pts patients #102
      enoxaparin fondaparinux #102
      40 microg #102
      venous thromboembolism women #102
      265 patients #102
      338 #103
      cteph patients #103
      endogenous thrombin #103
      therapeutic consequences #103
      pregnancy puerperium #103
      adjudicated #103
      arthroscopic anterior #103
      doppler method #103
      assay variation #104
      oral factor #104
      term treatment #104
      diagnostic imaging humans #104
      heparin pregnancy #104
      fibrin degradation products #104
      recurrence women #104
      antithrombin iii #104
      apparent increase #104
      absolute increase #104
      separate analyses #104
      partial restoration #104
      embryo loss #105
      7 children #105
      conventional therapy patients #105
      1089 #105
      study total #106
      314 #106
      essentials #106
      thrombophilia #106
      elevated levels #106
      thrombosis age #106
      thromboprophylaxis patients #106
      blind double #106
      chest ray #106
      hospitalized patients hf #106
      2479 #106
      fibrinolytic systems #106
      definition classification #107
      vte risk #107
      thromboembolic #107
      topic recurrence #107
      ddimer levels #107
      survival cancer patients #107
      simplified version #107
      human volunteers #108
      noncancer patients #108
      patients cancer #108
      cardiovascular death stroke #108
      specific subgroups #108
      grade 1c #108
      post thrombotic syndrome #108
      anticoagulants cohort #109
      routine coagulation #109
      viia #109
      embolism treatment #109
      synthetic pentasaccharide #109
      1235 #109
      039 #109
      thrombin antithrombin #109
      500μg #109
      evaluation studies #109
      factor mutation #109
      inferiority trial #110
      cancer activity #110
      primary safety #110
      thrombosis treated #110
      subsequent pregnancy #110
      antiplasmin #110
      embolism quality #110
      vka doac #110
      obstetric complications #111
      siset #111
      negative predictive 100 #111
      comparison control #111
      anticoagulants biomarkers #111
      treatment risk factors #111
      predefined #111
      humans intermittent #111
      chromogenic #112
      patients ventricular dysfunction #112
      topic guidelines #112
      epidemiology risk factors #112
      patients 70 #112
      thromboembolic diseases #112
      publication anticoagulants #112
      efficacy prevention #112
      rivaroxaban enoxaparin #112
      recurrence treatment #112
      risk rivaroxaban #112
      emergency situations #112
      heterozygous carriers #113
      nonionic contrast #113
      inappropriate treatment #113
      patients nephrotoxicity #113
      lmwh risk #113
      metabolic response #113
      cancerassociated vte #114
      0·0 #114
      dialysers #114
      patients intermediate #114
      study centre #114
      total knee replacement #114
      postphlebitic syndrome #114
      393 #115
      patients recurrent #115
      fibrinogen vwf #115
      global public #115
      positive predictive values #115
      hyperhomocysteinaemia #115
      anticoagulants arthroplasty #116
      topic dabigatran #116
      computed tomography patients #116
      major bleeding 95 #116
      heparin warfarin #116
      life treatment #116
      women severe preeclampsia #116
      reference standard #116
      effects tnf #116
      agents heparin #116
      vte data #116
      2460 #117
      arthroscopies #117
      vte complications #117
      women caesarean #117
      protein inhibitor pci #117
      fibrinolytic parameters #117
      vte children #117
      protein resistance #117
      proximal dvt #118
      arterial thrombosis patients #118
      4118 #118
      2744 #118
      patients extensive #118
      autopsyconfirmed #118
      compression stockings #119
      compared warfarin #119
      incidence pulmonary embolism #119
      patients doac #119
      humans leg #119
      mortality diseases #120
      lactoferrin leukocyte #120
      months follow #120
      healthy humans #120
      thrombosis study #120
      previous vte #120
      rivaroxaban patients #120
      risk thromboembolism #120
      dabigatran factor #120
      acquired deficiency #120
      patients prostatic cancer #121
      thrombocytopenia thrombosis #121
      fatal pulmonary embolism #122
      oral hormonal #122
      studies venous #122
      anti factor #122
      patients 6 #122
      100 patients #123
      heparin hirudin #123
      heparin #123
      acute infection #123
      early dynamics #123
      minor bleeding #123
      placebo standard #123
      venous thromboembolism pregnancy #123
      factor xia #123
      vte lmwh #124
      association level #124
      atherogenic lipid profile #124
      statin risk #124
      thrombophilia pregnancy #124
      treatment data #124
      ft4 levels #124
      bayer #125
      thromboembolism recurrence #125
      peripheral arterial disease #125
      fibrinolysis inhibitor #125
      nonsignificantly #125
      intravenous heparin #125
      treatment indication #125
      skin perfusion #125
      puerperal disorders #125
      diseases mortality #125
      incidence thrombosis #125
      elevated liver enzymes #125
      doacs treatment #126
      upper extremity #126
      distal dvt #126
      unacceptably #127
      occurrence vte #127
      thromboprophylaxis lmwh #127
      performance scores #127
      patients ventilation #127
      marder #127
      patients permanent #127
      treatment months #128
      prevention #128
      patients conventional therapy #128
      venous thromboembolism risk #128
      50 age #128
      development vte #128
      resistance apc #128
      direct factor #128
      060 #129
      mortality cancer patients #129
      1041 #129
      riete registry #129
      elevated biomarkers #129
      ctrough #129
      day 10 #130
      internists #130
      220 #130
      plaster cast #130
      anticoagulants antithrombins #130
      hospital discharge records #130
      patients episode #130
      194 patients #130
      tests specificity #131
      pooled incidence #131
      long‐term clinical outcomes #131
      05 patients #131
      linear interpolation #131
      obviating #131
      hoc analysis #132
      rivaroxaban versus #132
      postpartum period women #132
      hypocoagulability #132
      enoxaparin treatment #133
      fxa inhibitors #133
      80 anticoagulants #133
      cha2ds2vasc #133
      started #133
      avidin #133
      direct inhibitors #133
      rco vwf #134
      embolism acute #134
      risk pad #134
      selectin levels #134
      pulmonary angiography patients #134
      instituted #134
      bnp concentration #135
      prevalence dvt #135
      activator plasminogen #135
      anticoagulant prophylaxis #135
      clinical prediction #136
      0056 #136
      severe pph #136
      months anticoagulation #136
      apixaban edoxaban #136
      thrombotic syndrome #136
      east asian patients #136
      followup patients #136
      factor prothrombin #137
      99 patients #137
      acquired thrombophilia #137
      point‐of‐care #137
      sequential application #137
      phase 3 trials #137
      diagnostic work #137
      2283 #137
      intravascular coagulation dic #138
      bleeding warfarin #138
      national guidelines #138
      studies mortality #138
      complete inhibition #138
      enhanced factor #138
      antidote #138
      patients comparison #139
      95 major bleeding #139
      2465 #139
      factor viii factor #139
      direct inhibitor #139
      3 weeks #139
      reproducibility risk #139
      risk fatal #139
      oral anticoagulant treatment #139
      human activated #140
      80 cohort #140
      20 iu #140
      distal deep #140
      dvt incidence #140
      vwf rco #140
      12 95 #140
      ottawa #140
      0114 #140
      antidotes #141
      thromboembolic disorders #141
      pharmacy records #141
      carriership #142
      thrombin potential #142
      points 95 #143
      ischaemic events #143
      jugular veins #143
      geneva #143
      active malignancy #143
      treatment pulmonary #143
      escherichia humans #143
      warfarin administration #143
      compared treatment #144
      management vte #144
      topic practice patterns #144
      postoperative venous #144
      fatal pulmonary #144
      pregnancy female humans #144
      doac treatment #144
      patient populations #145
      thrombosis model #145
      dose rivaroxaban #145
      hyperthyroxinemia #145
      filters venous #145
      serial testing #145
      referred patients #145
      death cancer patients #146
      protein factor #146
      derived microvesicles #146
      months treatment #146
      personal fees #147
      tissue factor pathway #147
      acute medical illness #148
      rebuttal #148
      antithrombotic drugs #148
      10 years patients #148
      intention treat #148
      2076 #148
      embolism diagnosis #148
      partial thromboplastin #148
      long‐acting #148
      procoagulant #149
      relevant publications #149
      0·45 #149
      diagnostic score #149
      vte hospitalization #149
      risk subgroups #149
      thrombocyte #149
      individual patient data #149
      dimer level #150
      humans injections #151
      enoxaparin unfractionated heparin #151
      additional imaging #151
      coagulation dic #151
      longterm treatment #152
      patients primary outcome #152
      bleeding patients #152
      continuous venovenous #152
      patient eligibility #152
      point systems #153
      extracorporeal circuit #153
      thrombosis prevention #153
      cardiopulmonary bypass surgery #153
      hypercoagulable state #153
      bleeding scores #154
      angioplasty patients #154
      direct thrombin #154
      dimer levels #154
      thrombosis factor #154
      active cancer #154
      activity mortality #154
      tomography patients #155
      curve sensitivity #155
      warfarin apixaban #155
      drug factor #155
      fiia #155
      states venous #155
      thromboembolic event #155
      daily oral #156
      patients gastrointestinal #156
      fvl #156
      vte treatment #156
      09 #156
      recurrent symptoms #156
      stockings #156
      coagulant activity #156
      enoxaparin dose #156
      cross‐sectional survey #157
      increased thrombin #157
      hemodynamically #157
      prophylaxis patients #157
      2126 #158
      months chemotherapy #158
      97 #158
      duration anticoagulation #158
      dfl #158
      underlying malignancy #158
      increased risk thrombosis #159
      adjusted relative risk #159
      plasma dimer #160
      thrombotic disorders #160
      guidelines prevention #160
      schering #160
      children fh #160
      120 minutes #160
      145 patients #160
      antithrombotic efficacy #160
      pvo #161
      prophylactics #161
      antagonists patients #161
      patients imaging #162
      incidence vte #162
      women time #162
      2206 #162
      lysine analogues #162
      strain gauge #163
      198 patients #163
      imaging test #163
      increased plasma levels #163
      coagulation blood #163
      lmwh therapy #163
      rates vte #163
      venous thrombus #163
      factors bleeding #163
      028 #164
      justified #164
      age comorbidity #164
      inborn humans #164
      observer variability #164
      subhazard #165
      patients enoxaparin #165
      relatives patients #165
      mutation factor #165
      pravastatin therapy #166
      microvascular thrombosis #166
      strategies patients #166
      stockings compression #166
      phlebography #166
      viii factor #166
      management venous thromboembolism #166
      thrombin venous #167
      recurrent thrombosis #167
      3658 #167
      ankle brachial abi #167
      syndrome pts #168
      cstatistics #168
      warfarin #168
      treatment 3 months #168
      current clinical practice #168
      cvcs #168
      double heterozygosity #168
      recurrent acute #168
      patients infections #169
      fold increased #169
      risk profile #169
      postthrombotic syndrome pts #169
      3 12 #169
      preexistent #169
      therapeutic range #169
      interobserver agreement #170
      thrombosis cancer #170
      postoperative blood loss #170
      cart patients #170
      heavy menstrual bleeding #170
      57 years #171
      aged algorithms #171
      adamts‐13 #171
      recombinant factor #171
      venous thrombotic events #171
      pulmonology #172
      risk factors patients #172
      patients blood transfusion #172
      vaginal bleeding #172
      antifibrinolytic #172
      clinical trials patients #172
      lmw heparin #172
      pulmonary #173
      inr #173
      bleeds #173
      hospitalized medical patients #173
      patients initial #174
      arterial occlusions #174
      laboratory monitoring #174
      clinically bleeding #174
      bleeding tendency #174
      vte common #175
      data control #175
      reocclusion #175
      arterial venous #175
      fragment 1 #175
      mitsubishi #177
      prothrombin #177
      picotamide #177
      intention analysis #178
      122 #178
      short‐ #178
      aspirin ticlopidine #178
      hyperthyroidism hypothyroidism #178
      noninferior #179
      concomitance #179
      baseline day #179
      vte event #179
      oral female humans #179
      thromboplastin time #180
      referral bias #180
      additional risk factors #180
      patients deficiency #180
      ventilation perfusion #180
      isth #180
      aged partial #181
      acute episode #182
      testing patients #182
      antithrombin #182
      painkillers #182
      patients major #183
      biological variation #183
      2–4 #183
      hyperhomocysteinemic #183
      risk bleeding #184
      incidental #184
      prognosis pulmonary #184
      n110 #184
      subsequent diagnosis #184
      thromboinflammation #184
      antithrombin iii atiii #184
      4150 #184
      pregnancy vte #184
      coagulation factors #184
      treat analysis #184
      deficient patients #185
      vte age #185
      anticoagulated #186
      patients thromboprophylaxis #186
      symptomatic #186
      live birth rate #186
      patients intensive units #186
      brain natriuretic #186
      studies heparin #186
      hemostatic effects #186
      antifibrinolytic agents #187
      patients haemophilia #187
      risk composite #187
      cutoff level #187
      safety apixaban #187
      absolute rate #188
      926 #188
      ratio inr #188
      prevalence cancer #188
      doacs vkas #188
      spontaneous rupture #188
      humans international #188
      willebrand factor antigen #189
      viia female #189
      64slice #189
      blood loss patients #189
      heparin administration #189
      clinical validity #189
      fibrinolysis #189
      riete #189
      patients netherlands #189
      ccus #190
      ischemic event #190
      thrombosis patients #190
      current views #190
      anticoagulant drugs #190
      venous outflow #191
      acute thrombosis #191
      07 #191
      gogh #191
      score patients #191
      attending physicians #191
      058 #192
      stroke systemic #192
      1495 #192
      endothelial cell activation #193
      coagulation assays #193
      blood coagulation #194
      070 #194
      prothrombin activation #194
      heparin patients #194
      anticoagulation #194
      recurrent ischemic events #195
      risk major #195
      antixa levels #195
      65 months #195
      antagonist treatment #195
      target range #195
      complications cardiovascular #196
      coagulation status #196
      abnormal test #196
      29 95 #196
      sew2871 #198
      difference treatment #198
      treatment groups patients #198
      vii rfviia #198
      ate #198
      vwf adamts13 #198
      coagulation monitoring #199
      patient diagnosis #199
      cachectin #199
      patients 12 months #200
      obese controls #200
      screening patients #200
      incidence cardiovascular events #200
      validation sets #201
      patients abnormal #201
      thrombin factor #201
      thromboembolic disease #201
      vte incidence #201
      peritoneovenous #202
      arterial thrombosis #202
      johnson #202
      17 95 #202
      heparin dose #203
      invitees #203
      symptomatic pad #203
      induced activation #203
      worldwide survey #203
      levonorgestrel #204
      antithrombotic agents #204
      period time #205
      low incidence #205
      extended thromboprophylaxis #205
      stroke systemic embolism #205
      thrombophilia risk #205
      0 95 #205
      fgt #206
      data synthesis #206
      patients anticoagulant therapy #206
      venous ultrasonography #206
      varese #206
      methods consecutive #207
      desogestrel #207
      06 #207
      platelet activation patients #207
      imt patients #207
      fviii #207
      systematic review studies #207
      algorithms anticoagulants #207
      objectively #207
      death female humans #207
      cardiologist #207
      bleeding compared #208
      patients hypothyroidism #208
      thrombocythaemia #208
      free protein #209
      deficiency risk #209
      women frequency #210
      tgt #210
      antixa activity #210
      hirudins #210
      systemic embolism patients #211
      toxaemia #211
      ioxaglate #211
      stocking #211
      anticoagulation management #212
      atrial fibrillation study #212
      plasminogen activator activity #213
      heparitin sulfate #213
      topic practice #214
      correct interpretation #214
      dabigatran dose #214
      current developments #215
      factors vte #215
      thrombin inhibition #215
      studies rivaroxaban #215
      standard duration #215
      betatg #216
      deamino #216
      community hospital #216
      duplex venous #216
      warfarin stroke #216
      diagnostic algorithm #217
      studies difference #217
      mildest #217
      obviates #217
      undergoing total #217
      npv 100 #218
      conclusive evidence #218
      cstatistic #218
      plasminogen activator inhibitor #218
      g20210a #218
      cancer #219
      patients cart #219
      deamino arginine #219
      077 95 #219
      hip replacement surgery #220
      vii factor #220
      techniques female #220
      viii female #220
      data extraction #220
      preventive measures #221
      heparin humans #221
      postoperative vte #221
      healthy human subjects #221
      hmvec #221
      vte events #222
      apc resistance #222
      proximally #222
      engl #223
      substantial proportion #223
      pulmonologists #223
      1 january #223
      1541 #223
      thromboendarterectomy #224
      protein pathway #224
      topic factor #224
      subsequent cancer #224
      neoplasms prospective #225
      balloon coronary anticoagulants #225
      kruskalwallis #225
      thrombosis warfarin #225
      org #225
      0·67 #226
      vascular events patients #226
      16 95 #226
      extremity amputation #226
      inr monitoring #226
      haemostasis #227
      35 ± #227
      acute medical #227
      tests diagnosis #227
      ipe #228
      mild hyperhomocysteinemia #228
      dalteparin #229
      cgp #229
      scant #229
      residual thrombus #229
      037 #230
      advocated #230
      severe preeclampsia #231
      patients discontinuation #231
      ft4 #231
      habitual abortion #231
      6 studies #231
      equinox #231
      thiazoles #231
      urosepsis #231
      major orthopaedic surgery #231
      resource utilisation #231
      patients warfarin #232
      aspirin dipyridamole #232
      anticoagulant effects #233
      dimer #233
      cancer prevalence #233
      surgical embolectomy #233
      humans netherlands #233
      recurrence risk factors #233
      endogenous thrombin potential #233
      effective alternative #234
      prothrombotic state #235
      doac #235
      graduated compression #235
      humans meta #236
      venous thromboembolic events #236
      brain natriuretic peptide #236
      myocardial infarction 95 #237
      oral anticoagulants #237
      treatment continuation #237
      6500 #238
      predictive tests #238
      009 #238
      patients vkas #238
      factor tnf #239
      anticoagulants aspirin #239
      factor viii fviii #239
      crossover study #239
      rational approach #239
      arterial venous thrombosis #240
      patients initial treatment #240
      045 #241
      hip knee arthroplasty #241
      aspirin heparin #241
      time therapeutic range #242
      bleeding incidence #242
      prothrombin fragment #243
      pivotal trials #243
      patients intermittent claudication #243
      iohexol #244
      vte risk factors #245
      n89 #245
      casecontrol #246
      vte cases #246
      children neonates #246
      thrombogenesis #246
      23 95 #247
      antithrombotic #247
      lipoproteina levels #247
      warfarin aged #247
      treatment compared #248
      committees #248
      patients solid tumours #248
      coronary anticoagulants #248
      anti activity #248
      diagnostic models #249
      bleeding rates #249
      score risk #249
      multiple comorbidities #249
      ischemic strokes #250
      protein risk #250
      fv leiden #250
      ioxaglic #250
      8595 #251
      finalized #251
      patients contraindications #251
      microthrombosis #251
      vkas doacs #252
      somit #252
      simplification #252
      thrombin thrombosis #253
      incidence #253
      agents anticoagulants #254
      treatment duration #254
      palga #255
      fibrinolytic activity #255
      medea #256
      activation humans #256
      haul #256
      bleeding risk #257
      activity assay #257
      clinical utility #257
      continuous intravenous #257
      cost‐effectiveness #257
      q24h #257
      fibrin degradation #258
      ctpa #258
      patient subgroups #258
      30 50 #259
      unpublished data #259
      dvt risk #260
      sspe #260
      noncarriers #261
      thrombus size #261
      toxicosis #261
      heparin dosing #261
      patients hospitalization #262
      optimal duration #263
      risk pulmonary #263
      blind study #264
      graft type #265
      400 patients #266
      einstein #267
      pbac #267
      statins risk #268
      endotoxaemia #268
      malignancy patients #269
      randomised cross #269
      relation time #269
      versus aspirin #269
      propeptide #269
      lysis time #269
      discontinuing #270
      protein patients #270
      single test #270
      exclusion #270
      protein apc #271
      platelet serotonin #271
      hormonal replacement therapy #271
      orthopaedic patients #271
      thrombosis inflammation #271
      3·0 #271
      clopidogrel ticlopidine #272
      vte recurrence #272
      bleeding patient #272
      patients combination #272
      groups levels #272
      efficacy analysis #273
      ankle brachial #273
      months 12 #274
      cleavage sites #274
      prevalence pad #274
      risk levels #274
      parenteral nutrition patients #275
      performance score #275
      international normalized #275
      fourth quartile #276
      antithrombotic agent #276
      smoking hypertension #277
      time aptt #277
      dose reduction #278
      imaging sensitivity #278
      normalized ratio #278
      blood test #279
      rco #279
      aptt #279
      intracranial hemorrhage patients #280
      hospitalized medical #280
      propositi #280
      partial thromboplastin time #280
      obviate #280
      exclusion criteria #280
      patients presence #281
      diagnostic test #282
      thromboplastin #282
      thyroid diseases #283
      neutrophil degranulation #283
      presentation patients #283
      diagnostic sensitivity #283
      puerperal #283
      outpatient treatment #284
      test characteristics #284
      noninferiority margin #284
      favor #284
      departments #284
      animals anticoagulants #284
      major orthopaedic #285
      patients apixaban #286
      2630 #286
      plasma bnp #286
      gentamicin treatment #286
      disseminated intravascular #287
      clinically #287
      patients pancreatic cancer #287
      levels measured #287
      subdistribution #287
      oral combined #288
      md patients #288
      227 #288
      premature atherosclerosis #288
      cvt patients #289
      clot lysis #289
      vte women #289
      substantiation #289
      vte rates #289
      n59 #290
      thrombin time #290
      0·50 #290
      016 #291
      oral contraceptives #291
      current clinical #291
      extracted data #291
      carriers mutation #291
      activator inhibitor #292
      willebrand disease vwd #292
      2 studies #292
      1603 #292
      pentasaccharide #293
      patients dabigatran #293
      1000 personyears #293
      plasmin activity #293
      adverse outcome patients #293
      cardiac troponin ctnt #294
      tissuetype plasminogen activator #294
      lower extremities #294
      patients rivaroxaban #294
      1025 #295
      extremity dvt #295
      scenario analysis #295
      classified #296
      coagulation factor viii #296
      peripheral vascular #296
      observer agreement #297
      routine monitoring #297
      recurrent miscarriage #298
      episode patients #298
      specificity npv #298
      thrombocytes #298
      patients inr #299
      inferiority #300
      041 #301
      heparitin #301
      subclinical thyroid dysfunction #302
      155 patients #302
      toxemia #302
      thromboglobulin #302
      aged neoplasms #302
      1214 #304
      absolute difference #304
      rivaroxaban dabigatran #305
      medline embase #306
      prophylactic administration #306
      chimpanzees #307
      noninvasive testing #308
      complex concentrate #309
      vte pregnancy #310
      thrombotic #310
      surgery day #310
      hematologic pregnancy #310
      patients 100 #311
      clinical presentation #311
      105 patients #311
      antithrombins blood #311
      percentage points #311
      leg male #312
      598 #312
      obesity risk factor #313
      hereditary thrombophilia #313
      negative reactions #313
      vte 95 #313
      diagnosis #314
      funding #315
      puerperium #315
      postpartum haemorrhage #315
      cardiologists #315
      heparin aspirin #315
      apixaban versus #316
      therapeutic dose #316
      patients followup #317
      adjudicators #317
      deciding #318
      0·92 #318
      failure rates #319
      decision model #319
      safety outcomes #319
      bnp levels #320
      1731 #320
      patients pregnancy #320
      influenza infections #320
      catheter thrombosis #320
      combined administration #320
      ventricular dysfunction patients #321
      patients noacs #322
      intermediate phenotype #322
      additional data #322
      difference risk #322
      inrs #324
      glaxosmithkline #324
      peripheral arterial #324
      convincing evidence #325
      mortality odds ratio #325
      mechanical heart valves #326
      blood coagulation factor #326
      pulmonary embolus #326
      122 patients #326
      clinical #327
      surgery trauma #327
      association vte #329
      thrombotic event #331
      pregnancy outcome women #331
      incidence bleeding #331
      vitamin administration #331
      new oral #332
      embase databases #333
      analysis trials #333
      n69 #333
      95 percent #333
      complicate #334
      incidences #334
      95 confidence limits #334
      minor effects #334
      patients healthy volunteers #335
      fibrillation benzimidazoles #335
      rationale design #335
      central venous catheter #336
      pulmonary perfusion #336
      septicaemia #336
      total hip replacement #337
      recurrent #337
      plethysmographic #337
      2 points #337
      035 #337
      065 #337
      fatal bleeding #338
      coagulation abnormalities #338
      outpatient management #338
      aged netherlands #338
      noacs warfarin #339
      prospective clinical study #339
      placebo trials #339
      024 #340
      antithrombotic effects #340
      patients 12 #340
      activatable #341
      217 #341
      coagulation markers #341
      noac patients #342
      knee arthroscopy #342
      patients covid19 infection #344
      pretest #344
      vte prevention #345
      rfviia #345
      antithrombotic strategies #345
      splanchnic vein thrombosis #345
      diagnosis vte #346
      embolisms #346
      patients thrombosis #347
      activated protein resistance #347
      073 #347
      cochrane central #348
      044 #348
      chads2 #349
      2575 #349
      bsf #349
      tafia #350
      trousseau #350
      randomized studies #350
      brain predictive #350
      versus warfarin #351
      013 #351
      factor viii #351
      factor activation #352
      dermatan sulphate #352
      anticoagulants noacs #352
      selection bias #352
      vein #353
      1590 #353
      oral anticoagulant therapy #353
      relative efficacy #353
      5075 #353
      international normalized ratio #354
      aged pulmonary #354
      patients gp #355
      studies diagnostic accuracy #355
      protein deficiency #356
      post hoc #357
      tests prospective studies #357
      intestinal microbiome #357
      categorised #357
      127 patients #358
      pilots #360
      sucra #360
      intermittent claudication #361
      consensus agreement #362
      treatment risk #362
      anticoagulation patients #364
      conventional therapy #365
      humans risk #365
      bleeding rate #366
      topic female #366
      prediction models #367
      time recurrence #368
      patients 3 #368
      infrainguinal #368
      thrombin inhibitor #369
      6week #370
      patients acl reconstruction #370
      influenza infection #370
      endotoxin infusion #371
      venous stasis #371
      055 #372
      803 #372
      patients svt #373
      recombinant activated #373
      clinical suspicion #373
      knee surgery #373
      aprotinin blood #373
      patients scores #374
      human cytomegalovirus infection #374
      helical computed tomography #374
      hmb #375
      subcutaneous #375
      lyg #377
      subclinical hyperthyroidism #378
      stroke venous #380
      contraceptives oral #380
      ethinyloestradiol #381
      tafi #381
      antitnf #382
      prefilter #383
      standardized questionnaire #384
      0·8 #384
      reassessed #384
      thromboembolic complications #384
      multivariate regression analysis #384
      alpha2m #385
      systemic activation #385
      surrogate outcome #386
      conference proceedings #386
      bleeding events #386
      cumulative incidences #387
      antithrombins #387
      sensitivity npv #387
      major orthopedic #388
      delegates #388
      880 #389
      referred #389
      safety rivaroxaban #389
      systemic embolism #389
      vitt #390
      tinzaparin #390
      apixaban warfarin #390
      drug prescription #391
      comparison patients #391
      increased bleeding #391
      biosis #391
      postop #391
      abi #391
      time presentation #392
      patients chest #392
      topic female humans #392
      factors thrombosis #393
      kappa values #393
      pulmonary emboli #394
      injections intravenous #394
      background patients #394
      clinical score #394
      007 #395
      popliteal #396
      95 12 #396
      bleeding event #396
      factors factor #397
      665 #397
      hirudins humans #397
      replacement surgery #397
      embolic events #397
      risk score patients #399
      heparin induced #400
      risk factors asthma #400
      patients risk #400
      echography #400
      hemostatic parameters #401
      fibrinolytic agents #402
      dabigatran #403
      increased risk vte #403
      controversy #403
      massive pulmonary embolism #405
      2215 #406
      thrombolytic agents #406
      treatment patient #406
      075 #406
      oral anticoagulant #408
      factor levels #408
      biologic effects #410
      fviii levels #411
      safety combination #411
      noacs patients #411
      patients assigned #411
      major risk factor #412
      transfusion patients #412
      20 microg #412
      coagulation patients #414
      maastricht #414
      euthyroidism #414
      aged odds #415
      hypocortisolism #415
      xii #415
      pai1 levels #416
      deserve #416
      intravascular coagulation #416
      dose heparin #416
      data risk #417
      comparable #417
      95 10 #417
      95 #418
      carotid femoral #418
      pretest probability #418
      risk factors thrombosis #419
      dermatan #419
      269 #419
      ototoxicity #420
      xia #420
      fibrillation risk #421
      2850 #422
      tests radiography #422
      fibrillation clinical #422
      1989 #422
      fibrinolysin #423
      subanalysis #424
      fviia #424
      prevalence patients #425
      adjunct #426
      randomised double #426
      fii #426
      cancer cohort #426
      consecutive #427
      activated factor #427
      plg #428
      excessive bleeding #428
      conferences #428
      daily practice #428
      undergoing elective #429
      prolactin levels #429
      patients testing #429
      idiopathic myelofibrosis #429
      daily clinical practice #429
      1904 #430
      rule #431
      heparinoids #431
      bleeding complications #431
      04 #432
      incidence length #433
      outpatients #433
      patients systematic review #434
      ncb #434
      firstdegree relatives patients #436
      blood cultures #436
      bolus injection #437
      059 #437
      prostatic cancer #439
      composite point #439
      dose adjustment #439
      women compared #439
      proven #439
      concomitant medications #441
      highrisk populations #441
      rate vte #442
      074 #442
      –control study #444
      standard therapies #444
      prespecified #445
      febrile patients #446
      patients atrial fibrillation #446
      female fibrinolytic #447
      hellp #449
      58 #449
      patients parenteral nutrition #449
      utrecht #449
      3 12 months #450
      prevalence distribution #450
      category #451
      stigmatisation #451
      pipecolic #452
      thrombin generation #453
      noninvasive tests #453
      fatal disease #453
      aspirin risk #453
      portal blood #454
      30 40 #454
      placebo day #454
      factor xii #454
      12week #455
      026 #455
      microthrombi #455
      fviii vwf #456
      dichotomized #456
      squibb #457
      onwards #457
      dicumarol #457
      anti levels #458
      hazard ratio 95 #458
      iii complexes #458
      svt #460
      recommend #460
      plasma lipoprotein #460
      gastrointestinal cancer #461
      factor fxa #461
      hip arthroplasty replacement #462
      expert consensus document #462
      curve biomarkers #462
      haemolysis #463
      guidelines patients #463
      gp iib #464
      patients values #464
      studies ultrasonography #464
      month follow #465
      cancerassociated thrombosis #466
      diabetes stroke #466
      accuracy detection #467
      thrombin formation #467
      intimamedia thickness #468
      patients nsaids #468
      prophylaxis #468
      eligible studies #469
      bmi≥30 #469
      teaching hospitals #469
      inr patients #470
      077 #470
      test probability #470
      hemihepatectomy #470
      roc analysis #470
      placebo recipients #471
      hypercoagulability #472
      case control study #472
      prophylactic anticoagulation #472
      cardiovascular risk assessment #473
      thrombophilia testing #474
      intermittent pneumatic #475
      15 95 #475
      endotoxemia #475
      heterozygote humans #475
      patients heparin #475
      plethysmograph #475
      atria #477
      haemophiliacs #479
      08 #479
      patients score #479
      versus standard #480
      thrombosis cvt #481
      acutely #481
      hit patients #481
      postoperative blood #482
      transportability #482
      advisory #482
      1162 #482
      thrombin inhibitors #483
      events mortality #484
      patients hematologic malignancies #485
      diagnostic efficacy #485
      awaited #486
      secondary prophylaxis #487
      composite scores #487
      silent #488
      travel #488
      activity patients #489
      98 #490
      blinded #491
      treatment period #493
      new therapy #493
      p00007 #493
      pan troglodytes #493
      residual risk #493
      hemophilic #493
      vcf #494
      activated protein #495
      heterozygote #496
      favour #496
      replacement hip arthroplasty #496
      dose oral #496
      topic risk factors #497
      271 #497
      willebrand disease #498
      risk factors stroke #498
      discriminative ability #498
      blockages #498
      hip knee #501
      nri #502
      ptp #502
      ft4 tsh #503
      subcategories #503
      deficiencies #503
      rapid decrease #504
      nondiagnostic #505
      complications pulmonary #505
      1107 #505
      patients referred #505
      310 #506
      net clinical #506
      oftentimes #507
      nonionic #507
      day surgery #507
      inhibitors rivaroxaban #508
      contraceptives #509
      13 95 #509
      aminocaproates #509
      coagulation tests #509
      guidelines diagnosis #509
      degradation products #510
      new oral anticoagulants #510
      angiography patients #510
      thrombosis animals #510
      viii fviii #511
      epiphenomenon #512
      019 #512
      serial #513
      056 #514
      highintensity #514
      interim analysis #514
      daycare #515
      safety #516
      crcl #517
      thrombophilia thrombosis #518
      protein antithrombin #518
      bleeding outcomes #518
      thrombotic diseases #518
      sensitivity diagnosis #518
      groups treatment #519
      treatment cancer patients #519
      study sensitivity #520
      1599 #521
      duration intensity #521
      8090 #521
      warfarin therapy #524
      general practitioner #525
      fixed doses #525
      062 #527
      cancer age #528
      cindices #528
      051 #529
      convincing #529
      378 #529
      923 #529
      fatal #530
      health female #530
      thrombosis hemostasis #531
      betaalanine #531
      medically patients #531
      humans postoperative #531
      intensive units icu #532
      068 #532
      ≥50 years #532
      thrombosis risk #532
      factor thrombin #534
      therapy cancer #534
      730 #536
      factor pathway #537
      humans neoplasms #538
      449 #538
      patients idiopathic #538
      concise #539
      ddavp #539
      comprehensive search #539
      cbo #539
      clinical review #540
      diagnosis acute #540
      diagnostic accuracy studies #540
      234 #543
      vascular obstruction #543
      patients eligible #543
      thrombotic risk #543
      bleeding episodes #543
      conventional treatment #543
      pad abi #544
      jak2 mutation #544
      coagulative #544
      00 #544
      prospective cohort study #545
      perc #545
      hellp syndrome #545
      v617f #545
      screening strategies #546
      association statin #546
      bureau #547
      prothrombin complex #547
      primary #548
      adequate #549
      95 difference #549
      overt #549
      reviewers #550
      1103 #550
      percent patients #550
      cancer type #550
      platelet inhibitors #550
      conduction anesthesia #550
      day patients #552
      amsterdam #552
      studies sensitivity #552
      500 patients #552
      careful #552
      management bleeding #552
      femoral arteries #553
      general population patients #554
      ttr #556
      humans infusions #557
      factor vii #558
      66 patients #558
      vivo treatment #558
      orthopedic surgery #559
      bleeding time #559
      limulus #561
      patients transfusion #563
      female humans tests #563
      board directors #563
      risk development #563
      anamnesis #564
      hip replacement #564
      appears #564
      increasing risk #565
      hyperfibrinolysis #565
      solid tumours #566
      cardiac troponins #566
      withholding #566
      roc curves #568
      n46 #568
      patients 2 years #568
      levothyroxine #571
      alpha1antitrypsin #571
      aggravation #572
      ctnt #573
      cutoff point #574
      revascularization procedures #574
      menstrual bleeding #574
      subcutaneously #575
      women proportion #575
      major bleedings #575
      progression cancer #577
      patients vka #578
      endothelial barrier #578
      thiophenes #579
      endotoxin #579
      pharma #579
      diagnostic tools #580
      notice #580
      99 #580
      cancer thrombosis #581
      subgroups patients #583
      unselected patients #584
      dummy #584
      094 #585
      coagulation disorders #585
      chondroitin sulfates #586
      major orthopedic surgery #588
      feasibility safety #588
      helminth proteins #589
      healthy human #590
      thrombophilias #590
      malignancy #590
      reversal agents #590
      beta alanine #590
      doppler ultrasound #592
      conventional management #592
      massive pulmonary #592
      bmi30 #594
      factor fv #595
      severe bleeding #597
      major hemorrhage #597
      replacement knee #597
      patency rates #597
      ldf #597
      infusions intravenous #598
      analysis topic #599
      tests sensitivity #600
      loss surgical #600
      046 #601
      association patients #602
      vwd #603
      events occurred #604
      comorbid conditions #604
      clinical characteristics patients #604
      diagnostic studies #606
      patients antibodies #607
      initial increase #607
      activated coagulation #607
      0·3 #607
      treatment acute #608
      tissue factor #609
      pfizer #609
      arbitrage #609
      100 years #610
      benefit risk #610
      airline #610
      patients death #610
      clinical evaluation #611
      ultrasonography #613
      coagulation inflammation #614
      patients bariatric surgery #615
      reluctant #615
      leg #615
      complications risk #616
      arterial disease #617
      treatment rivaroxaban #617
      occurred #618
      467 #618
      stroke atrial fibrillation #618
      fh patients #620
      compared placebo #620
      patients elevated #621
      advisory committees #621
      1002 #622
      thyrotoxic #623
      sgs #623
      thrombocytopenia hit #623
      peptide bnp #625
      cochrane central register #625
      topic practice guidelines #626
      stopped #626
      stroke warfarin #627
      warfarin risk #628
      66 #628
      5000 #628
      women risk factors #628
      physical training #629
      referral patients #629
      human subjects #629
      diagnostic algorithms #629
      absolute #630
      sanofi #630
      atiii #632
      risk treatment #633
      screening strategy #634
      uneventful #635
      outweigh #635
      pentoxifylline #637
      travelling #638
      95 allcause mortality #640
      14 95 #640
      proceedings #641
      study quality #641
      predictive performance #642
      3050 #642
      neutrophilia #643
      threatening bleeding #643
      association mortality #647
      primary outcome measure #647
      statin treatment #648
      studies efficacy #648
      necessitating #648
      thrombolysis patients #651
      fixed #651
      036 #651
      organisations #652
      troglodytes #652
      fxa #653
      hemorrhagic stroke #653
      127 #655
      patients review #657
      69 #659
      bleeding death #659
      coronary stent implantation #659
      haematoma #660
      physical examination #661
      coagulation proteins #661
      tertiles #661
      clinical presentations #662
      haemophilia #662
      95 studies #663
      1028 #663
      long term treatment #664
      provoked #664
      sepsis shock #665
      deep #666
      phase iii studies #666
      presence patients #667
      onethird #667
      patients completed #667
      guideline adherence #667
      male medical #668
      8 wk #669
      1110 #671
      phenprocoumon #672
      patients cteph #673
      elevated plasma #673
      hospitalization hf #674
      managing #674
      il6 levels #675
      inhibitor 1 #675
      clotting factors #675
      highincome countries #676
      prothrombotic #676
      asymptomatic subjects #677
      favourably #678
      jugular #679
      medicine humans #681
      pulmonary endarterectomy #681
      suspicion #682
      conclude #687
      apolipoproteina #688
      efficacy safety #690
      ambulatory patients #692
      patients bleeding #692
      myocardial infarctions #693
      graduated #693
      activator pa #693
      composite outcome #694
      intracranial bleeding #694
      administer #694
      precise mechanisms #694
      1718 #695
      combined oral contraceptives #696
      stroke prevention patients #696
      moyamoya #696
      participant data #698
      ratio male #698
      difference 95 #698
      compression devices #700
      episode #700
      prothrombin gene #702
      therapeutic management #702
      diagnostic errors #702
      veins venous #703
      patients confirmed #703
      surgery risk #703
      willebrand #704
      data incidence #706
      subclinical hypothyroidism #708
      directors #709
      clinical expression #709
      starters #711
      gastrointestinal bleeding #712
      gynaecology #712
      medical patients #712
      048 #712
      radionuclide imaging #713
      1098 #714
      neurosurgical patients #714
      rate death #714
      intravenous bolus #715
      menstrual period #716
      rivaroxaban stroke #716
      cancer groups #717
      adequately #717
      10 30 #718
      solid cancer #718
      falsely #718
      reagent kits #719
      plasminogen #719
      pulmonary medicine #720
      clinical judgment #721
      accp #721
      pyrazoles pyridines #721
      nordisk #721
      s1p1 #722
      95 hazard ratio #724
      abnormal #726
      follow period #726
      gentamicins #727
      59 patients #727
      orthopaedic surgery #728
      diagnostic therapeutic #728
      diagnostic tests #730
      leeches #732
      gentamicin #732
      oral contraception #733
      tumor necrosis factor #733
      relative risk 95 #734
      patients levels #735
      hull #735
      disease pad #735
      clinical prediction rule #736
      tests retrospective studies #736
      atrial fibrillation risk #736
      6 12 #739
      post hoc analysis #739
      anti tnf #740
      evaluable patients #741
      040 #742
      unclear #742
      early pregnancy loss #742
      topic predictive #743
      illness time factors #744
      betathromboglobulin #744
      molecular weight #744
      285 #746
      antithrombin activity #746
      patients 50 years #746
      etp #746
      leukocyte activation #748
      thrombolytic therapy #749
      hospitalization heart failure #750
      indication #752
      fibrin formation #754
      advisable #754
      primary patients #755
      pneumatic compression #756
      95 combination #756
      answer #756
      hf risk #756
      95 risk factors #756
      venovenous #757
      1·7 #758
      loe #759
      85 #759
      inflammation coagulation #760
      patients peripheral #761
      435 #763
      proportion women #763
      start treatment #764
      cprs #764
      hip surgery #765
      689 #767
      aspirin clopidogrel #767
      risk pregnancy #767
      732 #768
      method drug #769
      groups patients #770
      566 #770
      relevant #770
      graft patency #772
      baseline values #772
      patients criteria #773
      subcutaneous injections #774
      bmi patients #774
      1·5 #776
      992 #777
      dose warfarin #778
      patients 65 years #778
      study groups #778
      dose intravenous #778
      miscarriage #779
      patients hyperthyroidism #780
      thromboembolism prophylaxis #780
      066 #780
      plasmin generation #780
      age ≥ #782
      onefifth #785
      factor ixa #785
      abnormalities patients #786
      100 personyears #787
      polypharmacy #787
      topic disease models #787
      general practitioners #787
      cteph #787
      preferable #788
      secondary outcome #791
      recombinant tissue #793
      mechanical heart #793
      inactivators #795
      047 #795
      risk factors risk #795
      patency #796
      patient years #796
      studies prevalence #797
      eligible #797
      netherlands #797
      femoropopliteal #798
      lupus anticoagulant #798
      estrogen therapy #799
      patients lower #799
      theme #799
      hemophilia patients #800
      willebrand factor #802
      randomized patients #804
      subclinical #804
      anticoagulant agents #805
      microvesicles #805
      fibrillation blood #806
      adverse outcomes patients #806
      stroke risk factors #807
      ventricular dysfunction #808
      hypertension cteph #809
      efficacy patients #809
      activator inhibitor1 #810
      069 #811
      model patients #813
      primary aim #814
      flights #816
      factor vwf #816
      0·4 #818
      vehicle control #820
      health predictive #820
      irrespective #820
      abruptio #821
      neuroradiologist #822
      reduction mortality #823
      prevention patients #823
      coc #824
      single administration #824
      risk benefit #825
      study incidence #827
      cardioembolic stroke #828
      gp #828
      patients anticoagulants #830
      cava filters #832
      myers #833
      antithrombotic treatment #833
      93 #833
      abortion habitual #835
      plough #836
      oral adult #836
      noac #837
      versus placebo #837
      87 #838
      057 #839
      genetic defect #841
      risk scores #844
      antithrombotic therapy #846
      49 #846
      072 #847
      multidetector row #847
      advise #848
      recurrence risk #849
      caesarean #850
      patients diagnosis #850
      area roc curve #852
      reference method #853
      30 patients #853
      pre‐eclampsia #853
      advanced prostate #854
      fibrin #855
      clopidogrel aspirin #855
      patients mutation #859
      ultrafiltrate #860
      dutch population #861
      microg #862
      cardiometabolic disease #863
      090 #865
      placebo study #866
      diagnostic methods #868
      1046 #869
      pyridones #870
      6 month #870
      individual participant #872
      longterm clinical outcomes #872
      favoring #873
      tasman #873
      thromboembolic pulmonary #874
      imaging reproducibility #874
      targeted inhibition #874
      titles #875
      plasminogen activation #875
      n15 #876
      cha2ds2 #877
      risk thromboembolic #878
      dabigatran rivaroxaban #878
      57 #879
      anticoagulants atrial #879
      oral #881
      angiograms #882
      control trial #883
      92 #884
      imaging tests #885
      prostate turp #888
      handbook #890
      domiciliary #894
      male mexico #894
      084 #894
      loading dose #896
      p011 #896
      repeatedly #897
      uln #901
      indefinite #902
      bleedings #904
      vkorc1 #905
      wml #906
      064 #908
      factor activity #908
      subcutaneous administration #909
      documented #911
      patients clinical trials #911
      haemostatic #912
      initially #912
      impedance #913
      specificity sensitivity #914
      haemodialysis patients #916
      combined approach #916
      317 #917
      thromboembolic events #918
      022 #918
      chronic thromboembolic #919
      antagonist oral #920
      standard patients #920
      randomeffects model #920
      ultrasound examination #921
      optimal dose #921
      loss patients #921
      practise #923
      estimate male #923
      multifactorial disease #925
      study medication #925
      total hip #926
      902 #928
      safer #928
      004 #929
      recurrent events #930
      fxi #931
      treatment placebo #934
      wording #934
      84 #936
      publication clinical trials #937
      60 patients #938
      subgroup patients #938
      rrr #940
      families patients #941
      teaching hospital #943
      women preeclampsia #944
      echocardiographically #944
      stroke atrial #944
      emboli #945
      predictive values #946
      ssc #946
      anticoagulation treatment #947
      diagnostic #948
      extensive disease #948
      knee replacement #948
      previous diagnosis #951
      adjudication #954
      dic #956
      cancer humans #956
      network metaanalysis #956
      registro #956
      reassuring #957
      venous insufficiency #957
      day1 #958
      efficacy #958
      retropubic #961
      combined oral #961
      guidelines recommend #962
      3 months #963
      blood product #964
      travellers #965
      inhibitor1 #966
      reference lists #966
      peaking #969
      greater risk #970
      allogeneic blood #971
      prevalence characteristics #973
      risk allcause mortality #973
      hoc #973
      antiplatelet #973
      segmental #974
      patients anticoagulation #975
      female fibrinogen #976
      vascular humans #976
      fvii #978
      false negative #979
      071 #980
      50 100 #980
      onset aged aged #980
      early gestation #984
      426 #986
      prophylactic treatment #987
      randomised trials #987
      patients safety #988
      vascular patency #989
      study treatment #990
      rises #991
      missed #991
      academic medical center #992
      seminar #992
      normal lung #993
      counteracted #993
      treatment bleeding #994
      aged #999
      226 #999
      lower extremity #1000
      thromboembolic risk #1000
      justification #1000
      tissue type #1001
      rivaroxaban apixaban #1002
      parenteral administration #1002
      eclamptic #1003
      extended #1005
      interleukin 6 #1005
      hyperprolactinaemia #1005
      pyridines #1006
      easier #1007
      orthosis #1007
      50 patients #1007
      valsalva maneuver #1009
      venous catheter #1011
      individual participant data #1012
      weighing #1014
      ticlopidine #1018
      pounds #1018
      clotting time #1019
      prostatic carcinoma #1020
      200 patients #1022
      cha2ds2 vasc #1023
      years risk #1023
      international prospective #1024
      humans randomized #1024
      076 #1025
      diagnostic challenge #1026
      prothrombin time #1027
      decision analysis #1030
      firstdegree relatives #1030
      ixa #1031
      prolactin #1032
      relatives #1033
      cardiovascular event #1033
      risk hemorrhage #1033
      052 #1035
      male netherlands #1037
      graft occlusion #1037
      2 hours #1039
      detect #1040
      025 #1041
      3 6 months #1046
      vwf levels #1047
      patients severe asthma #1047
      examiner #1050
      patients massive #1050
      continuation #1052
      patients analysis #1053
      221 #1054
      mean±sd #1054
      free triiodothyronine #1056
      diseases liver #1057
      birth rate #1060
      179 #1060
      coagulant #1060
      610 #1061
      pad #1061
      primary data #1062
      published literature #1062
      false #1064
      prekallikrein #1065
      150 #1065
      101 #1066
      00008 #1066
      live birth #1066
      lysosphingolipid #1067
      cut #1067
      pmol #1068
      register controlled #1070
      95 increased risk #1070
      observer variation #1071
      specialties #1072
      continued #1073
      thorax #1074
      laboratory diagnosis #1074
      systematic search #1078
      advocate #1080
      063 #1080
      drawbacks #1082
      f1 #1087
      longterm therapy #1087
      bandages #1089
      stopping #1095
      clarifications #1095
      mandated #1096
      diagnostic utility #1096
      idarucizumab #1096
      083 #1099
      1223 #1099
      62 #1102
      96 #1104
      fourfold #1105
      blueprint #1105
      peptide brain #1107
      clinical protocols #1107
      pending #1111
      incidence pulmonary #1112
      assigned #1113
      diagnostic approach #1115
      haemodialysis #1116
      bypass grafts #1116
      252 #1117
      qualified #1118
      sensitivity specificity #1119
      critical appraisal #1120
      randomized controlled trials #1122
      probands #1123
      resistance factor #1123
      new developments #1124
      advised #1125
      445 #1126
      new perspectives #1126
      cip #1127
      heparininduced thrombocytopenia #1127
      patients pad #1128
      discretion #1132
      judged #1132
      statistic #1133
      ≤10 #1133
      95 confidence interval #1134
      pulse rate #1135
      gram negative #1137
      1043 #1139
      disseminated #1140
      635 #1141
      superior efficacy #1141
      86 #1143
      734 #1145
      844 #1147
      roc curve #1150
      refusal #1150
      medline #1151
      medical records #1151
      embolectomy #1153
      longterm complications #1154
      risk recurrence #1155
      anticoagulation therapy #1156
      patients influenza #1156
      blood loss #1156
      prophylaxis treatment #1157
      3040 #1158
      patients increased #1159
      extension study #1161
      cvc #1162
      published guidelines #1163
      bristol #1163
      viii #1164
      safety concerns #1164
      stable angina #1164
      hyperhomocysteinemia #1164
      intermittent #1164
      thromboembolism risk #1165
      age 65 years #1165
      angiogram #1167
      crossover design #1172
      atherosclerotic disease #1172
      perioperative bleeding #1172
      glucocorticoid treatment #1172
      occlusive diseases #1173
      practice guideline #1173
      macroglobulin #1176
      5 years patients #1176
      findings patients #1178
      analysis studies #1178
      79 #1179
      concealed #1181
      conceive #1181
      patients obesity #1182
      unaware #1182
      hospitalized patients #1182
      combined therapy #1186
      conclusive #1186
      degree relatives #1189
      occult #1189
      adult analysis #1191
      cus #1194
      administration oral #1195
      21 patients #1197
      mandate #1199
      cardiotonic agents #1199
      international society #1199
      hypercortisolism #1200
      83 #1203
      quantitative trait locus #1204
      015 #1204
      categorized #1204
      increase plasma #1205
      31 #1207
      biomarkers blood #1210
      56 patients #1212
      pph #1214
      multicenter randomized #1214
      103 #1218
      warranted #1221
      scores patients #1221
      patient treatment #1221
      ultrasound screening #1222
      6months #1223
      peak levels #1224
      64 patients #1224
      vasc #1225
      16 patients #1226
      blind #1227
      sixfold #1227
      consensus guidelines #1228
      metabolic syndrome patients #1228
      peptide hydrolases #1229
      trial background #1229
      radionuclide #1229
      65 patients #1230
      rules #1232
      doubles #1232
      aspirin #1234
      postoperative hemorrhage #1238
      milliliter #1238
      coronary angiography patients #1238
      humans length #1240
      clinical criteria #1241
      patients fh #1242
      vte prophylaxis #1244
      neurohormone #1245
      multinational #1246
      thrombolytic #1247
      knee arthroplasty #1248
      intermediate risk #1250
      matter lesions #1252
      subgroups #1252
      ml1 #1252
      artery pulmonary #1254
      extensive #1257
      search strategy #1257
      oral vitamin #1257
      prospective cohort #1258
      symptomatic patients #1259
      major surgery #1262
      entity #1266
      visiting #1266
      troponins #1266
      macroglobulins #1267
      172 #1270
      amputations #1273
      intensive patients #1274
      equally #1274
      design study #1276
      antiplatelet agents #1278
      proportionally #1279
      routine screening #1281
      statin users #1281
      75 years #1281
      factors ultrasonography #1285
      thyroxine #1287
      050 #1288
      blockers #1290
      dermatan sulfate #1292
      perfusion defects #1295
      janssen #1295
      scan #1295
      predictive #1297
      hemofiltration #1297
      insufficiently #1298
      low prevalence #1299
      cardiovascular complications #1299
      dutch #1300
      prolong #1302
      61 #1303
      pf4 #1303
      pulmonary circulation #1304
      scores #1305
      95 mortality #1307
      cyproterone #1312
      apoa #1312
      1st #1312
      risk difference #1312
      adamts13 activity #1313
      0·7 #1314
      current strategies #1314
      tests severity #1314
      atrial fibrillation #1316
      claudication #1316
      carotid imt #1317
      international guidelines #1318
      replacement hip #1320
      study time #1321
      coagulation factor #1322
      vienna #1323
      increases risk #1324
      lipoproteina #1325
      glycoprotein gpiib #1325
      patients coronavirus disease #1326
      antibodies monoclonal antibodies #1329
      vascular diseases #1329
      beneficial #1329
      plasminogen activators #1330
      thyroid disorders #1330
      low moderate #1330
      77 #1331
      6 months patients #1331
      coagulation cascade #1331
      126 #1332
      frequent complication #1333
      adjusted age #1335
      transurethral resection #1336
      91 #1342
      likelihood ratio #1342
      venous catheters #1342
      blood sample #1343
      daily patients #1344
      antitrypsin #1347
      surgical trauma #1347
      patients relatives #1351
      neurosurgery #1355
      arthroplasty patients #1356
      patients stable angina #1357
      15 patients #1359
      allcause mortality 95 #1359
      experimental model #1359
      limb salvage #1363
      vwf #1363
      arsenal #1363
      vtes #1365
      95 patients #1366
      operatively #1367
      12 month #1369
      heart valves #1370
      starting #1372
      ethinyl #1373
      acetylsalicylic #1375
      costeffectiveness analysis #1376
      utmost #1378
      consented #1382
      management patients #1383
      gps #1384
      dl1 #1385
      noninferiority #1385
      224 #1385
      disorders blood #1386
      ivt #1389
      patients cvd #1392
      substitute #1394
      screening tests #1399
      patients control subjects #1400
      record linkage #1400
      equipoise #1402
      antisense oligonucleotide #1402
      82 #1402
      mandatory #1403
      clinical challenges #1404
      1886 #1405
      patients advanced cancer #1405
      obese patients #1406
      pregnancy loss #1406
      categories #1408
      515 #1408
      994 #1409
      reflected #1410
      inception #1411
      tranexamic #1413
      adamts13 #1417
      0·1 #1418
      thrombotic complications #1419
      3 6 #1419
      7 weeks #1419
      6 weeks #1419
      total knee #1420
      95 0 #1421
      university hospitals #1422
      followup data #1422
      ≥55 #1424
      061 #1424
      daily #1424
      eightfold #1425
      080 #1427
      randomised controlled trials #1427
      rgs #1430
      casecontrol study #1430
      outcome pregnancy #1438
      imaging radiopharmaceuticals #1439
      096 #1439
      78 #1443
      principal #1443
      1123 #1445
      outcome studies #1446
      drug levels #1446
      weight bmi #1446
      underreporting #1451
      support systems #1452
      confusion #1454
      population patients #1454
      platelet factor #1455
      aged blood #1455
      dip #1456
      mbe #1457
      conclusions patients #1459
      prospectively #1460
      multicenter studies #1461
      humans #1463
      inaccuracy #1464
      funded #1466
      actual #1466
      avoided #1468
      0·9 #1468
      heart failure hf #1469
      26 patients #1469
      groin #1471
      risk factors mortality #1472
      1215 #1473
      prevalences #1473
      centrally #1474
      systemic infection #1477
      probability #1477
      lowest tertile #1478
      remained #1480
      atherothrombotic #1481
      undetermined #1482
      dysfunction patients #1483
      cushing syndrome #1485
      analysis randomized #1485
      methodologic #1486
      phase iii trials #1486
      general practice #1491
      procoagulant activity #1495
      patients control #1495
      randomly #1496
      64 #1498
      aged natriuretic #1499
      exposing #1501
      imt #1507
      fracture surgery #1510
      specificity 100 #1512
      odds ratio 95 #1513
      growing body #1514
      adverse outcome #1514
      proximal #1516
      ganz #1520
      pregnancy postpartum #1520
      patients 10 #1520
      subgroup #1521
      factor deficiency #1522
      gsk #1524
      chills #1526
      contraindicated #1527
      thrombotic events #1527
      score #1529
      time study #1529
      oral contraceptive #1534
      mechanical compression #1536
      immobilisation #1539
      comparator #1540
      patients life #1541
      humans neoplasm #1542
      hemostatics humans #1545
      089 #1548
      tsh levels #1551
      live births #1552
      patients severe sepsis #1552
      23 #1554
      vascular thrombosis #1555
      fees #1556
      neonatal period #1558
      patients year #1559
      discriminatory #1562
      hypothyroidism #1563
      pfa #1564
      enfermedad #1564
      iii topic #1565
      treatment prevention #1566
      topic #1566
      hyperlipoproteinemia type #1568
      95ci #1568
      cushings syndrome #1568
      deficient #1568
      aged biomarkers #1571
      36 #1575
      plasminogen activator #1575
      humans platelet #1576
      012 #1577
      hyperlipoproteinemia #1580
      risk myocardial infarction #1584
      thyroid dysfunction #1586
      study entry #1586
      activation markers #1586
      cocs #1586
      studies association #1587
      adjusted hazard ratio #1589
      volunteers #1591
      total mortality #1594
      1·1 #1594
      translates #1597
      placebo #1598
      noncancer #1598
      exclude #1599
      lmw #1601
      figures #1604
      paroxetine #1606
      abdominal surgery #1607
      complement pathway #1609
      curability #1610
      162 #1613
      general surgery #1613
      ethinylestradiol #1614
      recommending #1615
      tests reproducibility #1616
      prospective cohort studies #1616
      factors tomography #1616
      postpartum period #1616
      positive effects #1616
      perinatal outcome #1618
      155 #1618
      cvd patients #1619
      imaging tomography #1619
      female hemostasis #1619
      proportion #1620
      uncertain #1621
      12month followup #1621
      079 #1623
      competing risk #1628
      isis #1630
      major #1631
      pa patients #1632
      incidentally #1632
      venous disease #1632
      clinical patients #1633
      fresh frozen plasma #1633
      study outcomes #1639
      double #1639
      029 #1642
      181 #1643
      stroke prevention #1644
      ctni #1644
      patients hospitalized #1647
      mismatched #1648
      dorsiflexion #1651
      997 #1651
      35 years #1652
      ≤4 #1652
      thrombin activity #1653
      studies data #1653
      clotting #1656
      remaining #1660
      plasma concentration #1661
      outcome data #1663
      spiral #1669
      disease adult #1670
      homocysteine levels #1670
      thrombi #1674
      inpatient treatment #1676
      daily dosing #1676
      plasma level #1677
      deficiency #1677
      warfarin dose #1680
      arthroscopy #1684
      unreliable #1686
      steroidal anti #1686
      patients acs #1687
      thrombin #1690
      severe renal #1694
      patients brain metastases #1695
      prospective #1702
      necrosis factor #1705
      highest risk #1707
      cancer screening #1708
      awaiting #1710
      yielded #1712
      033 #1712
      hemorheology #1715
      intravenous #1715
      bronchospasm #1720
      hematologic malignancies #1720
      female femoral #1721
      mb #1721
      diagnostic evaluation #1721
      cardioembolic #1722
      cumulative incidence #1723
      laser doppler #1724
      conference #1726
      107 #1726
      derived microparticles #1729
      021 #1730
      volunteer #1730
      161 #1733
      percentage patients #1734
      clinical scores #1735
      east asian #1735
      patients icu #1736
      rico #1737
      500 #1738
      minor #1739
      revised #1744
      table #1745
      patients ventricular #1745
      691 #1745
      profession #1746
      risk cardiovascular events #1747
      hyperinsulinaemia #1747
      apc #1749
      turp #1749
      homozygosity #1750
      pselectin #1750
      replacement #1750
      128 #1752
      intracranial hemorrhages #1753
      133 #1753
      3 studies #1755
      spontaneous #1756
      arterial occlusive #1758
      patients randomized #1759
      assessor #1760
      audiometry #1760
      treatment recommendations #1760
      current treatment #1761
      primary setting #1762
      long‐term #1763
      human insulin #1764
      fx #1764
      duplicate #1769
      arteriosclerosis #1770
      initial management #1770
      hemorrhage #1770
      2 6 #1774
      allcause death #1774
      28 weeks #1781
      hemostasis humans #1782
      trough levels #1785
      infusions #1787
      ethinyl estradiol #1789
      selfmanagement #1790
      clinical consequences #1790
      reid #1793
      microparticle #1793
      cardiac troponin #1794
      vascular surgical #1794
      healthy male volunteers #1799
      042 #1800
      aggregation inhibitors #1802
      020 #1802
      retrospective analysis #1805
      hemophilia humans #1808
      unpublished #1810
      95 specificity #1812
      slc6a4 #1812
      tumor necrosis #1812
      overlapped #1814
      51 #1815
      078 #1818
      conjoint #1819
      economic evaluation #1819
      interobserver #1823
      awareness #1824
      screening middle #1825
      preference #1825
      303 #1828
      placebo 95 #1832
      undergoing coronary #1834
      definite #1837
      compressibility #1837
      cushing #1838
      kaplanmeier estimate #1838
      severe sepsis #1839
      1 week #1842
      central venous #1842
      workup #1848
      orthopaedic #1849
      explanations #1852
      hydroxyethyl starch #1852
      160 #1854
      fibrinopeptide #1862
      cancer therapies #1865
      alpha 2 #1867
      gramnegative #1869
      serially #1870
      humans pregnancy #1874
      separately #1876
      oral anticoagulation #1880
      diagnostic techniques #1892
      thromboses #1892
      shrs #1892
      lower incidence #1893
      stable patients #1895
      5 10 #1897
      067 #1897
      contraindications #1900
      diagnostic testing #1901
      tnf #1901
      extremity #1901
      clt #1905
      plaster #1906
      hazard ratio #1906
      induced thrombocytopenia #1906
      differential effects #1907
      95 year #1909
      referral #1910
      efficacy treatment #1910
      random #1911
      plato #1913
      experimental mice mice #1916
      238 #1918
      randomized #1919
      793 #1920
      13 patients #1920
      administration #1921
      pregnancy treatment #1922
      stroke 95 #1923
      868 #1923
      biotin #1924
      55 years #1924
      venous pressure #1926
      trials patients #1926
      intracranial hemorrhage #1927
      μg #1927
      coronary syndromes #1928
      272 #1929
      cardiovascular events patients #1930
      chimpanzee #1931
      adjusted #1932
      glucocorticoid #1934
      nonfatal #1934
      3months #1935
      relative risks #1935
      acute #1936
      17 #1936
      thrombolytic treatment #1937
      27 #1938
      randomized placebo #1947
      femoral vein #1950
      safety effectiveness #1950
      0·5 #1952
      medical illness #1954
      overtreatment #1955
      prolongation #1958
      intravascular #1959
      major risk #1960
      advanced age #1961
      observer #1962
      investigators #1962
      1050 #1965
      permanent #1966
      80 female #1967
      hyperglycaemia #1970
      coronary angioplasty #1971
      48 hours #1973
      surgical blood #1973
      fibrin clot #1973
      potent inhibitor #1976
      renewed #1976
      topic clinical trials #1978
      771 #1981
      specificity ultrasonography #1981
      hyperaldosteronism #1981
      computerised #1982
      patients pancreatic #1985
      1·0 #1986
      treatment cancer #1986
      randomized controlled #1988
      coumarins #1990
      177 #1991
      018 #1992
      prospero #1992
      drug drug therapy #1994
      cmax #1994
      computerized #1995
      cvt #1995
      hemorrhage patients #1996
      ors #1998
      602 #1999
      autopsy #2000
      transient increase #2000
      clinical severity #2000
      3 months patients #2000
      53 #2003
      pneumonia patients #2006
      7 patients #2006
      pih #2011
      mantel #2013
      catheterization central #2014
      angina unstable #2017
      mongrel #2017
      poc #2019
      225 #2020
      type plasminogen #2023
      pathophysiologic #2024
      35 #2025
      patients statins #2026
      annual #2028
      15th #2031
      atheroma #2032
      097 #2033
      patients lung #2033
      pertechnetate #2036
      costs cost #2041
      medical record #2041
      undergoing major #2042
      abstracts #2042
      questioned #2043
      thrice #2045
      prediction rule #2045
      dichotomous #2046
      normal #2048
      superior vena cava #2051
      quartiles #2051
      inadequately #2052
      pregnancy trimester #2053
      277 #2053
      controversial #2055
      stent implantation #2056
      adherence guidelines #2056
      hospitalized #2057
      randomized comparison #2060
      outpatient #2061
      interobserver variability #2062
      requested #2063
      varies #2063
      clinical indications #2064
      biological neoplasms #2064
      hemostatics #2070
      national institute #2074
      mcnemar #2074
      188 #2074
      familial hypercholesterolemia #2077
      unavailable #2079
      searched #2082
      disseminate #2083
      ristocetin #2086
      media thickness #2087
      bypasses #2087
      03 #2089
      versions #2091
      114 #2092
      square distribution #2092
      tissue plasminogen #2093
      preformed #2099
      reference range #2099
      038 #2100
      lifetime risk #2101
      desmopressin #2101
      59 #2101
      placebos #2102
      concealment #2104
      hospital treatment #2106
      fibrin deposition #2107
      argatroban #2108
      1966 #2109
      031 #2109
      substantial #2109
      aged 80 #2111
      debated #2116
      jugular vein #2117
      independently #2118
      unnecessary #2118
      exists #2119
      initial #2119
      development validation #2120
      coronary stent #2122
      clinicaltrialsgov #2122
      11 #2122
      original #2125
      acl reconstruction #2125
      topic surveys #2127
      patients cardiovascular disease #2127
      chose #2129
      controlled #2129
      current recommendations #2131
      odds ratios #2132
      protamines #2134
      congress #2134
      190 #2136
      788 #2137
      hip arthroplasty #2139
      heterozygous #2141
      antagonists #2142
      live #2145
      clot #2145
      bodyweight #2146
      professionals #2146
      pancreatic cancer patients #2157
      oestrogens #2160
      committee #2160
      lowdose aspirin #2163
      academic medical #2167
      drains #2170
      embase #2171
      fibrinogen #2175
      1998 #2178
      trimesters #2179
      reproductive age #2182
      674 #2183
      advanced cancer #2183
      2 × #2185
      fifty #2185
      giant cell arteritis #2185
      patients diagnosed #2187
      631 #2188
      controlled study #2192
      superficial #2194
      difference incidence #2198
      adjust #2202
      diagnostic performance #2204
      increased patients #2205
      pravastatin #2205
      antagonist #2206
      clinical implications #2208
      lower limbs #2209
      diagnosis differential #2212
      neutrophil elastase #2212
      doubled #2213
      364 #2219
      pao2 #2219
      insufficient #2221
      comparing #2222
      94 #2225
      differential female #2225
      lung perfusion #2226
      italian society #2227
      76 #2233
      takeda #2236
      nationwide cohort study #2245
      clot formation #2247
      congenital heart disease #2252
      hemorrhages #2253
      clots #2257
      hivinfected patients #2257
      kilogram #2259
      aprotinin #2261
      8000 #2264
      hyperthyroidism #2265
      stroke aged #2265
      12 #2266
      metaanalysis #2267
      6 months #2267
      patients developed #2273
      reverses #2273
      arterial #2274
      intrinsic pathway #2275
      famine #2278
      656 #2279
      ultrasonographic #2281
      setting #2284
      based case #2284
      14 patients #2286
      ft3 #2288
      case control #2291
      patients heart failure #2293
      aged molecular #2295
      daily dose #2296
      sole #2298
      strategy #2303
      88 #2308
      0047 #2310
      normalised #2312
      metaanalysis studies #2314
      tests #2314
      nephelometry #2316
      initial therapy #2316
      obstetrics #2317
      adjustments #2319
      method female #2324
      humans myocardial #2324
      methodological #2325
      60 #2327
      normalized #2329
      brachial #2332
      gradually #2335
      random sample #2336
      positive predictive #2337
      transfusion requirements #2340
      ultrasonography doppler #2341
      543 #2343
      inhibitor #2344
      lacked #2344
      prescribe #2347
      illness severity #2350
      20 weeks #2351
      thr #2353
      prefer #2354
      cancer progression #2364
      053 #2371
      118 #2372
      receiving #2374
      099 #2375
      risk bias #2375
      patients active #2376
      predictable #2377
      hemostasis #2377
      enrolling #2379
      acute coronary syndromes #2379
      187 #2381
      dosing regimen #2382
      anticardiolipin #2382
      145 #2387
      scintigraphy #2389
      140 #2391
      244 #2393
      complication rate #2400
      patients liver cirrhosis #2401
      757 #2401
      086 #2402
      letters #2405
      curable #2406
      postinjection #2413
      periodicals #2413
      protein #2413
      risk estimates #2414
      sphingosine1 #2415
      22 #2415
      internal medicine #2424
      study drug #2424
      32 #2425
      guidelines #2426
      sensitivity 100 #2426
      0048 #2430
      coagulants #2430
      legs #2430
      002 #2430
      patients adult #2431
      ci95 #2432
      normal range #2433
      ptca #2434
      prolonging #2434
      aminoglycoside #2435
      cindex #2437
      030 #2438
      cumulative #2439
      166 #2441
      endogenous #2445
      microplate #2446
      turbidimetry #2448
      719 #2448
      administration schedule #2449
      transmigration #2453
      homocysteine #2454
      anticoagulant activity #2455
      ≥75 #2459
      extensively #2463
      prognostic patients #2464
      watchful #2464
      potential benefits #2466
      nephrotoxic #2468
      therapy acute #2468
      comprised #2469
      477 #2469
      pharmacologic #2473
      consisted #2474
      current review #2476
      cancer population #2476
      05 #2481
      50 #2482
      pathway inhibitor #2485
      648 #2485
      treatment efficacy #2489
      1015 #2490
      829 #2490
      chest #2493
      duration #2493
      25 #2495
      illness tomography #2503
      616 #2503
      bnp #2504
      subsequent pregnancies #2505
      522 #2507
      movie #2508
      recurrence retrospective #2509
      unstable angina #2510
      presentation #2512
      superinfection #2513
      comprising #2515
      479 #2516
      drug female humans #2516
      sulfates #2519
      750 #2520
      neutrophil extracellular traps #2521
      463 #2521
      accurate diagnosis #2523
      152 #2523
      treatment arms #2524
      scientific #2529
      establish #2534
      0046 #2537
      874 #2537
      164 #2537
      nematode #2540
      67 #2542
      pyrazoles #2547
      arrive #2549
      decided #2552
      effectiveness analysis #2553
      hydroxyethyl #2560
      haematology #2560
      hours #2560
      928 #2565
      radiologist #2566
      roc #2568
      biologic #2569
      clinical settings #2570
      infrequent #2572
      kits #2574
      humans logistic #2574
      73 #2574
      pill #2575
      prevalence #2575
      patients total #2577
      translate #2577
      973 #2578
      specificity #2580
      cancer chemotherapy #2581
      374 #2582
      591 #2585
      efficacious #2585
      pivotal #2588
      analysed #2589
      bolus #2595
      657 #2596
      multiple organ failure #2599
      hypercholesterolaemia #2600
      doppler duplex #2602
      laboratory investigation #2603
      burden disease #2605
      manifest #2605
      metaregression #2606
      parenteral #2606
      patients 2 #2608
      fatal outcome #2608
      098 #2610
      p0001 patients #2613
      died #2615
      886 #2618
      percent #2619
      cost analysis #2620
      aviation #2620
      concentrate #2621
      occlusive #2622
      presenting #2625
      assess #2626
      prescribed #2631
      agents steroidal #2633
      coincided #2635
      trials rcts #2635
      chondroitin #2635
      10 day #2637
      attractive #2641
      345 #2641
      mutation patients #2642
      greatest risk #2643
      23 patients #2645
      decision #2649
      risk cardiovascular disease #2656
      134 #2659
      recurrence #2660
      hamilton #2661
      benzimidazoles #2662
      c677 #2662
      679 #2663
      shr #2667
      quartile #2674
      receive #2675
      439 #2677
      valsalva #2680
      trials #2682
      516 #2683
      outcome ultrasonography #2683
      initial dose #2685
      iii #2685
      inconclusive #2686
      tmax #2687
      mortality 95 #2688
      tissue plasminogen activator #2690
      594 #2691
      aso #2691
      bleed #2692
      schedule female #2694
      stillbirth #2698
      patients risk factors #2702
      early discharge #2703
      14 #2706
      previous stroke #2720
      prematurely #2725
      897 #2727
      txb2 #2729
      management strategies #2732
      dose low #2732
      cart #2736
      595 #2737
      427 #2739
      classifications #2739
      therapeutic options #2744
      risk ratio #2745
      predetermined #2746
      848 #2746
      patients asthma #2747
      baseline characteristics #2747
      direct comparison #2752
      pan #2755
      nephrotoxicity #2758
      randomised trial #2764
      contusions #2765
      143 #2768
      management acute #2768
      confounded #2769
      expert consensus #2772
      alpha animals #2772
      antithyroid #2772
      active control #2775
      inpatient #2776
      thrombomodulin #2776
      563 #2777
      compression #2778
      dosages #2779
      leukocyte count #2781
      mass screening #2782
      466 #2783
      hemostatic #2784
      primary outcomes #2785
      percentiles #2788
      90th #2789
      nadph2 #2791
      consecutive series #2802
      402 #2802
      cirrhosis patients #2805
      reaching #2805
      international #2809
      standardized #2811
      secondary #2811
      embolic #2812
      follow studies #2813
      406 #2813
      prevalence risk factors #2814
      httlpr #2816
      discriminant analysis #2817
      selectins #2819
      consisting #2823
      equivalency #2825
      bid #2826
      antiplatelet drugs #2826
      genetic variations #2830
      557 #2833
      male mass #2834
      recurrence rate #2835
      contacting #2835
      ketoprostaglandin #2836
      helminth #2836
      kruskal #2839
      crossover #2839
      554 #2843
      partum #2847
      anterior cruciate ligament #2850
      carboxypeptidase #2851
      doppler ultrasonography #2852
      iii trials #2852
      ≤2 #2853
      postoperative patients #2854
      new treatment #2857
      post discharge #2857
      specialised #2858
      methods prospective #2862
      497 #2870
      discontinuation #2871
      264 #2876
      628 #2877
      52 #2879
      excessive #2880
      trimester pregnancy #2880
      hit #2884
      mdct #2885
      balloon angioplasty #2886
      anterior cruciate #2887
      670 #2895
      eligibility #2896
      systematic review metaanalysis #2897
      21 #2897
      central venous catheters #2900
      statin #2902
      slight #2903
      severe asthma #2903
      feasible #2903
      12 patients #2908
      concomitantly #2910
      supposed #2911
      insulin receptors #2914
      leading death #2917
      lowrisk patients #2917
      39 #2919
      routine clinical practice #2920
      referrals #2921
      older children #2922
      993 #2928
      proportions #2928
      clear #2932
      risk stratification patients #2934
      2400 #2934
      aggregation platelet #2941
      control subjects patients #2945
      meier estimate #2946
      addison #2952
      portal #2954
      100 #2956
      returned #2957
      270 #2960
      010 #2960
      20 #2961
      exercise therapy #2962
      followup #2962
      transabdominal #2963
      132 #2974
      echocardiography patients #2975
      123 #2978
      risk myocardial #2981
      lecture #2984
      declare #2984
      eclampsia pregnancy #2986
      glucose levels #2987
      preoperatively #2988
      adult blood #2990
      point #2991
      pneumatic #2991
      n4 #2992
      undefined #2993
      treatable #2996
      cvr #2997
      microvessels #2998
      499 #3004
      prostacyclin #3012
      dipyridamole #3013
      factors surveys #3015
      antigen levels #3015
      2 patients #3016
      081 #3019
      double‐blind #3022
      35 patients #3023
      early recognition #3025
      nested case #3025
      comorbidity #3026
      contraindication #3028
      intention #3035
      extremities #3038
      50 years #3040
      419 #3040
      patients hf #3041
      lymphopenia #3043
      relevant articles #3044
      095 #3045
      prenatal exposure #3047
      summarize #3050
      respondents #3052
      respects #3060
      subcutaneous injection #3062
      nomogram #3063
      80 #3063
      fourteen #3065
      95 p0001 #3066
      patients data #3067
      study prevalence #3071
      subsequently #3076
      2 4 #3076
      disease aged #3077
      524 #3082
      342 #3083
      angioplasty #3088
      chronic renal failure #3088
      independent risk factors #3089
      healthy #3090
      clinical risk factors #3098
      lancet #3102
      reviewer #3104
      practice guidelines #3109
      trimester #3110
      benchmark #3110
      npv #3115
      pregnant woman #3119
      neutrophil activation #3120
      oac #3122
      wallis #3122
      lifelong #3122
      inadequacy #3123
      intravenously #3129
      claimed #3132
      136 #3134
      12 months #3134
      meta‐analysis #3137
      levels risk #3142
      082 #3142
      placentae #3143
      randomized clinical trial #3145
      time interval #3147
      arthroscopic #3149
      idiopathic #3153
      507 #3153
      marathon #3155
      mega #3156
      avoiding #3158
      radiologists #3165
      initial presentation #3172
      seventh #3173
      cornerstone #3182
      test #3184
      494 #3188
      revascularisation #3191
      409 #3193
      pregnancy women #3194
      diethylstilbestrol #3194
      pacientes #3197
      plasmin #3198
      945 #3198
      therapy risk #3199
      tenth #3199
      gold standard #3200
      vivo model #3205
      res #3207
      patient preference #3211
      catheter #3212
      suggested #3219
      cancer types #3219
      153 #3223
      intravenous infusion #3223
      72 hours #3225
      605 #3227
      methodological quality #3238
      observers #3239
      meetings #3241
      recombinant #3241
      intravenous administration #3242
      risk stroke #3246
      alternative #3249
      198 #3251
      bivalirudin #3251
      hypothyroid #3253
      29 #3253
      scoring #3255
      judgement #3255
      normotensive #3256
      054 #3257
      patient preferences #3261
      glargine #3265
      validated #3266
      patients evidence #3267
      116 #3268
      immunoassay #3271
      414 #3275
      6 #3277
      tranexamic acid #3279
      gbd #3280
      contraceptive #3281
      inclusion #3284
      arthroplasty replacement #3288
      coumarin #3289
      tumor markers #3289
      replace #3290
      65 years #3291
      swan #3292
      recurrence rates #3294
      efficacy outcomes #3299
      812 #3314
      rtpa #3315
      reversibility #3316
      anticardiolipin antibodies #3319
      discriminant #3321
      vascular risk #3322
      104 #3325
      hemophilia #3328
      972 #3329
      465 #3330
      reduces #3330
      cruciate ligament #3331
      patients symptoms #3334
      74 #3337
      meta #3338
      acute coronary syndrome #3339
      inpatients #3344
      cerebrovascular disease #3344
      evaluating #3349
      362 #3349
      spontaneous abortion #3354
      diagnosing #3354
      273 #3355
      common complication #3356
      diagnosis cancer #3356
      15 #3357
      lysate #3358
      581 #3359
      092 #3361
      miscarriages #3365
      prevalent #3371
      thrombolysis #3376
      treatment modalities #3377
      363 #3378
      301 #3379
      humans lower #3379
      concluded #3379
      intima media #3380
      computed tomography #3382
      hematomas #3387
      function patients #3389
      calf #3389
      contraception #3390
      repeated #3394
      413 #3395
      p0002 #3397
      cava #3399
      311 #3400
      acute treatment #3403
      553 #3403
      tunica #3403
      humans kaplan #3408
      saved #3415
      differs #3418
      randomisation #3419
      preventive #3419
      hypothesised #3420
      study risk #3420
      surgical patients #3420
      thrombocythemia #3422
      odds #3424
      confirm #3425
      testimony #3430
      competing #3434
      natriuretic #3437
      70 #3439
      ease #3443
      asian patients #3444
      124 #3445
      519 #3447
      487 #3451
      prevalence incidence #3452
      168 #3452
      evening #3458
      covid19 infection #3464
      differ #3470
      34 #3470
      intensive chemotherapy #3471
      patients receive #3472
      pregnancy complications #3472
      worsened #3476
      induced platelet #3479
      undiagnosed #3482
      antiphospholipid #3485
      cancer metastasis #3485
      increased morbidity #3486
      asymptomatic #3487
      lower leg #3487
      paradox #3490
      personyears #3490
      pacemaker #3493
      statistical methods #3494
      convergent validity #3496
      failure hf #3497
      201 #3504
      inhibitors #3506
      treat #3506
      hemorrhagic complications #3506
      938 #3513
      tomography angiography #3521
      discusses #3522
      confirmed #3522
      291 #3527
      quintiles #3529
      95 confidence intervals #3530
      lupus #3533
      human cytomegalovirus #3533
      areas covered #3537
      societies #3541
      guidance #3541
      113 #3544
      current practice #3551
      gastro #3551
      10 #3552
      stroke risk #3559
      baboons #3560
      344 #3562
      benefits risks #3564
      neutralize #3565
      nsaids #3566
      bibliographic #3567
      depends #3571
      patients recurrence #3573
      inconsistent #3575
      safety profiles #3580
      508 #3584
      evaluates #3592
      necessity #3596
      prognosis prospective #3596
      patient management #3598
      prognostic significance #3604
      vitamin #3605
      risk stratification #3606
      consensus document #3617
      platelet function #3619
      treated #3619
      interval #3622
      platelet activation #3622
      mutation #3624
      lipid profiles #3626
      q3 #3629
      kappa #3629
      organ damage #3635
      analysis performed #3640
      75 #3641
      undergo #3642
      homozygote #3642
      bypass surgery #3642
      externally #3645
      p006 #3645
      occlusions #3646
      1960 #3649
      30 #3649
      interindividual variability #3651
      fibrillation #3651
      coronary events #3656
      atherogenic #3658
      newer #3662
      patients 95 #3667
      optimal management #3671
      outcome administration #3671
      endovascular treatment #3678
      blinding #3679
      treatment complications #3680
      limited data #3683
      68 #3684
      clopidogrel #3685
      mammography #3693
      myalgia #3703
      478 #3706
      rationale #3707
      813 #3708
      rebound #3720
      drug monitoring #3721
      diagnostic process #3721
      pharmacodynamics #3725
      inhibitors humans #3725
      130 #3729
      unknown #3731
      patient population #3733
      serine proteases #3736
      349 #3738
      effective #3739
      humans intracranial #3739
      factor 4 #3741
      585 #3743
      299 #3744
      network meta #3746
      homozygous #3747
      495 #3750
      practitioner #3752
      randomised #3754
      deterioration #3754
      objectives #3759
      8 patients #3762
      subgroup analyses #3762
      00001 #3765
      host defense #3769
      statin therapy #3772
      scarce #3773
      computed ultrasonography #3774
      clinicians patients #3774
      inherited #3775
      517 #3778
      interpretable #3778
      483 #3782
      total knee arthroplasty #3789
      aminoglycosides #3789
      thyroid hormones #3789
      525 #3791
      412 #3795
      441 #3797
      life illness #3801
      333 #3802
      versus #3803
      compelling #3804
      vessel wall #3804
      preexisting #3808
      outcome measure #3814
      330 #3815
      patients lung cancer #3815
      valid #3816
      iu #3818
      55 patients #3821
      fv #3823
      stasis #3824
      lost #3825
      compares #3830
      itching #3831
      proved #3834
      osmolar #3837
      elective #3838
      hydrolases #3839
      patient education #3843
      197 #3849
      irs #3856
      meeting #3856
      anaesthesia #3857
      4 patients #3858
      congresses #3859
      review data #3860
      acquired resistance #3860
      male neoplasms #3862
      preferred #3864
      occurring #3867
      death #3880
      optimisation #3884
      cancer survival #3884
      record #3885
      sensitivity #3885
      avoids #3887
      calculated #3888
      351 #3890
      184 #3890
      difference #3890
      10000 #3902
      methylamines #3903
      halflives #3903
      methimazole #3904
      patients time #3905
      incidence prevalence #3908
      specificity tomography #3915
      angiography #3915
      coronary thrombosis #3918
      decide #3927
      474 #3931
      ankle #3932
      955 #3935
      458 #3938
      jak2 #3939
      extravasation #3945
      case fatality #3946
      405 #3946
      preeclampsia #3952
      neurology #3953
      56 #3956
      p004 #3961
      dichotomy #3961
      randomized clinical trials #3963
      women #3964
      carboxypeptidases #3965
      postoperatively #3966
      clinical effectiveness #3968
      risk cancer #3970
      uncontrolled #3970
      austrian #3971
      behalf #3971
      cardiovascular events #3972
      data studies #3975
      2nd #3975
      quality assurance #3980
      986 #3982
      pregnancy #3982
      continuous infusion #3983
      flying #3986
      unstable #3986
      month #3987
      488 #3990
      systematic analysis #3994
      sequentially #4006
      calculate #4010
      lower risk #4011
      limited evidence #4014
      patients evaluated #4016
      scored #4023
      secondary prevention #4026
      538 #4028
      equivalence #4029
      gln #4031
      meyer #4032
      cerebral venous #4041
      introduction #4045
      296 #4045
      423 #4047
      262 #4051
      ended #4052
      validating #4058
      received #4062
      recurrent disease #4066
      cruciate #4073
      elevated #4074
      compare #4075
      bariatric #4077
      pcc #4077
      avoid #4080
      429 #4081
      326 #4083
      hour #4088
      oligosaccharides #4089
      natriuretic peptide #4089
      angioplasty balloon #4091
      maneuver #4092
      3000 #4093
      16 #4098
      cutoff #4099
      indications #4099
      activation #4099
      contact #4102
      pharmacological #4106
      infusion rate #4109
      392 #4113
      335 #4117
      6 months treatment #4119
      ptm #4120
      completing #4125
      patients low risk #4133
      008 #4137
      withdrawn #4137
      41 #4138
      bms #4146
      patients died #4149
      medical students #4152
      haemorrhagic #4154
      continue #4158
      study control #4161
      nulliparous #4167
      2030 #4171
      patients prostate cancer #4171
      antitumour #4177
      steroidal #4178
      multidisciplinary approach #4189
      direct #4192
      therapy combination #4198
      casts #4200
      485 #4212
      411 #4212
      medical center #4214
      408 #4215
      weighted #4221
      additional #4222
      452 #4223
      289 #4226
      121 #4226
      trough #4229
      crosssectional analysis #4230
      p0005 #4230
      hormonal #4234
      veins #4235
      patients mortality #4242
      cox regression #4242
      178 #4246
      nsaid #4261
      263 #4263
      abbreviated #4267
      encountered #4268
      atrial fibrillation patients #4274
      fab #4279
      late pregnancy #4285
      pai1 #4286
      rise #4287
      oral aged #4294
      q4 #4296
      228 #4303
      share #4304
      10 patients #4306
      105 #4310
      rehospitalization #4314
      patients increased risk #4315
      185 #4316
      tat #4319
      separate #4322
      concentrates #4328
      intima #4329
      devised #4331
      294 #4339
      455 #4340
      102 #4340
      pronounced #4342
      incidental findings #4345
      managed #4350
      potential risk factors #4350
      detrimental #4356
      253 #4359
      agreed #4360
      young age #4363
      specialist #4379
      rapid #4383
      minutes #4383
      retrospective studies #4384
      447 #4385
      cd11b #4387
      288 #4391
      170 #4392
      slice #4394
      concurrently #4394
      risk cardiovascular #4396
      steadily #4402
      239 #4406
      71 #4407
      negative #4407
      bowel diseases #4407
      general #4407
      guideline recommendations #4408
      postoperative day #4409
      ventilation #4413
      lacking #4417
      splanchnic #4417
      immunoassays #4419
      dose aspirin #4419
      recombinant proteins #4423
      3 patients #4426
      author #4427
      148 #4428
      281 #4429
      primary myelofibrosis #4430
      appropriateness #4433
      profoundly #4436
      completed #4438
      platelet #4440
      cellulitis #4441
      sixteen #4442
      concomitant #4445
      assays #4453
      334 #4458
      192 #4459
      vascular surgery #4459
      proband #4461
      cytomegalovirus infection #4461
      total costs #4474
      377 #4479
      443 #4482
      cd18 #4486
      clinical manifestations #4486
      pancreatic cancer #4487
      inadequate #4487
      coronavirus disease covid19 #4489
      smr #4492
      risk prediction #4493
      bus #4497
      current management #4498
      476 #4499
      doubling #4500
      infected patients #4502
      comprises #4503
      activation platelet #4503
      54 #4513
      primary diagnosis #4515
      alpha2 #4516
      therapeutic #4532
      septic #4534
      3 groups #4535
      male pulmonary #4541
      526 #4542
      elastase #4544
      hitherto #4546
      fairly #4552
      cardiovascular death #4559
      985 #4564
      1250 #4567
      cerebrovascular disorders #4571
      calculating #4571
      multicenter trial #4574
      2c #4585
      debate #4586
      disadvantage #4588
      plasma concentrations #4591
      283 #4592
      preserves #4594
      attenuating #4594
      eventually #4595
      gradual #4595
      204 #4596
      simplified #4596
      4000 #4601
      4 #4601
      encouraged #4603
      icer #4610
      frequently #4611
      acetylsalicylic acid #4613
      vii #4613
      vaginal #4614
      917 #4619
      assay #4634
      subclinical atherosclerosis #4636
      hospital costs #4640
      risks benefits #4640
      242 #4642
      genetic risk factors #4644
      escalating #4648
      priori #4654
      003 #4658
      habitual #4658
      survey #4659
      transurethral #4663
      myelofibrosis #4670
      171 #4670
      thyroid hormone #4673
      40 #4675
      407 #4679
      day #4680
      fh #4680
      recurrent stroke #4681
      wheezing #4693
      unchanged #4698
      ranging #4698
      5 patients #4701
      complicated #4703
      truncated #4709
      therapeutic intervention #4715
      differential humans #4719
      immobilization #4725
      129 #4727
      orthopedic #4735
      cardiovascular morbidity #4738
      current guidelines #4739
      therapeutic strategies #4744
      ranged #4769
      027 #4774
      chronic renal #4775
      baseline patients #4775
      acute coronary #4784
      44 #4785
      scheduled #4785
      molecular #4792
      knee #4800
      insulin glargine #4801
      prophylactic #4802
      arthroplasty #4803
      alternatively #4810
      extracranial #4813
      courses #4819
      diagnostic imaging #4825
      therapy humans #4836
      echocardiography #4846
      174 #4848
      cholesterol levels #4853
      acl #4861
      definition #4861
      efficiency #4869
      gpiib #4870
      nonvalvular atrial fibrillation #4870
      increased plasma #4875
      unexposed #4876
      gynecological #4880
      antiphospholipid syndrome #4881
      screening tool #4884
      322 #4886
      total #4891
      antiplatelet therapy #4891
      treating #4896
      abstracted #4897
      doses #4902
      ischemic heart disease #4905
      preparations #4906
      tests prognosis #4906
      served #4910
      fmd #4913
      chlamydophila #4913
      560 #4914
      recommendation #4918
      geriatrics #4920
      acute ischemic #4923
      renal dysfunction #4929
      556 #4932
      154 #4933
      870 #4934
      cpb #4939
      325 #4951
      26 #4952
      satisfied #4957
      appeared #4959
      fund #4972
      dose #4976
      manufacturers #4976
      albeit #4982
      orthopedics #4982
      recommended #4987
      cardiology #5000
      references #5006
      389 #5006
      epoprostenol #5009
      reminder #5009
      probnp #5014
      point mutation #5018
      risk women #5023
      syndrome patients #5033
      156 #5040
      screening test #5040
      proposal #5042
      global burden #5044
      primary health #5045
      analytic #5047
      obstetrical #5048
      lasted #5049
      patients sepsis #5051
      limitations #5055
      diagnosis management #5058
      patients myocardial infarction #5062
      spinal surgery #5065
      255 #5068
      conflicting #5070
      saphenous #5075
      inaccessible #5078
      1a #5079
      switched #5084
      evaluable #5089
      regarded #5089
      hip fractures #5090
      relation #5090
      transluminal #5093
      menstrual #5094
      fashion #5098
      amputation #5102
      external validation #5103
      arteritis #5107
      inflammatory responses #5109
      oxadiazoles #5110
      dalys #5112
      tailor #5115
      admission patients #5118
      composite #5120
      discriminative #5123
      vivo studies #5124
      bay #5124
      108 #5125
      282 #5129
      ischaemic stroke #5130
      0018 #5130
      female #5131
      131 #5131
      transfused #5134
      balancing #5136
      contrast media #5136
      fetal death #5138
      activator #5139
      scans #5143
      341 #5146
      n6 #5150
      kg1 #5151
      shortly #5157
      disagreement #5157
      preclinical studies #5160
      doppler #5165
      11 patients #5170
      predispose #5170
      hazard #5171
      readers #5173
      prescriptions #5174
      graft failure #5178
      weaknesses #5185
      renal impairment #5186
      70 patients #5190
      infarctions #5191
      screening #5193
      threefold #5198
      highest #5202
      extracellular vesicles #5204
      acs #5205
      144 #5206
      hospital patients #5208
      remains #5209
      excess mortality #5210
      doppler color #5221
      polysaccharides #5223
      heparan #5229
      emergencies #5233
      articles #5233
      indwelling #5241
      flowmetry #5242
      gram #5244
      3 #5248
      platelet aggregation #5252
      considerably #5253
      comparison #5262
      testing #5264
      plasma levels #5265
      estimate #5288
      365 #5289
      pooling #5289
      aware #5300
      thrombus #5301
      36 patients #5301
      urokinase #5302
      atherogenesis #5302
      triage #5303
      case reports #5305
      benefit #5308
      reversal #5310
      stroke treatment #5314
      contrasted #5316
      orthomyxoviridae #5319
      openlabel #5320
      70 years #5325
      aged postoperative #5330
      animal drug evaluation #5332
      dizziness #5334
      absent #5335
      factor humans #5336
      stratify #5340
      acute ischemic stroke #5341
      reagent #5341
      blood vessel #5343
      ultrasound imaging #5344
      fatality #5347
      contrast agents #5355
      arose #5361
      male #5363
      schedule drug #5363
      based guidelines #5370
      hyper #5372
      obstetric #5376
      accepted #5383
      thyrotropin #5401
      informed consent #5402
      blood products #5405
      selected patients #5406
      adult #5407
      heart valve #5409
      intracranial #5411
      questionnaire #5414
      register #5415
      summarized #5416
      19 #5417
      noninvasive #5421
      clinical risk #5424
      nonsignificant #5429
      protein levels #5430
      concerns #5439
      charts #5440
      hyperprolactinemia #5441
      familiarity #5442
      37 #5445
      630 #5448
      retrieved #5450
      cancer growth #5455
      presently #5456
      congenital heart #5465
      registered #5470
      recombinant human #5474
      intermediate #5475
      340 #5476
      395 #5484
      allocation #5488
      247 #5490
      occurrences #5490
      moyamoya disease #5491
      ntprobnp #5493
      kaplan meier #5496
      patient risk #5497
      260 #5497
      continuing #5499
      discomfort #5499
      9 patients #5500
      postal #5503
      ssris #5515
      correctly #5517
      weight #5524
      309 #5530
      period #5533
      limitation #5539
      erythema #5539
      suggestions #5541
      survival benefit #5542
      imputed #5545
      receptor1 #5563
      established #5563
      175 #5565
      545 #5566
      management #5569
      46 #5573
      reduce risk #5573
      324 #5595
      excludes #5597
      equivalent #5598
      circulating levels #5598
      categorical #5600
      stm #5607
      grounds #5617
      expert #5620
      02 #5624
      microgram #5626
      minus #5627
      premenopausal women #5629
      retrieve #5633
      food preferences #5637
      drug administration #5641
      platelet count #5643
      reclassification #5644
      80 years #5644
      65 #5651
      trial #5653
      087 #5667
      published data #5671
      48 #5676
      seventy #5684
      214 #5689
      latex #5690
      platelet glycoprotein #5692
      reproducible #5696
      1997 #5698
      meier #5714
      370 #5718
      return #5721
      40 years #5729
      atherosclerotic #5730
      89 #5732
      perform #5734
      995 #5748
      091 #5755
      stand #5756
      0014 #5761
      metabolic effects #5764
      milder #5771
      semiquantitative #5771
      241 #5777
      recurrence patients #5781
      varied #5784
      creatinine clearance #5788
      3rd #5791
      mpo #5804
      incidence rates #5804
      95 women #5809
      orthopedic procedures #5810
      male middle aged #5811
      url #5812
      1000 #5819
      aircraft #5819
      income countries #5828
      diagnosed #5840
      undergoing surgery #5843
      true #5852
      atrial #5852
      088 #5854
      attending #5856
      women pregnancy #5857
      290 #5857
      hip #5866
      advantageous #5875
      complete resolution #5878
      occurrence #5894
      reliable #5894
      excluded #5899
      aged models #5919
      adding #5923
      safety patients #5927
      22 patients #5928
      aged platelet #5928
      graded #5934
      premenopause #5938
      revision #5938
      353 #5945
      prodrugs #5946
      rrs #5949
      141 #5952
      gastrointestinal hemorrhage #5954
      janus kinase #5959
      43 #5962
      rcts #5962
      families #5967
      328 #5971
      deemed #5977
      savings #5980
      counseling #5985
      blood platelets #5987
      blood #5990
      receiver operating #5996
      guideline #5998
      cancer incidence #6006
      current standard #6013
      therapeutic interventions #6028
      nadir #6034
      registries risk #6039
      patients experience #6042
      allocated #6044
      ≥3 #6052
      wash #6059
      advance #6062
      quarter #6065
      spect #6068
      glycosaminoglycans #6069
      decompensated #6074
      24 #6076
      bacteremia #6090
      type iii #6101
      topics #6101
      suggestive #6105
      emerging evidence #6113
      prevent #6117
      safety data #6120
      directly #6133
      72 #6135
      267 #6136
      lipid profile #6140
      ≥2 #6144
      normalization #6151
      centuries #6153
      47 #6157
      ffa #6160
      generation #6160
      lobar #6161
      agents blood #6164
      292 #6165
      informed #6173
      pharmacodynamic #6188
      lung male #6190
      updating #6192
      advantages disadvantages #6194
      lower #6195
      bilateral #6198
      cyclosporine #6208
      tumour growth #6212
      pathogenetic #6221
      femoral artery #6224
      terminated #6228
      mortality morbidity #6228
      new drugs #6229
      312 #6230
      evidence base #6232
      vitro studies #6234
      crp #6235
      discontinued #6236
      111 #6240
      abdomen #6248
      denmark #6254
      proportional #6268
      colleagues #6273
      practitioners #6273
      administered #6277
      1978 #6283
      screened #6293
      infused #6297
      840 #6318
      prostatectomy #6330
      017 #6334
      saphenous vein #6339
      135 #6340
      63 #6340
      percentile #6344
      higher doses #6345
      adequacy #6347
      divided #6348
      apache #6351
      screen #6357
      opinions #6360
      opposed #6362
      percentage #6370
      longterm followup #6372
      risk mortality #6386
      dyslipidemias #6390
      kaplan #6391
      consensus #6392
      208 #6397
      potential mechanisms #6404
      roche #6405
      factor gene #6405
      initiated #6408
      compensated #6411
      investigating #6427
      ultrasound #6441
      restenosis #6442
      bootstrap #6452
      collection #6457
      post operative #6464
      enzyme linked #6467
      bariatric surgery #6468
      coronary syndrome #6469
      decreased risk #6471
      218 #6472
      perfusion #6475
      imbalance #6484
      angina pectoris #6493
      calendar #6498
      accuracy #6501
      peripheral artery disease #6501
      cancer cell #6502
      incidence risk #6502
      complement activation #6505
      pregnancies #6519
      surgical procedure #6520
      supervised #6521
      models male #6522
      138 #6523
      washout #6524
      318 #6524
      triiodothyronine #6524
      peripheral #6525
      vena #6527
      increased incidence #6532
      cochrane #6532
      highrisk patients #6532
      placebo patients #6536
      replaced #6537
      exogenous #6538
      bowel #6538
      aspirin patients #6540
      thirteen #6540
      year #6546
      superior #6549
      clinical assessment #6550
      cohorts #6555
      dilemma #6560
      crt #6561
      dosing #6576
      tertile #6581
      231 #6586
      limited #6589
      md #6592
      prediction #6596
      treatment choice #6600
      pooled #6601
      occurs #6610
      510 #6611
      belgium #6620
      crude #6621
      injections #6638
      pancreatic neoplasms #6641
      genetic testing #6641
      individual #6650
      complications #6650
      complaints #6652
      degranulation #6663
      methylenetetrahydrofolate #6665
      liver diseases #6674
      patents #6680
      smoking cessation #6696
      17 patients #6704
      routinely #6706
      tumour progression #6708
      saline #6709
      194 #6713
      approval #6727
      recognised #6729
      hazard ratios #6729
      thromboxane #6734
      allcause mortality #6744
      multicenter #6747
      appropriately #6748
      increasing age #6751
      body temperature #6766
      385 #6766
      q1 #6768
      clinical signs #6771
      age patients #6774
      defined #6780
      2 groups #6780
      expense #6781
      42 patients #6791
      train #6796
      hyperglycemia #6801
      reached #6803
      premedication #6803
      plasma proteins #6807
      response relationship #6807
      benefits #6810
      cardiovascular risk #6821
      256 #6831
      280 #6838
      iqr #6839
      glucocorticoids #6840
      summary #6850
      279 #6854
      cancer diagnosis #6856
      systematic #6870
      points #6877
      ambulatory #6883
      weekly #6884
      reviews #6891
      physicians #6893
      fibrillation patients #6898
      adverse event #6912
      disturbances #6912
      sought #6918
      112 #6923
      251 #6940
      complications patients #6948
      vasopressin #6957
      failure #6965
      subsequent #6971
      hematologic #6974
      246 #6976
      intensity #6976
      humans hydroxymethylglutaryl #6982
      papers #6983
      tpa #6986
      intervals #6987
      addressed #6989
      259 #6992
      222 #6995
      shock septic #6995
      adapted #6998
      disclosed #7001
      incidence risk factors #7008
      hazards models #7015
      cardiovascular disease #7019
      myeloperoxidase #7020
      lung cancer patients #7023
      stenting #7024
      responded #7026
      cohort #7037
      1 patient #7038
      unacceptable #7039
      interleukin8 #7042
      reductases #7045
      preventing #7056
      curve #7058
      patients baseline #7065
      animal doseresponse relationship #7071
      reduced risk #7075
      written #7080
      applicability #7084
      asymptomatic patients #7086
      monoclonal antibody #7098
      hospitalization humans #7101
      computed #7104
      betacoronavirus covid19 #7104
      novartis #7108
      complications pregnancy #7111
      infarction stroke #7114
      superiority #7116
      interquartile range #7120
      select #7122
      carotid intima #7141
      internationality #7146
      surveys questionnaires #7160
      163 #7166
      pharmacy #7167
      patients renal #7171
      physicians patients #7177
      randomization #7184
      liver cirrhosis #7187
      211 #7188
      brain metastases #7190
      oral animals #7192
      walking #7195
      drawn #7196
      combination #7197
      5year #7204
      withdrawal #7204
      cardiovascular disease cvd #7210
      acting #7210
      disposition #7212
      paucity #7218
      humans lung #7221
      20 patients #7225
      sulfate #7240
      operating characteristic #7244
      treatment children #7250
      vldl #7250
      hematocrit #7255
      199 #7257
      retrospective cohort study #7257
      alongside #7258
      clinical benefit #7265
      controls #7267
      diagnostics #7270
      option #7273
      grouped #7275
      young women #7278
      products #7282
      likelihood #7284
      modest #7290
      sensitivity analysis #7290
      atrium #7291
      360 #7303
      types #7304
      factors stroke #7305
      undergoing #7327
      partial #7330
      patients isolated #7332
      pectoris #7338
      ischemic stroke #7338
      1c #7352
      interleukin6 #7352
      myocardial infarction #7356
      standardised #7356
      p0001 #7356
      betacoronavirus #7357
      simple #7360
      radiology #7379
      pap #7392
      patients aspirin #7400
      angiopathies #7401
      regimens #7405
      109 #7409
      bias #7411
      peptide fragments #7413
      iiia #7424
      intravenous injection #7429
      420 #7431
      propranolol #7438
      favourable #7440
      hypercholesterolemia #7441
      respective #7444
      dose dependent #7447
      infusion #7448
      clinical setting #7454
      ways #7465
      risk adverse #7497
      il6 #7510
      mortality rates #7515
      209 #7516
      considerations #7517
      exclusions #7518
      patient safety #7520
      angina #7522
      urgently #7522
      cmv infection #7541
      phase iii #7555
      257 #7558
      #7559
      interim #7561
      injection #7564
      cinahl #7578
      comorbid #7578
      191 #7578
      pheochromocytoma #7585
      ischaemic #7598
      antibodies monoclonal #7601
      reasons #7602
      tended #7608
      pooled analysis #7609
      azathioprine #7615
      13 #7616
      predictor #7620
      femoral #7640
      random allocation #7646
      29 patients #7647
      epidemiological studies #7647
      abrupt #7655
      derivation #7662
      interquartile #7675
      manifestation #7676
      temporary #7679
      positive patients #7687
      medical conditions #7705
      18 #7705
      seventeen #7710
      304 #7719
      ligament #7732
      consent #7733
      study association #7735
      cytomegalovirus #7736
      severe #7742
      adverse outcomes #7745
      costs #7753
      cardiac surgical #7760
      189 #7770
      cochrane library #7771
      pregnancy outcome #7787
      110 #7802
      manufacturer #7802
      #7803
      9 #7811
      oxygenases #7813
      male gender #7815
      interleukin #7816
      pts #7819
      31 patients #7828
      label #7828
      hormone replacement #7828
      cpr #7829
      5 #7833
      abortion #7838
      influenza #7845
      radiation exposure #7850
      regular #7877
      tramadol #7878
      academic #7878
      septic patients #7880
      95 confidence #7884
      replacing #7886
      patients chemotherapy #7888
      iib #7908
      journals #7922
      strict #7927
      expertise #7928
      bioavailability #7930
      adoption #7934
      highrisk #7939
      urogenital #7939
      diseased #7944
      increasing evidence #7947
      disadvantages #7949
      243 #7965
      patients 1 #7972
      human blood #7973
      fragment #7975
      new class #7976
      28 #7989
      individualized #7990
      aim #7992
      premenopausal #7995
      advice #8016
      qol #8022
      malignant disease #8026
      pulmonary disease #8031
      99mtc #8034
      oligonucleotides #8040
      vascular disease #8049
      600 #8051
      medical #8051
      preventable #8051
      list #8059
      selective #8062
      routine clinical #8068
      fact #8078
      lasting #8080
      helpful #8084
      36 months #8086
      outcome acute #8092
      extracorporeal #8095
      248 #8113
      90 #8114
      patients heart #8120
      training #8120
      2004 #8122
      initiating #8123
      tsh #8125
      cholesterol ldl #8138
      sensorineural #8140
      investigational #8141
      imaging studies #8141
      mild #8156
      nosocomial #8164
      multiple organ #8175
      stroke #8176
      237 #8183
      158 #8184
      arteries #8190
      parenteral nutrition #8204
      confidence #8204
      renal dialysis #8209
      33 #8223
      impairment #8228
      renal function #8228
      81 #8233
      therapy #8235
      quantitative #8240
      smoking #8243
      lowest #8250
      lists #8250
      version #8260
      125i #8264
      activated #8264
      minimum #8270
      mortality #8280
      leukopenia #8281
      0008 #8284
      agents #8286
      119 #8290
      utilisation #8298
      practice #8310
      suffered #8316
      schedule #8320
      thrombectomy #8322
      postulated #8338
      endothelium vascular #8338
      immunosorbent assay #8339
      elimination #8341
      linked immunosorbent #8345
      hematology #8351
      absence presence #8382
      2 years #8382
      cell derived #8384
      229 #8394
      draw #8405
      28 patients #8415
      occur #8415
      ≥50 #8416
      reports #8427
      137 #8433
      mentioned #8436
      covid19 coronavirus #8447
      265 #8452
      glucuronidase #8458
      patient characteristics #8459
      procedures operative #8463
      transient ischemic #8463
      295 #8466
      exceed #8486
      knowledge #8493
      27 patients #8496
      evaluate #8501
      covariate #8501
      criterion #8504
      inborn #8519
      validate #8528
      rabbits #8537
      atherosclerosis #8557
      large cohort #8558
      menstrual cycle #8563
      193 #8565
      250 #8568
      adjusted life #8574
      leukocytes #8581
      adolescent #8582
      146 #8582
      row #8590
      thirty #8596
      carotid arteries #8596
      safety profile #8602
      cox #8604
      intensities #8605
      risks #8606
      15 years #8624
      fish oil #8624
      attenuates #8625
      entry #8639
      thresholds #8646
      presumed #8652
      emissioncomputed #8654
      223 #8655
      hydroxymethylglutaryl coa #8656
      valves #8658
      syndrome #8664
      factors patients #8666
      evaluations #8679
      certainty #8687
      markers #8689
      renal failure #8690
      biomarkers #8693
      polytetrafluoroethylene #8698
      publication aged aged #8706
      portal vein #8708
      hold #8723
      1 2 #8723
      additional studies #8726
      cardiotonic #8729
      definitions #8731
      address #8733
      judgment #8744
      platelet counts #8754
      requiring #8755
      practical #8756
      cardiovascular #8756
      endovascular #8756
      vasoactive #8762
      236 #8763
      interpret #8766
      undetected #8778
      subpopulation #8789
      medical treatment #8792
      illnesses #8798
      cardiovascular mortality #8802
      249 #8834
      internship #8836
      convenient #8837
      hydroxymethylglutaryl #8837
      resolving #8863
      representative #8864
      2 #8872
      cesarean #8876
      merits #8887
      endarterectomy #8896
      chronic liver disease #8902
      mimics #8903
      early treatment #8910
      surgical intervention #8911
      planned #8914
      micrograms #8914
      epoxide #8916
      aged myocardial #8919
      influenced #8934
      normal subjects #8936
      signs symptoms #8945
      proportional hazards #8945
      clinicians #8956
      cessation #8958
      experienced #8960
      heparan sulfate #8962
      leads #8973
      24 hours #8977
      rct #8980
      patients placebo #9002
      options #9002
      comprise #9005
      chemoprevention #9005
      societies medical #9007
      clinical events #9007
      reply #9017
      receiver #9026
      rank #9043
      7 #9061
      databases factual #9064
      early mortality #9075
      diagnose #9080
      mps #9080
      frequency #9083
      jan #9088
      statins #9090
      alpha1 #9115
      blood proteins #9116
      prone #9142
      time points #9147
      valve prosthesis #9147
      patient patients #9150
      pelvis #9158
      square #9165
      life threatening #9170
      molecular mechanisms #9179
      75 patients #9183
      advanced stage #9184
      lysis #9190
      editor #9193
      consensus statement #9209
      361 #9213
      considerable #9225
      platelets #9226
      1 month #9227
      dyspnea #9230
      pci #9230
      performs #9233
      contrast #9238
      4 hours #9259
      extrinsic #9263
      illness surveys #9264
      hazards #9264
      experts #9266
      uncomplicated #9267
      mumol #9278
      attenuation #9283
      positive #9286
      rabbit #9286
      trial registration #9297
      corresponded #9298
      dialysis #9319
      feasibility #9320
      earlier #9339
      suboptimal #9342
      p0004 #9355
      patients negative #9355
      preceded #9376
      loss #9378
      014 #9380
      higher incidence #9380
      purposes #9383
      invited #9384
      single center #9385
      death patients #9391
      radioactivity #9394
      bacterial infections #9401
      fourth #9402
      2b #9412
      ascending #9415
      haemorrhage #9425
      167 #9436
      properly #9442
      rheumatic #9446
      hospitalised #9448
      dysfunction #9460
      belonged #9480
      secondary analysis #9483
      respiratory tract #9486
      169 #9490
      240 #9493
      ipd #9502
      factual #9503
      valvular #9505
      thyroid function #9507
      selectin #9509
      hrs #9524
      inflammatory agents #9529
      confirms #9530
      designed #9535
      cardiopulmonary bypass #9540
      swelling #9542
      3 4 #9544
      insight #9557
      cooperation #9561
      requirements #9566
      hemoglobins #9573
      rose #9592
      il10 #9597
      observational cohort #9598
      lpa #9600
      rates #9617
      comparative effectiveness #9630
      kidney failure #9638
      primary point #9638
      successful treatment #9639
      laboratories #9644
      cardiogenic #9645
      optimal treatment #9650
      2008 #9656
      hf #9670
      published #9674
      congestive #9695
      pathophysiological #9704
      patients hospital #9713
      spontaneously #9720
      modalities #9721
      inappropriate #9724
      reuptake #9727
      acts #9729
      identifier #9730
      2007 #9732
      lactoferrin #9734
      42 #9744
      substitutes #9747
      hypothetical #9754
      nested #9764
      nonesterified #9768
      90 patients #9777
      reproducibility #9778
      sepsis #9802
      210 #9803
      absence #9813
      straightforward #9814
      precise #9817
      easily #9817
      nmol #9828
      coa reductase #9828
      classification #9836
      craniotomy #9839
      212 #9839
      0006 #9849
      utility #9855
      danish #9857
      labile #9865
      heterozygotes #9871
      nonhuman primates #9871
      discordant #9908
      moderately #9919
      cmv #9930
      60 years #9933
      lower limb #9936
      promise #9937
      degradation #9941
      2003 #9941
      tomography #9944
      treatment strategy #9951
      216 #9958
      low dose #9971
      investigator #9983
      detecting #9992
      regimen #9995
      casecontrol studies #9997
      pancreatic #9997
      12 hours #9997
      213 #10000
      neoplasm metastasis #10001
      chance #10008
      physician #10015
      extending #10027
      informative #10028
      hereditary #10041
      obstacles #10045
      protective #10045
      addressing #10051
      medication adherence #10052
      mthfr #10079
      presentations #10082
      familial #10087
      higher prevalence #10089
      chart #10108
      recipients #10113
      qualitative #10117
      1980 #10134
      completely #10145
      tested #10150
      aged obesity #10170
      182 #10176
      invasive #10181
      abnormalities #10186
      regularly #10189
      cast #10193
      multicentre #10198
      investigations #10199
      cell activation #10199
      cardiovascular risk factors #10209
      clinical data #10213
      medical therapy #10213
      tumor necrosis factoralpha #10215
      replacement therapy #10225
      routine #10234
      syndrome humans #10253
      heart failure #10265
      183 #10280
      gaps #10291
      blood transfusion #10293
      hospitalization #10293
      postpartum #10305
      measuring #10314
      aetiology #10315
      8 #10318
      photon emission #10329
      032 #10336
      dilution #10336
      worldwide #10337
      667 #10337
      greatly #10352
      aorta #10352
      indirectly #10377
      restoration #10378
      creatinine #10381
      cardiopulmonary #10385
      pneumonia viral #10397
      medical management #10404
      p0003 #10408
      outcome measures #10408
      tissue injury #10411
      bidirectional #10419
      circulation #10432
      reductase inhibitors #10432
      transfusion #10435
      enrolment #10446
      reflux #10457
      priority #10461
      patients age #10461
      quality life #10471
      phase 3 #10481
      activity levels #10489
      increased prevalence #10489
      1991 #10491
      style #10491
      147 #10501
      predictive factors #10514
      sex age #10526
      assessing #10529
      necrosis #10534
      matched #10556
      lower rate #10558
      portable #10563
      patients moderate #10570
      ray #10570
      125 #10574
      p002 #10576
      pulmonary artery #10578
      inform #10580
      antisense #10583
      recurrences #10583
      293 #10584
      180 #10598
      manifestations #10601
      closer #10602
      microvascular #10605
      159 #10605
      vasoconstrictor #10607
      hospitals #10612
      medical oncology #10615
      november #10628
      percutaneous coronary #10633
      persist #10635
      fragments #10637
      ascertained #10641
      1b #10647
      publication administration #10653
      postoperative #10659
      held #10674
      concerned #10674
      pulmonary vascular #10690
      discriminate #10697
      term #10697
      risk developing #10704
      synergism #10709
      multivariable analysis #10713
      neutrophil #10729
      consultation #10735
      centres #10751
      median duration #10755
      decisions #10759
      entire #10774
      haemoglobin #10797
      perioperative #10798
      patients cirrhosis #10804
      term mortality #10829
      300 #10832
      38 #10849
      prospective observational #10855
      sustained #10865
      randomised controlled #10867
      anatomical #10873
      diagnoses #10903
      airways #10903
      neurosurgical #10905
      monoclonal antibodies monoclonal #10909
      coronavirus infections #10921
      maximal #10924
      threatening #10963
      amniotic #10987
      coronary intervention #10989
      relative #10990
      blocker #10996
      needed #11009
      obese #11037
      neutropenia #11057
      ischemic #11057
      ethical #11062
      summarizes #11062
      attained #11062
      treatment option #11070
      balloon #11071
      12 weeks #11074
      originally #11083
      location #11108
      inability #11108
      catheters #11143
      beta2 #11159
      ischemic attack #11165
      hematoma #11189
      confirmation #11199
      neoplasms risk #11201
      metabolic syndrome #11202
      iia #11204
      strokes #11217
      choice #11228
      eligible patients #11247
      risk groups #11263
      1992 #11272
      humans kidney #11281
      cerebrovascular #11281
      waiting #11282
      ≥1 #11291
      endothelial function #11297
      troponin #11304
      determine #11306
      202 #11308
      aged prevalence #11331
      post #11332
      adherent #11338
      acute respiratory #11345
      acute myocardial infarction #11361
      event #11363
      combination therapy #11380
      glycoprotein #11391
      factors smoking #11395
      reconstructive #11397
      apply #11399
      developed #11405
      2005 #11415
      competent #11416
      medically #11426
      treatment decisions #11427
      prostaglandins #11434
      diuretics #11439
      hematological malignancies #11443
      morbidity #11445
      media #11464
      protocol #11487
      satisfying #11502
      performances #11525
      hospital admission #11526
      occlusion #11533
      placebo treatment #11533
      multicenter study #11542
      outflow #11542
      enrolled #11545
      humans intensive #11570
      55 #11577
      chronic inflammation #11600
      definitive #11621
      baseline #11624
      younger patients #11624
      sct #11638
      investigate #11670
      normal controls #11684
      contribution #11687
      reference #11694
      life qol #11697
      lipopolysaccharides #11699
      hypotension #11715
      ascites #11717
      myoglobin #11741
      independent risk #11745
      acute myocardial #11753
      radiopharmaceuticals #11783
      extent #11786
      orally #11790
      involving #11792
      2010 #11802
      nonspecific #11809
      vena cava #11829
      distinction #11841
      episodes #11865
      eclampsia #11872
      release #11874
      woman #11885
      151 #11891
      006 #11906
      elicited #11912
      icu patients #11915
      vasculitis #11937
      activating #11948
      age #11953
      sulphate #11955
      began #11957
      lethality #11967
      collectively #11970
      inferior #11978
      serum creatinine #11979
      myocardial injury #11980
      adp #11981
      immunosorbent #12006
      cardiovascular diseases #12015
      mortality rate #12041
      reduced #12043
      thirds #12057
      dietary intake #12057
      minority #12058
      monitored #12061
      differently #12066
      early pregnancy #12076
      humanized #12077
      wounds injuries #12079
      fair #12096
      thoracotomy #12111
      evidenced #12130
      1995 #12135
      elevated risk #12140
      085 #12141
      profile #12143
      prostate #12153
      149 #12157
      120 #12170
      digoxin #12177
      offset #12179
      uncommon #12187
      healthcare #12202
      lung #12208
      causality #12208
      spent #12219
      takes #12233
      tendency #12271
      pregnancy risk #12276
      expectancy #12281
      resolve #12300
      flaps #12302
      micromol #12326
      mismatch #12335
      favored #12342
      births #12351
      obstructive pulmonary #12358
      epinephrine #12365
      dependently #12372
      prescription #12394
      registration #12398
      incremental #12399
      switzerland #12409
      inflammatory response #12409
      consistent #12418
      potential confounders #12425
      echocardiographic #12450
      fifty patients #12451
      arginine #12475
      patient discharge #12480
      apparent #12483
      prospective randomized #12486
      sensitivity analyses #12490
      117 #12494
      switch #12513
      10 years #12521
      standards #12524
      requires #12540
      guide #12540
      statistically #12548
      prognostic #12579
      chronic obstructive #12584
      monoclonal #12589
      rapidly #12597
      tomography ray #12611
      lipoprotein #12619
      literature #12637
      repeat #12653
      single dose #12673
      drug interactions #12680
      hypertension pulmonary #12684
      physiological #12687
      pharmacogenetics #12706
      prostatic #12708
      45 #12708
      endocrine #12709
      ifngamma #12722
      minute #12733
      dosage #12736
      congestive heart failure #12747
      cardiac surgery #12756
      personal #12770
      estrogens #12778
      animal model #12796
      thyroid #12808
      settings #12820
      malignancies #12823
      infections #12836
      burden #12849
      intraoperative complications #12862
      cancer patient #12864
      reporting #12866
      196 #12881
      1999 #12904
      cvd #12906
      raised #12910
      endpoints #12912
      extracted #12940
      confirming #12947
      18 years #12976
      ray computed #12983
      postoperative complications #12990
      filters #13009
      monotherapy #13017
      transiently #13024
      oral administration #13041
      instance #13041
      located #13049
      tumor angiogenesis #13067
      based cohort #13094
      fold #13100
      severity #13106
      cancer risk #13107
      escalation #13107
      vomiting #13112
      physical #13112
      latin #13125
      sexes #13143
      drug therapy #13144
      0 #13145
      ratio #13159
      focused #13189
      appearance #13195
      compliance #13199
      pregnant women #13202
      optimal #13213
      expensive #13226
      support #13231
      exist #13235
      142 #13236
      lack #13240
      narcotic #13261
      formal #13262
      commercially #13265
      participant #13273
      median follow #13286
      indirect #13288
      emission computed #13352
      mediator #13366
      maintain #13391
      electronic databases #13394
      hypothesized #13395
      advantage #13432
      admitted #13437
      p00001 #13442
      anti #13455
      reliably #13459
      surveys #13463
      endothelial dysfunction #13466
      transient #13478
      patients experienced #13481
      provided #13489
      crosssectional study #13491
      patients patient #13494
      surrogate #13537
      vivo #13545
      retrospectively #13548
      maintained #13555
      195 #13556
      pulmonary hypertension #13563
      accurate #13563
      longterm outcomes #13585
      monitoring #13620
      laboratory #13629
      elucidated #13643
      abdominal #13652
      whilst #13665
      mitral #13682
      north america #13705
      marker #13707
      competence #13708
      vascular #13708
      45 years #13716
      2009 #13734
      icu #13748
      drug effects #13753
      medicine #13755
      healthy individuals #13758
      inhibitory effects #13763
      establishing #13766
      pelvic #13773
      explanation #13773
      participating #13774
      phospholipid #13776
      heart diseases #13789
      women risk #13816
      conservative #13820
      circulating #13824
      condition #13859
      kidney diseases #13860
      systematically #13868
      tissue #13876
      coronary angiography #13889
      internal #13916
      techniques #13923
      microparticles #13927
      dissemination #13928
      1993 #13939
      176 #13979
      require #13986
      castration #13998
      radioisotopes #14011
      48 patients #14013
      insufficiency #14022
      algorithms #14029
      risk death #14033
      members #14033
      requirement #14046
      independent predictors #14058
      continuous #14060
      organ failure #14072
      situations #14084
      focus #14084
      vasoconstriction #14119
      offer #14137
      supporting #14164
      activates #14188
      cardiac output #14194
      leukocyte #14204
      mitral valve #14205
      sensitivities #14216
      document #14242
      primary prevention #14248
      newborns #14256
      nausea #14276
      making #14285
      effectiveness #14304
      independent #14342
      inhibition #14357
      4 years #14367
      meaningful #14371
      pathologic #14372
      female fetal #14377
      acquired #14378
      6 patients #14391
      min1 #14391
      amniotic fluid #14403
      substances #14409
      pregnant #14423
      disease chronic #14460
      interleukin1 #14489
      infarction #14491
      influence #14509
      interventions #14510
      costeffectiveness #14535
      locations #14586
      participated #14592
      similarities #14608
      205 #14632
      renal insufficiency #14637
      statistics #14637
      reasonable #14646
      comparative #14648
      natural #14667
      blood samples #14672
      surgery patients #14696
      entered #14698
      pandemics #14707
      classify #14715
      institutes #14736
      surveyed #14741
      39 patients #14742
      sampled #14749
      2017 #14783
      arms #14785
      validity #14787
      independent predictor #14787
      databases #14808
      heart association #14814
      white matter #14816
      complete #14819
      stable #14828
      cox proportional #14835
      pge2 #14844
      duplex #14845
      population #14872
      contribute #14928
      retest #14931
      criteria #14938
      premature #14952
      critical illness #15004
      phospholipids #15030
      european society #15041
      cardiac catheterization #15042
      prostheses #15059
      questionnaires #15082
      treatment failure #15087
      sf36 #15089
      elective surgical #15107
      controlled clinical #15109
      flight #15110
      ldl #15120
      relate #15127
      health costs #15128
      initiation #15140
      obstruction #15142
      obstructive #15146
      stratification #15164
      proper #15177
      selection #15187
      registries #15197
      copd #15201
      decrease #15201
      randomized controlled trial #15210
      unilateral #15223
      ongoing #15230
      induces #15231
      individuals #15239
      young patients #15247
      previous #15250
      methods retrospective #15255
      disorders #15278
      drug #15278
      myocardial #15279
      4 weeks #15296
      quantitation #15298
      fewer #15300
      hospital discharge #15328
      quantify #15340
      activators #15356
      neonates #15370
      consequence #15405
      locally #15441
      impaired #15446
      pedigree #15471
      randomised controlled trial #15474
      women age #15474
      grafts #15484
      zealand #15509
      asthma #15511
      undetectable #15512
      current literature #15513
      records #15520
      1994 #15522
      aggregation #15535
      thrombocytopenia #15537
      implementation #15538
      pa #15540
      intended #15567
      reviewed #15577
      surgery #15590
      updated #15592
      discharged #15616
      immunoenzyme #15617
      purpose #15634
      heterozygosity #15660
      centre #15666
      standard #15679
      patients admitted #15702
      perinatal #15711
      explain #15726
      view #15729
      unexpected #15737
      detection #15766
      start #15808
      effectively #15813
      examination #15813
      prescribing #15823
      vary #15829
      febrile #15847
      confer #15849
      serologic #15853
      reach #15876
      interpretation #15881
      janus #15892
      numerous #15899
      inter #15907
      quality adjusted #15919
      dyslipidemia #15942
      prominent #15961
      blocked #15985
      severely #15997
      discuss #15997
      alanine #15998
      external #16007
      causal #16021
      hepatectomy #16025
      complication #16054
      compared controls #16057
      rarely #16076
      systemic inflammation #16077
      fever #16082
      metabolic #16112
      demonstrates #16117
      insensitive #16125
      affect #16135
      conditional #16136
      basis #16144
      carotid #16168
      bypass #16221
      early #16262
      antiretroviral #16271
      neoplasms #16294
      hospital #16314
      special #16336
      signs #16384
      cost #16418
      recommendations #16420
      aimed #16432
      area #16442
      syndromes #16485
      unable #16508
      prevented #16513
      develop #16513
      cancer treatment #16516
      106 #16543
      radiography #16545
      calibrated #16568
      multivariable #16576
      2021 #16583
      descriptive #16618
      alternatives #16629
      integrins #16641
      creactive protein #16645
      gained #16652
      consists #16666
      weeks #16674
      downregulation #16681
      residual #16708
      prior #16725
      explained #16763
      fat #16775
      electrocardiography #16807
      epidemiology #16821
      potent #16848
      thought #16868
      genetic risk #16876
      survival #16892
      093 #16911
      humans liver #16932
      constitute #16939
      gestational age #16946
      vasodilator #16950
      driven #16958
      critically patients #16965
      enable #16976
      verify #16984
      smokers #16998
      inherent #17023
      carotid artery #17040
      apolipoproteins #17063
      individual patients #17078
      markedly #17097
      units #17139
      estimates #17144
      assayed #17145
      elderly patients #17150
      regard #17197
      critically #17220
      adjustment #17237
      cooperative #17262
      lung neoplasms #17262
      estimated #17274
      largest #17288
      acute phase #17288
      400 #17295
      clinician #17339
      desirable #17347
      2019 #17393
      limb #17439
      dilated #17443
      disease cvd #17451
      synthetic #17459
      increasingly #17488
      kinds #17510
      antibodies #17538
      prompt #17565
      demographics #17584
      cirrhosis #17586
      0002 #17604
      finding #17620
      applicable #17636
      obtaining #17637
      coronary #17653
      sex factors #17688
      prosthesis #17710
      independent risk factor #17712
      distal #17714
      multivariate analysis #17792
      gastrointestinal #17804
      selecting #17815
      3 years #17833
      2006 #17840
      illustrated #17852
      1 #17853
      hemorrhagic #17855
      drugs #17878
      current evidence #17881
      undergone #17883
      marked #17903
      epidemiologic #17920
      hospitalizations #17922
      nationwide #17924
      global #17933
      percutaneous #17942
      essential #17964
      corticosteroids #17975
      distant #18007
      intensive #18031
      reductase #18047
      verified #18052
      peptide #18060
      defects #18070
      000 #18092
      operated #18111
      trend #18115
      centers #18134
      protein crp #18152
      clinical significance #18164
      consistently #18169
      quality #18175
      chemotherapy #18203
      prenatal #18250
      participate #18252
      deaths #18263
      year follow #18286
      ventricular function #18296
      metastases #18296
      inflammatory bowel #18314
      gestation #18344
      tolerated #18425
      attributable #18434
      and or #18480
      coa #18497
      larger #18513
      mutations #18533
      humans hypertension #18543
      stratified #18569
      heart disease #18579
      commercial #18589
      bayes #18675
      #18700
      extra #18726
      mechanisms #18742
      questions #18760
      plasma #18797
      conventional #18799
      monoclonal antibodies #18844
      increases #18850
      life #18851
      vessel #18855
      oligopeptides #18887
      clearance #18903
      validation #18907
      classical #18919
      hormone #18938
      molecular basis #19034
      single #19069
      worse #19094
      statistical #19103
      soluble #19124
      simultaneously #19131
      tailored #19134
      real #19158
      5 years #19189
      variable #19205
      moderate #19239
      contributes #19241
      decade #19291
      infarct #19308
      ages #19312
      pubmed #19345
      0005 #19412
      essentially #19469
      ventricular #19481
      investigates #19493
      2 3 #19507
      therapies #19511
      called #19515
      partially #19535
      explore #19544
      endothelium #19553
      systemic #19561
      january #19567
      uterine #19582
      reversed #19601
      procedures #19611
      tka #19675
      etiology #19677
      operating #19692
      guided #19709
      histology #19727
      characterised #19753
      inflammation #19779
      median followup #19863
      exclusively #19881
      autologous #19886
      graft #19904
      endothelial cell #19986
      controlled trial #20019
      comorbidities #20045
      2002 #20050
      gestational #20050
      additionally #20057
      cytokines #20058
      salvage #20102
      inversely #20149
      concentration #20153
      predisposition disease #20162
      diastolic #20170
      small #20201
      alterations #20228
      body #20230
      alpha #20261
      polymorphism genetic #20264
      variables #20277
      subjects #20283
      combine #20369
      adjusting #20377
      catheterization #20391
      introduced #20458
      1 3 #20492
      younger #20499
      hormones #20508
      length #20512
      theoretically #20515
      ability #20536
      analyses #20553
      clarify #20561
      persistent #20562
      elisa #20562
      improves #20570
      september #20598
      persons #20696
      humans models #20753
      active #20756
      observational #20823
      incorporated #20843
      prognosis #20934
      fetal #20955
      reduce #21005
      measure #21033
      auc #21046
      report #21048
      intrinsic #21055
      responsible #21081
      constructed #21098
      innate #21135
      operative #21137
      attenuated #21137
      1 year #21144
      designated #21167
      october #21177
      performing #21185
      × #21191
      upper #21226
      reflecting #21230
      selected #21264
      depending #21267
      preschool female #21270
      005 #21324
      hemodynamics humans #21403
      symptoms #21425
      center #21469
      differed #21501
      1990 #21507
      0004 #21546
      logistic #21639
      explored #21757
      animals antibodies #21767
      young #21860
      139 #21894
      majority #21894
      observe #21969
      facilitate #21994
      decreased #22047
      progression #22078
      genotype #22116
      imaging #22125
      coronary disease #22178
      tract #22180
      neoadjuvant #22207
      generally #22291
      regression #22321
      surgical procedures #22327
      authors #22330
      demonstrated #22352
      inhibiting #22426
      newborn male #22473
      varying #22556
      significance #22586
      represented #22593
      slower #22607
      allogeneic #22614
      grade #22615
      phase #22698
      older #22831
      differential #22835
      july #22843
      modified #22851
      march #22907
      application #22920
      combining #22961
      ratios #22986
      2012 #23037
      anti inflammatory #23123
      offered #23214
      protocols #23283
      2016 #23284
      challenging #23285
      yielding #23334
      prevents #23432
      resting #23488
      includes #23496
      renal #23566
      median #23599
      inhibits #23686
      inbred c57bl mice #23705
      increasing #23723
      endopeptidases #23727
      advanced #23745
      adverse #23767
      naive #23767
      reactive protein #23807
      minimal #23827
      interestingly #23831
      showing #23885
      longer #23967
      surgical #24020
      vascular endothelial #24085
      prolonged #24478
      generate #24487
      count #24514
      december #24569
      unrelated #24572
      determining #24577
      activity #24581
      changed #24651
      implies #24682
      underlying #24749
      suggests #24813
      august #24821
      linearly #24940
      february #24945
      frequent #25109
      june #25175
      representing #25214
      acceptable #25300
      carried #25310
      illness #25373
      suitable #25501
      enhance #25503
      0003 #25598
      linked #25616
      local #25663
      mm #25732
      fully #25888
      reducing #25912
      describes #25923
      difficult #26054
      supported #26091
      scanning #26181
      differentiate #26212
      respect #26378
      promising #26384
      asked #26410
      define #26421
      defective #26510
      female heart #26685
      dependent #26722
      leading #26774
      improving #27057
      contained #27059
      national #27215
      strongest #27229
      quantitatively #27333
      recognized #27386
      commonly #27411
      mass bmi #27411
      implicated #27484
      caused #27495
      remain #27689
      correlate #27710
      artery #27999
      cross #28142
      recorded #28182
      detected #28405
      inflammatory #28439
      multivariate #28454
      examine #28475
      beta #28655
      allowed #28793
      hypothesis #28801
      improved #28920
      required #29047
      large #29116
      chemically #29137
      short #29272
      patients chronic #29316
      genetic predisposition #29434
      bmi #29470
      female health #29531
      achieved #29589
      001 #29634
      underwent #29797
      2011 #30149
      indicating #30233
      approved #30511
      declined #30756
      participants #30828
      predisposition #30981
      genotype humans #31051
      aims #31216
      measured #31265
      antineoplastic agents #31706
      expected #31791
      specific #31901
      endothelial #32294
      modality #32386
      inhibit #32629
      conducted #32675
      predicted #32889
      inhibited #33631
      agreement #33673
      sensitive #34362
      antineoplastic #34560
      correlated #34744
      greater #34856
      poor #35078
      neoplasms male #35230
      humans magnetic #35433
      0001 #35646
      free #35793
      sectional #35852
      include #39773
      collected #40746
      examined #41010
      mediated #41310
      neoplasm #47468

       

      Prominent publications by Harry Roger Büller

      KOL-Index: 23031

      BACKGROUND:  Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.

      OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.

      METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.

      RESULTS: For the ...

      Known for Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines
      KOL-Index: 20177

      OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.

      BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...

      Known for Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk
      KOL-Index: 17342

      This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...

      Known for Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range
      KOL-Index: 16684

      PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...

      Known for Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized
      KOL-Index: 16378

      BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...

      Known for Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors
      KOL-Index: 15975

      BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.

      METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...

      Known for Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome
      KOL-Index: 15905

      ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.

      BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...

      Known for Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score
      KOL-Index: 15571

      BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.

      METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...

      Known for Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio
      KOL-Index: 15512

      BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.

      METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...

      Known for Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome
      KOL-Index: 15505

      CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.

      OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.

      DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...

      Known for Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months
      KOL-Index: 15415

      BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.

      METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...

      Known for Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients
      KOL-Index: 14849

      BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.

      METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...

      Known for Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte
      KOL-Index: 14797

      BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.

      METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...

      Known for Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections
      KOL-Index: 14727

      OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.

      DESIGN: Systematic review and meta-analysis.

      DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).

      STUDY SELECTION: Randomised controlled trials and prospective cohort ...

      Known for Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval

      Key People For Pulmonary Embolism

      Top KOLs in the world
      #1
      Samuel Zachary Goldhaber
      pulmonary embolism atrial fibrillation major bleeding
      #2
      Henri M Bounameaux
      pulmonary embolism deep vein thrombosis clinical probability
      #3
      Harry Roger Büller
      pulmonary embolism venous thrombosis major bleeding
      #4
      Menno V Huisman
      pulmonary embolism atrial fibrillation major bleeding
      #5
      Paul D Stein
      pulmonary embolism deep venous thrombosis aortic valve
      #6
      Philip Stephen Wells
      pulmonary embolism major bleeding deep vein thrombosis

      Harry Roger Büller:Expert Impact

      Concepts for whichHarry Roger Büllerhas direct influence:Pulmonary embolism,  Venous thromboembolism,  Venous thrombosis,  Major bleeding,  Deep vein thrombosis,  Atrial fibrillation,  Vein thrombosis.

      Harry Roger Büller:KOL impact

      Concepts related to the work of other authors for whichfor which Harry Roger Büller has influence:Venous thromboembolism,  Pulmonary embolism,  Atrial fibrillation,  Deep vein thrombosis,  Oral anticoagulants,  Major bleeding,  Vte patients.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therap

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.